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To understand and modify the secondary cell walls of plants the project group 
Enzyme Discovery in Hybrid Aspen for Fiber Engineering (EDEN) was founded 
composed of nine laboratories with funding from the European Commission.  The main 
target of EDEN´s research is to genetically engineer fiber structure in order to produce 
transgenic trees with modified properties for the pulp and paper industries.   
In this target framework, the Populus tremula x tremuloides xyloglucan 
endotransglycosylase (PttXET16A) was selected for in-depth study of its 
transglycosylase activity catalyzing cleavage and reconection of xyloglucan molecules, 
which is proposed to be involved in secondary cell wall morphogenesis.   
The creation of a family 16 carbohydrate active enzyme β-glucanase/XET 
hybrids were attempted in order to design a chimeric enzyme with one or more of the 
following altered properties: specificity, activity, and or stability.  
The two enzymes, Bacillus licheniformis 1,3-1,4-β-glucanase and Populus 
tremula x tremuloides xyloglucan endotransglycosylase, are members of the same 
enzymatic family and have highly homologous 3-dimensional structures.  However, the 
enzymes exhibit different activities, one a hydrolase the other a transferase; different 
specificities, one accepts only linear glcosydic substrates while the other branched 
substrates; and different stabilities.  
Hybrid enzyme construction represented an investigational challenge in order to 
understand what physical characteristics of both enzymes attribute to the specific 
pattern of activity and specificity observed. 
Removal of the 1,3-1,4-β-glucanase major loop resulted in a folded protein 
which still maintained some β-glucan hydrolase activity.  However, no xyloglucan 
endotransglycosylase-like activity or specificity was observed.  Next, point mutations of 
the β-sheets forming the enzymatic binding site cleft were mutated to resemble 
PttXET16A residues.  The final chimeric protein neither exhibited XET nor β-glucanase 
activities. Structural analysis by X-ray crystallography revealed a major unexpected 






























































1. - A brief history of plant use and modification 
Agriculture has played a key role in the development of human civilization, it is 
widely believed that the domestication of plants and animals allowed humans to settle 
and give up their previous hunter-gatherer lifestyle.  With the invention of agriculture, 
humans started to genetically modify plant species.  Initially, humans selected more 
adequate variants of plants for given traits such as larger seeds for greater caloric 
intake, lack of bitterness, and increased yields. This process of domestication allowed 
the crops to adapt and eventually become larger, more easily harvested, more 
dependable in storage and more useful to the human population.  Development and 
widespread diffusion of agricultural techniques has steadily increased agricultural 
productivity. 
Over the past century, in response to new technologies, a remarkable shift in 
agricultural practices has occurred.  Traditional selection of plant variants showing 
desired traits continues.  However now it is possible with molecular biology, to 
specifically target genes responsible for certain traits and modify, suppress, or add 
these traits to the given plant specie. 
A profound knowledge of the genetic and biochemical mechanisms of plant 
development are necessary for the correct targeting of the desired trait to be modified.  
Therefore, the general objective of this investigation is to understand the molecular 
characteristics and mechanisms involved in plant cell wall biosynthesis and 
modification. 
 
2. – EDEN 
To understand and modify the secondary cell walls of plants the project group 
Enzyme Discovery in Hybrid Aspen for Fiber Engineering (EDEN) was founded 
composed of nine laboratories in seven countries with funding from the European 
Commission.  The main target of EDEN´s research is to genetically engineer fiber 
structure in order to produce transgenic trees with modified properties for the pulp and 
paper industries. There is great interest in the genetic modification of wood fiber 
properties.  Possible applications include transgenic trees which require less toxic 
chemicals, and energy to form the final paper product, thereby creating both a higher 
quality and more economically viable product.  Examples of enzymes presently used 
by the pulp and paper industry for paper product formation include xylanases, 
laccases, and peroxidases. 
 The goal of the EDEN project was the analysis of key enzymes involved in 




database containing over 5500 Expressed Sequence Tags (EST) [1]. The comparison 
of mRNA expression levels in different cell life stages revealed enzymes which are up-
regulated during secondary cell wall formation and which have also been demonstrated 
to effect wood fiber composition. 
 
3. – Wood fiber formation 
 Wood formation is the result of secondary cell growth of vascular 
cambium cells.  These cells make the tree stem thicker as opposed to primary cell 
growth which makes the tree longer. The vascular cambium cells undergo 
differentiation during secondary cell growth; the cells differentiating towards the outer 
side of the cambium become phloem cells whereas cells differentiating towards the 
inner side of the cambium become xylem cells, or wood [2]. Figure 1. 
 
 
Figure 1 . Transverse section of wood-forming tree. 
 
Wood formation or xylogenesis is a highly complex procedure which starts with 
the division of a xylem mother cell.  During the expansion of this newly formed cell, 
there is only a primary cell wall.  After completion of cell expansion, a secondary cell 
wall is deposited on the inner side of the primary cell wall, forming wood.  The last step 
of the wood forming procedure is lignification of the cell wall followed by programmed 




Initially the plant cell wall was considered an inanimate rigid box for housing 
plant cells, however overtime our view of the cell wall has changed and is now 
described as a dynamic and highly regulated organelle located outside the plasma 
membrane [4]. 
 
4. – The role of the cell wall 
The plant cell wall performs a variety of roles in plant growth and development 
such as:  
a) Mechanical support: The inherent role of the cell wall is to maintain cellular 
shape and structure while affording mechanical strength to the plant.  The cell wall 
dictates plant cell morphology and as a consequence it is responsible for the final plant 
shape. Plant cells treated with cell-wall degrading enzymes, which effectively removed 
the cell wall, are invariably spherical in contrast to the different cell shapes observed 
when the wall is present.  Therefore the rigidity that defines cell morphology and plant 
morphology and structure are inherited by the cell wall [5].  
b) Defense: The cell wall functions as the frontier defense system against 
various microbial pathogens and stress from the surrounding environment [6]. 
c) Signaling: The cell wall has an important role in cell-to-cell communication 
with other cells or microbes, particularly in symbiotic interactions [6-9]. Fragments of 
bacterial or viral polysaccharides can provoke the plant to secrete defense molecules 
and/or induce impregnation of the cell walls with proteins and lignin to armor it against 
invading fungal and bacterial pathogens [5]. 
d) Expansion regulation: The cell wall governs the rate and direction of 
expansion, and the ultimate size and shape of the cell [7]. 
e) Transport: The cell wall regulates the uptake of water and nutrients which are 
critical for plant viability [10]. 
 
5. – Cell wall components 
The components of the plant cell wall have been shown to harbor remarkable 
complexity.  A combination of chemical and physical techniques that include HPLC, 
gas chromatography-mass spectrometry, and NMR coupled with isotopic labeling, 
linkage analysis, and the use of pure degradative enzymes with defined specificity, 
have slowly revealed the remarkable chemical heterogeneity of the cell wall [11].  Plant 
cell wall components can be separated by their basis of solubility in different solvents 
[12].  However, chemical treatments primarily solubilize a mixture of cell wall 




be overcome by using purified glycanases to degrade wall polymers into lower 
molecular weight oligosaccharides units which help solubilize wall components [13]. 
Due to the great diversity of plants and differentiated cells in the same plant, it 
is difficult to make a precise and consensual description of the cell wall structure. 
However, there are some general characteristics: 
The principal constituents of the cell wall are polysaccharides: Cellulose, 
hemicelluloses, pectins, but also non-carbohydrate components are present such as 
lignin, proteins, minerals, etc [5].  
Cellulose  is the most abundant plant polysaccharide; it is a 
homopolysaccharide of β-(1→4)-D-glucopyranosyl units, where two adjacent units are 
oriented with 180º of rotation. Cellulose polymers are organized by inter and intra 
hydrogen bonds forming semi crystalline structures named microfibrills (Figure 2). 
 
 
Figure 2 . Schematic representation of fibrils, microfibrils and structure of cellulose 
polysaccharides showing inter and intramolecular hydrogen bonds (dotted line). 
 
Callose  consists of a β-(1→3)-D-glucopyranosyl polymer chain grouped in 
helical duplexes and triplexes. Callose is produced in few cell types at specific stages 
of wall development, such as in growing pollen tubes, in cell plats of dividing cells, etc 
[5]. 
Hemicellulose  is a general name for polysaccharides that have a backbone 
substituted with other oligosaccharides at different positions. Hemicellulose can 
hydrogen-bond cellulose microfibrils forming crosslinks between microfibrils. For this 























































wide range of hemicelluloses: xyloglucans (XG), glucuronoarabinoxylans and the less 
abundant galactomannans, glucomannans, galactoglucomannans, etc. (Figure 3).  
Of specific interest in this investigation is the hemicellulose xyloglucan, it is one 
of the most frequently occurring hemicelluloses found in the primary cell wall of 
dicotyledons and approximately half of the monocot species.  In the primary cell wall of 
dicots xyloglucan accounts for 20 to 25% of the dry mass [14].  By forming hydrogen-
bonds with cellulose microfibrils, xyloglucan is thought to restrain cellular expansion [15].  
Likewise, cleavage of xyloglucan is thought to loosen the cell wall, enabling growth.  It 
has been shown that xyloglucan decreases in mean Mr (molecular mass) and is 
partially solubilized during auxin or acid induced plant growth [16]. Also, supporting 
evidence for cell wall growth by xyloglucan loosening was reported by the experimental 
treatment of stem segments with xyloglucan-binding antibodies. These antibodies 
restrict access of endogenous degradative enzyme(s), to wall bound xyloglucan, 
thereby blocking auxin induced cell elongation and cell wall loosening [17]. 
 Xyloglucan is composed of a backbone of β(1-4)-D-glucopyranose 
residues of which approximately 75% have a single α-D-xylopyranose residue attached 
at the O-6 position. Some of the xylose residues are β-D-galactopyranosylated at O-2 
and some of the galactose residues are α-L-fucopyranosylated at O-2.  A repeating 
motif of xyloglucan appears to be as seen in Figure 3. 
Pectin  is a broad group of branched and ionic polysaccharides rich in                
D-galacturonic acid. It modulates cell wall porosity, pH and ion balance, and it also 
seems to regulate cell-cell adhesion, as well as it is proposed to contain recognition 
molecules that alert plant cells to the presence of symbiotic organisms, pathogens and 
insects [14]. Pectins are composed of three main polymers: the homogalacturonan 
(HGA) composed of highly methyl sterified α-(1→4)-D-galacturonic acid, the 
rhamnogalacturonan I (RG-I) composed of a repeating disaccharide α-(1→2)-D-
rhamnose-α-(1→4)-D-galacturonic acid, and rhamnogalacturonan II (RG-II) a complex 
structure with different monosaccharides and linkages which is able to form boron 






























Figure 3 : Schematic representation of some of the most important structural 
polysaccharides of the plant cell wall [5]. (Xyl: xylose, Gal: galactose, Glc: glucose, Fuc: Fucose, 
GalA: galacturonic acid, GalAMe: methyl galacturonate, Rha: rhamnose, and Ara: Arabinose). 
 
Lignin  is a complex polyphenolic molecule formed by polymerization of three 
different monomers: coumaryl alcohol, coniferyl alcohol and sinapyl alcohol (Figure 4). 
Lignin is mainly deposited in the cell walls of tissues involved in mechanical support or 
in water conduction; lignin also plays a major role in the plant’s defense system. 
Lignification (lignin deposition) occurs when cell growth is completed and the cell wall 
undergoes secondary cell wall thickening provoking a drastic change in cell wall 








Figure 4 . monomers that form lignin. 
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Structural proteins  are classified in four major classes: hydroxyproline-rich 
glycoproteins, proline-rich proteins, glycine-rich proteins and proteoglycans [5,9]. All of 
these related proteins are located in different parts of the cell wall and interact with 
different wall polymers such as pectins, lignins, etc.  Structural proteins have been 
proposed to function in development, wound healing, plant defense, plant vascular 
tissues, initial nucleus lignification, cell division control, cell adhesion, XG-cellulose 
matrix locking, etc [5,20].  
Primary cell walls are classified into two types (I and II) depending on the cross-
linking glycans (hemicelluloses) that they contain: Type I primary cell walls, in which 
xyloglucan is the most abundant hemicellulose material, are present in dicots and in 
almost half of all monocots. Type II primary cell walls, where the major cross-linking 
glycans are glucuronoarabinoxylans, and are present in the “commelinoid” line of 
monocots. In this study we will focus on the type I primary cell wall. 
 
6. – Cellular architecture 
The primary cell wall type I is made of two or sometimes three different but 
interacting networks: The XG-cellulose network, the pectin matrix and the structural 
protein network.  
The XG-cellulose network  is, in dry weight, the most abundant constituent of 
plant cells. The XG matrix is thought to position cellulose microfibrils and has been 







Figure 5 . Graphical representation of cell wall architecture. 
 
XG-cellulose interactions were studied by determining the quantity of XG 
recovered from cell walls using different extraction protocols. Thereby, different XG 
domains could be defined depending on the strength of the extraction protocol 
implemented and which may also indicate the cellulose interaction strength [12,13,23,25].  
Briefly three XG domains will be described: 
1. The first XG domain extracted from cell walls is by treatment with specific 
XG-endoglucanases; This XG domain forms cross-links between different cellulose 
microfibrils, locking them into correct spatial arrangement. These connecting fragments 
have been observed by electron microscopy [21]. 
2. The second XG domain is extractable with basic solutions and has been 
proposed to bind the exposed faces of cellulose microfibrils by hydrogen bonding.  
Also, the second XG domain is covalently linked with the first XG domain.  
3. The third XG domain seems to be entrapped in cellulose microfibrils since it 
is only extractable by cellulase digestion of cell wall material.  Once the two first XG 
domains are extracted from cell walls, cellulases can break the cellulose structure 
liberating the third XG domain. This entrapped XG could also be covalently connected 
with the first domain, but to a lesser extent.  It seems that the third XG domain, in 
conjunction with cellulose microfibrils, has a lower stiffness and   greater extensibility in 




The XG-cellulose matrix is mostly responsible for the final cell wall structure and 
seems to have a major role in cell-wall structural modifications.  
The XG-cellulose network is embedded in a pectin matrix (Figure X above) 
which controls different physiological properties (pH, porosity, etc.). The pectin matrix is 
cross-linked by Ca2+ junctions, interacting with the non-methylated carboxylates of 
pectin polysaccharides. The spacing of these junctions defines the cell wall pore size. 
Modification of the pore size, conversely modifies diffusion of cell wall enzymes and 
molecules [5,18,21] . 
The third cellular architecture network which can be present is the structural 
protein network . The structural protein network is able to interact with the pectin 
network or form intermolecular bridges without necessarily binding to the 
polysaccharide components, although in some cases covalent links between 
polysaccharides and structural proteins have been described [5,16] (Figure 5 above). 
The structural protein network seems to have a definite role in cell expansion while 
other roles in plant defense, initial lignification, cellular division control, and XG-
cellulose matrix locking when cell wall extension ceases, etc [5,21]. 
 
7. – Plant cell wall expansion  
Although the cell wall is responsible for plant cell strength and rigidity, it also 
has to be extremely flexible and dynamic in order to allow the huge changes 
experienced by a plant cell during its life. Cells can expand a thousand fold from their 
original length, while maintaining their cell wall thickness [5]. Thereby, indicating the 
existence of a coordinated action of different cell wall loosening enzymes and 
deposition of nascent material.  
 There is a general agreement that the cellulose-XG network serves to 
hold the primary cell wall together and is the key determinant of wall extensibility 
[5,7,21,27-29]. Current hypotheses propose that modification of the cellulose-XG network is 
the key process controling cell wall extensibility. Clearly, the deposition of new wall 
material is necessary to maintain wall strength and wall thickness during extension.  
 In the present work, a basic enzymatic plant cell wall model will be 
presented.  In this model, 4 distinct wall-modifying enzyme classes which seem to have 
important roles in cell wall modification and expansion are presented. Of specific 
interest are two of the following four wall-modifying enzyme classes (Polysaccharide 
hydrolases and Xyloglucan endotransglycosylases / hydrolases ( XTHs):  
1) Expansins  were identified as mediators of acid-induced wall extension [30,31], 
and is one of the only enzyme classes that directly modulates wall mechanical 




between wall polysaccharides, acting as a kind of “molecular grease” allowing 
polymers to slide between them [24,32]. 
2) Yieldins  are characterized by their ability to lower the threshold for extension 
(minimum force or pressure necessary to drive the extension of cell wall) [33,34]  
although their mode of action has still not been revealed. 
3) Polysaccharide hydrolases  are present in cell walls and they are able to 
hydrolyze the major components of the cell matrix. Then, it is easy to think of these 
enzymes as being possible actors in cell wall loosening due to the hydrolysis of load-
bearing links between cellulose microfibrils.  Numerous genes encoding secreted, 
soluble hydrolases have been isolated from various plant species and assigned 
specific roles in cell wall loosening associated with fruit ripening, abscission and 
elongation. While a new group of plant hydrolases consist of membrane-anchored 
endo-1,4-β-glucanases, the specific function of membrane-anchored hydrolases is 
currently unknown, but located at the plasma membrane they seem to be acting on the 
innermost layers of the cell wall and may play a role in cell wall biosynthesis during cell 
wall assembly [35-38]. 
4) Xyloglucan endotransglycosylases / hydrolases ( XTHs) are proposed to 
have a key role in all changes that xyloglucan polymers experience during cell 
expansion.  Since repeated cleavage of the xyloglucan network would weaken the cell 
wall, the reformation of xyloglucan bonds must be of equal importance [39].  A strict 
hydrolytic activity would result in irreversible bond breakage whereas bond breakage 
during growth has been shown to be reversible [40]. Therefore, an enzyme which has 
the ability to not only cut the xyloglucan network, but also expand the network was 
proposed responsible for cell wall loosening and subsequent growth.  The enzyme 
xyloglucan endotransglycosylase (XET) has been proposed for this function [41-43].  By 
forming a stable (covalent) glycosyl-enzyme complex XET can transfer and expand 










Figure 6 . Hypothesized XET catalyzed transglycosylation causing cell wall expansion. 
First XET binds to a XG polymer (A) which acts as a tether between two microfibrils, next, XET 
cuts the XG molecule forming a stable intermediate and allows intra-microfibril movement (B). 
Finally, another XG molecule, acting as an acceptor, liberates the XG-XET intermediate 
reforming a tether between microfibrils [29]. 
 
XET activity and XET gene expression can be found in almost, if not all, 
expanding plant cells [42-49].  Furthermore, specific XET genes have been shown to be 
up-regulated by the growth-promoting hormones auxin, gibberellins, and 
brassinosteroids [50-54]. XET has also been implicated in the wall degradation of fruit 
ripening and wall strengthening during thigmomorphogenesis [55-57]. However, XET 
activity does not always correlate with growth rate, and XET activity has also been 
detected in vegetative tissues that have ceased to elongate [58-60].  
 
8. – XET substrate nomenclature 
Since the xyloglucan endotransglycosylases / hydrolases (XTHs) wall-modifying 
enzyme class is of specific interest in this work, the nomenclature for xyloglucan 
oligosaccharide XET substrates will be further discussed. In order to rationalize and 
facilitate the descripition of XG related structures the following nomenclature was 




(XGOs) have a β-(1→4)-glucopyranosyl backbone, while some are substituted with one 
or more additional residues.  In the proposed nomenclature, a code letter is defined for 
each glucosyl residue in the backbone depending on the pattern of side-chain 
substitution as it is described in the following list [61] (Table 1): 
 















Table 1: Codification for XG related structures. The code names each glucose in the 
backbone and the side chain substitution it presents. 
 
One code-letter is assigned to each glucose on the backbone with its branching 








As example, the given names of the following xyloglucan oligosaccharides are: 
 
 
Figure 7 . Examples of specific nomenclature of some xyloglucan oligosaccharides. 
 
9. – Carbohydrate Active Enzymes 
 Simple and complex carbohydrates have been described as “the last 
frontier of molecular and cell biology” [49].  Both the extreme chemical and functional 
diversity of carbohydrates and the difficulties in characterization of the substrates and 
the enzymes themselves reflects an enormous challenge in the post-genomic era [62]. 
These so called “carbohydrate active enzymes” (CAZymes) are involved in a vast 
myriad of cellular processes ranging from synthesis and modification of carbohydrates 
to degradation of oligosaccharides and polysaccharides.  However, carbohydrate 
active enzymes can be classified into unique enzymatic families by comparison of 
amino acid sequence similarity, enzyme mechanism (stereochemistry), catalytic 
apparatus and global three-dimensional structure [63].    
Not always conserved within families are substrate specificity and activity. The 
sequence derived families, in contrast to some classification systems, have enormous 
predictive power [63].  Active site residues, molecular mechanism and 3-D structure are 
all conserved within families. This has major implications in drug design; for example, 
inhibitors designed to interact with conserved features of active centers, such as 
inversion or retention mechanisms, have implications across a wide range of enzymes 
within a sequence based family [64]. 
There are currently 112 classified glycoside hydrolase carbohydrate active 
enzyme families containing both glycosylase and transglycosylase activities.  The 































































































































families with the activity of annotated enzymes and 3-D structural representation (if 
available).  It is very difficult to have a definitive census of how many carbohydrate 
active enzymes are present in the genome of any one species due to the constant 
revision, modifications, and additions of genomic sequences, but it is thought that 
approximately 3% of the Arabidopsis coding genome codes for CAZymes [65]. 
 
10. – Family 16 
All members of carbohydrate active enzyme family 16 are highly structurally 
related and share the same catalytic motif -DEIDFEGL-.  However, members of family 
16 display different substrate specificity; although sharing a common catalytic 
mechanism with retention of the sugar moiety α-carbon configuration.  Family 16, of the 
carbohydrate active enzymes, is composed of all hydrolases  (1,3-1,4-β-Glucanase, 
1,3-β-Glucanase, carrageenase, agarase, etc...) except one transferase  Xyloglucan 
endotransglycosylase (XET).  The 3-dimensional structure of XET has recently been 
resolved and the structure shows very high homology with the other members of family 




















Figure 8 . Carbohydrate active enzyme family 16 3-D structural comparison: β-
glucanase with β-glucan hexasaccharide substrate (left).PttXET16A with xyloglucan 
disaccharide (right). Substrates shown in blue licorice.  
 
 
11. – Xyloglucan endotransglycosylases 
 
11.1. - XET kinetic assays  
Since XET is of specific interest in this scientific work the kinetic assays used 
for XET characterization will be discussed in more detail. There are three main types of 




exploitation of XET transglycosylase activity. Measuring transglycosylase activity is 
difficult due to both the substrate and product of a transglycosylase being 
indistinguishable. That is, there is no change in substrate reducing ends, and also no 
change in substrate structure.  
The methods usually employed for transglycosylase activity measurement 
include dye staining, radio-labeled acceptor substrates, and/or xyloglucan 
disproportioning reaction. 
 
11.1.1. - Dye staining  
The dye staining method of observing XET activity relies on the addition of a 
high ratio of low molecular weight xyloglucan oligosaccharides to a low ratio of high 
molecular weight xyloglucan polysaccharides.  By the transferase activity of XET, the 
high molecular weight polysaccharides will decrease in size as the low molecular 
weight oligosaccharides slightly increase in size [66].   
This evolution of size can be observed by the addition of a chemical dye which 
can bind to the polymer substrate, but not the monomer substrate [67]. For example, 
both Congo Red dye and Iodine have the unique property of being able to form a 
visible complex with high molecular weight polymers, while conversely lacking the 
ability to form a complex with low molecular weight monomers.  Therefore, by following 
the loss of Congo Red or Iodine intensity, as the average molecular weight decreases, 
the transferase activity of XET can be observed. 
 
11.1.2. - Radio labeled acceptor substrate  
 XET activity can be measured by use of radioactive xyloglucan 
oligosaccharides and polymeric xyloglucans as acceptor and donor substrates, 
respectively [68]. The radioactive oligosaccharids are synthesized by labeling the 
position 1 Hydrogen of the reducing terminal glucosyl unit with 3H (tritium) thereby 
creating an [reducing terminus-1-3H] (RT-1-3H) xyloglucan molecule.  The reaction 
mixture contains xyloglucan polymer and 3H xyloglucan oligosaccharide. The reaction 
is terminated by the addition of acid, and applied to filter paper followed by drying and 
subsequent washing in running tap water to remover free/unbound 3H xyloglucan 
oligosaccharide. The transglycosylase activity is quantified by measuring the 
radioactivity adsorbed on the filter paper by scintillation counter [68]. 
Radio labeled acceptor products are the most widely used on XET studies, since 
they allows accurate measurement of the reaction progress and also permit 




labeled acceptors (14C-fucosylated [69], 3H-labelled [70-74], and fluorescently labeled 
acceptors [75]). 
 
11.1.3. - Xyloglucan disproportioning reaction 
 This procedure relies on both donor and acceptor substrates with a 
defined Mr distribution profile. The fixed molecular weight donor and acceptor substrate 
are incubated with the enzyme; at given time points the reaction is stopped by boiling 
water bath, freezing or acid and the reaction product resolved by gel permeation 
chromatography.  The enzymatic reaction causes the broadening of the original 
xyloglucan peak. The xyloglucan peak broadening is the result of the transfer of large 
segments of xyloglucan from one xyloglucan donor molecule to another xyloglucan 
acceptor molecule; producing higher and lower Mr xyloglucan products than the starting 
substrate [72].  
 
11.1.4. - Encumbrance of transferase activity monit oring  
 Since XET cuts chains of xyloglucan and transfers the new reducing end 
to another xyloglucan acceptor, no net gain of reducing ends is generated.  Therefore 
conventional reductometric methods for glycoside hydrolases cannot be used to 
monitor XET’s transferase activity.  Moreover, multiple turnovers of the polymeric donor 
substrate render a complex enzymatic behavior that prevents detailed XET kinetic 
analysis [76]. 
 
11.1.5. - Overcoming transferase activity monitorin g hurdles 
 The evident drawbacks of transferase activity monitoring have recently 
been overcome by employment of an activity assay based on High Performance 
Capillary Electrophoresis (HPCE).  A donor substrate of low molecular weight 
xyloglucooligosaccharide and acceptor substrate of the heptasaccharide XXXG 
derivatized with 8-aminoaphtalen-1,3,6-trisulphonic acid (ANTS) are used in the 
reaction mixture. The ANTS label is transferred from the acceptor substrate to the 
reaction product providing an electronic charge for the differential migration in capillary 
electrophoresis, and a chromophore/fluorophore for spectrophotmetric detection. 
Thereby multiple turnovers of the donor substrate are inhibited allowing for the in-depth 
study of mechanistic action and enzymatic subsite recognition [76]. 
 
11.2. - PttXET16A   
Since comparison of up-regulated mRNA expression levels during secondary 




xyloglucan endotransglycosylase 16A (PttXET16A) was a key enzyme that effected 
wood fiber composition, and also XET is the ONLY transferase  in carbohydrate active 
enzyme family 16, this enzyme was elected for future investigational studies. 
Therefore, a more in-depth discussion of PttXET16A characteristics follows.  
 
11.3. - PttXET16A  mechanism 
The activity of PttXET16A is such that it cleaves a β-(1-4) bond in the backbone 
of a xyloglucan molecule and transfers the xyloglucanyl segment onto an O-4 of the 
non-reducing terminal glucose acceptor residue.  This transglycosylase activity always 
occurs via retaining mechanism. The retaining mechanism involves two inverting steps 
that give a net retention of the sugar anomeric carbon.  XET cleaves the xyloglucan 
donor molecule in two, and forms a covalent substrate-enzyme intermediate.   
Subsequently, XET transfers the newly formed reducing end of the donor molecule to 
the non-reducing end of the acceptor xyloglucan molecule [77].  In the framework of the 
EDEN project, our group has established that the kinetic mechanism of PttXET16A is a 
ping-pong bi-bi mechanism with competitive inhibition by the acceptor substrate (AB) 
on binding to the free enzyme (E), and inhibition by the donor substrate (C) on binding 
to the acceptor subsites of the intermediate complex (Figure 9).  
 
 
Figure 9 . Proposed enzymatic ping-pong mechanism of XET. Note that elongation of 
the xyloglucan polysaccharide occurs by the preferential transfer of xyloglucan subunits through 
the XET-XG glycosyl-enzyme intermediate to other xyloglucan saccharides [76]. 
 
The known XET acceptors can range from polysaccharide xyloglucan molecule 
to a saccharide consisting of three glucose units with two xylose units attached [76]. 
 
11.4. - PttXET16A  subsite mapping and specificity 
Enzymes that bind oligomeric substrates have an extended binding site 
composed of subsites. One subsite is defined as the set of amino acid residues in the 
binding site that interact with one unit of the substrate. 
Subsites are named using negative numbers starting from the catalytic 




numbers starting from the scissile glycosydic bond to the reducing end [77]. For XET, 
roman numerals are used to identify the glucosyl backbone position and also each 
xylosyl substitution is named with the same roman numeral assigned as the branched 
glucosyl unit however primed (Figure 10). 
 
- III - II - I- IV +I +II +III +IV
Glc – Glc – Glc – Glc – Glc – Glc –Glc -Glc
Xyl XylXyl Xyl Xyl Xyl
-IV’ -III’ -II’ +I’ +II’ +III’
 
Figure 10.  XET subsite numbering with a bound xyloglucan oligosaccharide. 
  
Recently in our group, by mapping the PttXET16A enzyme binding site with a 
xylogluco-oligosaccharide library, the minimal substrate requirements of XET have 
been elucidated. Donor substrate kcat/km values show that a GG-XXG with the “-“ being 
the bond cleaved for transfer as the minimal donor substrate required for enzymatic 
activity [78]. 
 Also, donor binding is dominated by the higher affinity of a XXXG moiety for 
positive subsites than for negative subsites; resulting in relaxed negative subsite 
substrate specificity as seen by the free energy contributions shown in Figure 11.  In 
addition, the best xylogluco-oligosaccharide donor, with the highest kcat/km values, was 




- 2.1 - 1.5 ~ 0 ~ 0
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Xyl XylXyl Xyl Xyl Xyl
+0.2 - 0.3
- 0.2






-IV    -III     -II     -I      +I     +II    +III   +IV  
Figure 11.  PttXET16A subsite free energy contributions. Contributions are given in 
kcal/mol, negative values indicate stabilization while positive values indicate destabilization.  
 
11.5. - PttXET16A  pH profile  
The pH-dependence of PttXET16A enzymatic activity has been analyzed by 
High Performance Capillary Electrophoresis (HPCE) at 30ºC using 1 mM donor 
XXXGXXXG  and 5 mM XXXG-ANTS acceptor.  Maximum activity was detected 




catalysis with a single ionization curve at high pH values with a kinetic pKa of 6.1. At 
lower pHs, a rapid loss of activity was observed. Enzyme inactivation at pH < 5 has 
previously been observed for PttXET16A using standard iodine assays with XG 
substrate [66].  This enzyme inactivation at pH < 5 seems to be common feature of 











Figure 12.   pH profile of PttXET16A using XXXGXXXG donor and XXXG-ANTS acceptor [79]. 
 
11.6. - XET temperature profile 
The temperature dependence of PttXET16A (Figure 13) was evaluated at pH 
5.5, using the same donor and acceptors as used for the pH profile [79]. Maximum 
activity was observed between 30 and 40ºC, followed by rapid inactivation at higher 













Figure 13.   Temperature profile of PttXET16A using XXXGXXXG donor and XXXG-ANTS 
acceptor [79]. 
 



























Even though PttXET16A has a temperature optima between 30 and 40ºC, the 
temperature range of XTH activities are quite large. There are some cold tolerant 
XTHs, for example At-XTH22 shows more than 50% activity at -5 ºC [72]. Likewise, the 
enzymes At-XTH14 and At-XTH22 have maximum activities near 18 ºC [80].  Other 
XTHs have their maximum activity between 20-30 ºC, while maintain up to 80% of their 
activity at 45 ºC [80]. 
 
12. - β-glucanase 
In order to compare exactly which characteristics grant PttXET16A the ability to 
be a strict transferase in a family of hydrolases and also accept branched substrates 
while other Family 16 members cannot, another Family 16 Carbohydrate Active 
Enzyme was chosen.  This enzyme, 1,3-1,4-β-glucanase, has had a rich history of 
investigation in our laboratory and was therefore a logical choice as a comparative 
enzyme.  The exact characteristics of 1,3-1,4-β-glucanase follows. 
 
12.1. - The role and history of 1,3-1,4- β-glucanase 
 The endo-glycosidase 1,3-1,4-β-glucanase is responsible for the 
degradation of 1,3-1,4-β-glucan polysaccharides in plants, bacteria, and fungi.  One of 
the roles which 1,3-1,4-β-glucanase plays within the plant, is the enzymatic 
depolymerisation of 1,3-1,4-β-glucans in the germination phase [81, 82].  In bacteria and 
fungi, 1,3-1,4-β-glucanase is secreted into the environment in order to degrade 
polysaccharides for use as an energy source. The 1,3-1,4-β-glucanase family is of 
biotechnological importance due to its role in the malting process of both beer and 
livestock food stuffs [83, 84].  Normally, endogenous 1,3-1,4-β-glucanase is heat-
inactivated during the malting process leaving large quantities of non-hydrolyzed  high 
molecular weight β-glucans.  These high molecular β-glucans reduce yields of extracts, 
lower filtration rates and decrease digestibility of barley based livestock diets.  To 
overcome the heat-inactivation of endogenous β-glucanase and increase hydrolysis, a 
thermostable bacterial 1,3-1,4-β-glucanase is artificially added [85].  
1,3-1,4-β-glucanase is the most active enzyme among the endo-glycosidase 
family [86].  Specific activities range from 1200-4500 µmol min-1mg-1 with Km values from 
0.8-2.0 mg ml-1 depending on substrate and reaction conditions.   
One 1,3-1,4-β-glucanase, which is routinely used, is the family 16 carbohydrate 
active enzyme, Bacillus licheniformis 1,3-1,4-β-glucanase.  Bacillus licheniformis 1,3-




optimum of 550C [87]. The Bacillus β-glucanase contains a native secretion signal [88]. 
Also, due to the enzyme’s inherent stability, activity is maintained at elevated 
temperatures. 
 
12.2. - 1,3-1,4-β-glucanase mechanism 
Like XET, Bacillus 1,3-1,4-β-glucanase acts by glycosidase retaining 
mechanism [60].  Bacillus 1,3-1,4-β-glucanase undergoes a double-displacement 
reaction by use of a general acid-base catalysis. The first step involves the nucleophile 
amino acid displacing the aglycon in an inversion reaction resulting in the formation of 
a covalent glycosyl-enzyme intermediate.  The second step involves the attack of a 
water molecule to the glycosyl-enzyme intermediate resulting in a free saccharide with 
retention of anomeric configuration.   Transglycosylation reactions are possible, 
however kinetically unfavorable and in direct competition with hydrolysis.  Therefore, 














Figure 14 . glycosidase enzymatic hydrolysis mechanism  
 
12.3. - 1,3-1,4-β-glucanase substrate 
1,3-1,4-β-glucanase exhibits a strict substrate specificity for hydrolysis of linear  
β-1,4 glycosidic bonds in 3-O-substituted glucopyranose units [86].  Figure 15 shows a 
chemical diagram of a β-glucan saccharide.  The resulting product from β-glucan 
hydrolysis is a complex mixture of low molecular weight oligosaccharides with a high 





















































Figure 15 . Chemical diagram of β-glucan saccharide. Note the lack of branched side-
chain saccharides. 
 
12.4. - 1,3-1,4-β-glucanase subsite mapping and specificity  
From 1,3-1,4-β-glucanase kinetic analysis, with a series of substrates with a 
varying degree of oligomerisation it has been deduced that the extended carbohydrate 
binding cleft is composed of four 4 negative (non-reducing end) subsites (subsites –IV 
to –I) and two positive (reducing end) subsites (subsites +I and +II).  Subsites –II to –IV 
and +II have a stabilizing effect on the enzyme-substrate transition state complex, in 
the rate-determining step leading to the glycosyl-enzyme intermediate, with subsite –III 
having the largest contribution (-3.5kcal mol-1) (Figure 16.). The substrate specificity 
and cleavage pattern indicates that subsites –III and –IV possess a certain degree of 







































Figure 16.   Subsite mapping and energetic contributions to transition state stabilization 
[86]. 
 
Based on the minimal structural requirements of natural polysaccharides to be 
hydrolyzed by 1,3-1,4-β-glucanase, a series of low molecular weight oligosaccharide 
derivatives with and without chromogenic aglycons have been synthesized for kinetic 
studies and a minimum G3G-X core structure was found necessary for efficient 









-1) km (mM) kcat/km (M
-1 s-1) 
G-MU   0.348 ± 0.008 
G3G-MU 0.138 ± 0.012 16.8 ± 2.2 8.27 ± 1.80 
G4G3-MU 4.58 ± 0.06 2.69 ± 0.06 1700 ± 60 
G4G4G3-MU 8.86 ± 0.10 0.79 ± 0.02 11200 ± 500 
G4G4G4G3-MU 8.78 ± 0.20 0.66 ± 0.03 13300 ± 900 
G4G3G4G-OMe 304.2 ± 6.4 2.72 ± 0.14 (112 ± 8) x 10 3 
G4G3G4G4G-OMe 729.2 ± 31.7 3.69 ± 0.30 (197 ± 25) x  103 
G4G3G4G4G4G-OMe 735.0 ± 19.2 3.62 ± 0.19 (203 ± 16)  x 103 
G3G4G3G-OMe 17.1 ± 1.3 7.77 ± 0.85 2200 ± 400 
G3G4G3G4G3G-OMe 333 ± 39 3.82 ± 0.74 (87 ± 27) x 10 3 
Table 2. Steady-state parameters of B. licheniformis 1,3-1,4-β-glucanase with low molecular 




12.5. - 1,3-1,4-β-glucanase pH profile  
Bacillus 1,3-1,4-β-glucanases normally have a pH optimum around neutrality (6-
7.5); however, some β-glucanases such as one found in Bacillus brevis have a pH 
optimum at 9 [95], while the alkalophilic Bacillus sp strain N137  retains >80% activity in 
a pH range of 7-12 [96]. Shown below is the B. licheniformis 1,3-1,4-β-glucanase pH 
profile (Figure 17) [97]. 
 
 
Figure 17 . pH profile B. licheniformis 1,3-1,4-β-glucanase kcat/km. Conditions: 11mM 
citrate, 11mM phosphate buffer for the pH range 4 to 8.3, 11mM TAPS for the pH range 8-10, 
0.1mM CaCl2, ionic strength to 0.1M with added KCl, 530C [97]. 
 
12.6. - 1,3-1,4-β-glucanase temperature profile  
Bacillus 1,3-1,4-β-glucanases  show elevated temperatures for optimal enzyme 
activity which vary from 45oC for B. polymyxa [98], 55oC for B. licheniformis [99], B. 
amyloliquefaciens [100], and B. subtilis [100], to 65oC for B. macerans [100], B. brevis [95] 
and B. sp.  N137 [96]. Shown below is the B. licheniformis 1,3-1,4-β-glucanase specific 






Figure 18 . Specific activity of wild-type B. licheniformis 1,3-1,4-β-glucanase at different 
temperatures [99]. Conditions: citrate-phosphate buffer pH7.0; 6mg/mL β-glucan: enzyme 





13.1. - Oligo- and polysaccharide synthesis by glyc osynthases  
Uses of conventional synthetic chemistry approaches have been insufficient for 
the stereo- and regio- specific synthesis of polysaccharides due to the vast number of 
possibilities for the combination of monomeric units [102].  Therefore, in vitro 
polysaccharides synthesis by enzymatic catalysis has received considerable attention 
[103, 104]. 
The use of native glycosidases has proved disappointing for the synthesis of 
polysaccharides since the yields rarely exceed 50% due to the hydrolysis of glycosidic 
linkages [86]. However, a novel enzymatic approach to oligo/polysaccharide synthesis 
has recently been advanced by use of specifically engineered retaining glycosidases, 
called glycosynthases [105 108].  Glycosynthases are enzymes which have had their 
catalytic nucleophile removed, rendering them incapable of catalyzing the hydrolysis of 
glycosidic linkages.  But by mimicking the covalent glycosyl-enzyme intermediate with 
an activated glycosyl donor of the opposite anomeric configuration as the normal 


















Figure 19 . Saccharide synthesis by a nucleophile-less glycosynthase with an activated 
glycosyl donor. 
 
Oligo/polysaccharide synthesis yields have reached as high as 90-98% by use 
of glycosynthases.  In addition, regio- and stereo- specific polysaccharide chains of up 
to an average of 46 glucosyl units have been successfully synthesized [106].  Besides 
the practical interest of polysaccharide synthesis, glycosynthases can be used for the 
in vitro enzymatic synthesis of new biomaterials with defined structures that either 
mimic natural polysaccharides or have unnatural structures and functionalities [102, 107]. 
 
13.2. - Glycosynthase kinetic assays 
In order to monitor glycosynthase activities, the following kinetic assays were 
employed in this investigational work:  
 
13.2.1. - HPLC monitorization 
For glycosynthase kinetic analysis, a hydrophobic stationary phase was utilized.  
As the glycosynthase reaction progresses, the product hydrophobicity increases, which 
likewise allows the synthesized glycosynthase products to be easily identifiable from 
the starting donor and acceptor products by use of a hydrophobic interaction column.  
For UV detection, the acceptor substrate was labeled with a chromophoric 4-
nitrophenyl group.  Therefore, the glycosynthase kinetic parameters could be 
analytically quantified [109]. 
 
13.2.2. - Fluoride selective electrode monitoring 
Ion-selective electrodes (ISEs) have been shown to be very useful for 
monitoring analytical reactions for kinetic analysis. These electrodes can monitor either 
one of the reactants or products of a reaction without any serious interference from the 
co-existing substances. Therefore, the combination of kinetic methods of analysis with 






































Since fluoride ions are released as the glycosynthase reaction progresses 
(Figure 19 above), monitoring the evolution of fluoride ions with a fluoride selective 





































Two general objectives are proposed: 
 
1. Immobilized Glycosynthases for solid-phase enzym atic synthesis of 
oligosaccharides (Chapter 1).  
 
In order to improve the protein production yield and introduce a affinity tag for 
immobilization, the Bacillus licheniformis 1,3-1,4 β-glucanase enzyme was inserted into 
a vector containing a polyhistidine-tag. The polyhistidine-tag can be utilized for 
immobilization of proteins on surfaces containing nickel or cobalt and therefore is ideal 
for construction of a immobilized biocatalyst. 
 
2. β-glucanase-XET chimera. Engineering enzyme specific ity from a β-glucan to 
a xylogluco-oligosaccharide acting enzyme (Chapters  2 and 3).  
 
The creation of a family 16 carbohydrate active enzyme β-glucanase/XET 
hybrids will be attempted in order to design a chimeric enzyme with one or more of the 
following altered properties: specificity, activity, and or stability.  
The two enzymes, Bacillus licheniformis 1,3-1,4-β-glucanase and Populus 
tremula x tremuloides xyloglucan endotransglycosylase, are members of the same 
enzymatic family and have highly homologous 3-dimensional structures (Figure 8).  
However, the enzymes exhibit different activities, one a hydrolase the other a 
transferase; different specificities, one accepts only linear glcosydic substrates while 
the other branched substrates; and different stabilities.  
Hybrid enzyme construction represented an investigational challenge in order to 
understand what physical characteristics of both enzymes attribute to the specific 
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CHAPTER 1,  Immobilized biocatalyst 1,3-1,4- β-glucanase vector construction  
Bacillus licheniformis 1,3-1,4-β-glucanase and its glycosynthase mutant E134A 
are expressed in a pUC-derived vector under the control of a Lac promoter and 
containing a Bacillus signal peptide for secretion to the extracellular medium.  In order 
to improve the protein production yield and introduce a affinity tag for immobilization, 
the Bacillus licheniformis 1,3-1,4 β-glucanase enzyme was inserted into a vector 
containing a polyhistidine-tag. The polyhistidine-tag can be utilized for immobilization of 
proteins on surfaces containing nickel or cobalt and therefore is ideal for construction of 
a immobilized biocatalyst. 
Further removal of the catalytic nucleophile (Glutamate 134) of the retaining 
1,3-1,4-β-glucanase by mutation to alanine yields an enzyme with no wild-type 
glycosidase activity. However, the alanine mutant is able to catalyze the regio- and 
stereospecific glycosylation of α-laminaribiosyl fluoride with different glucoside 
acceptors through a single-step inverting mechanism. The main advantage of the 
mutant as glycosylation catalyst with respect to the kinetically controlled 
transglycosylation using the wild-type enzyme is that the reaction products cannot be 
hydrolyzed by the mutant enzyme, and the yields of glycosylation rise to 90%. 
Once the Bacillus licheniformis 1,3-1,4 β-glucanase enzyme contained both the 
polyhistidine-tag and catalytic nucleophile mutation, it could be employed for the 
continuous synthesis of oligosaccharides with mixed β-1,3- and β-1,4-linkages by 
immobilized biocatalyst methods.  
Three β-glucanase vector constructs were fabricated: 
1. C-terminal His-tag and V5 epitope (pET101/D-TOPO-β-glucanase). 
2. N-terminal His-tag and Factor Xa protease recognition site (pET16b-β-
glucanse-His). 
3. Wild-type enzyme, with no affinity tag and under the T7/lac promoter 
system (pET16b-β-glucanase-No-His). 
 
First, the C-terminal His-tag experimental design and characterization will be 
discussed followed by discussion of the N-terminal His-tag and wild-type enzyme 
experimental design and characterization respectively. 
 
1.1.  β-glucanase C-terminal His-tag experimental design 
The pET101/D-TOPO® vector (Figure 20) features a linearized, topoisomerase 
I-activated pET expression vector for directional cloning of blunt end PCR fragments. 
Furthermore, the pET101/D-TOPO®, vector carries a T7/lac promoter for subsequent 
high-level expression in E. coli. The T7/lac promoter contains a lac operator sequence 
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immediately downstream of the T7 promoter for added regulation of basal expression, 
and the vector carries the low-copy pBR322 origin of replication to further reduce basal 
expression levels in the uninduced state.  Additionally, the pET101 vector contains a C-
terminal V5 epitope for protein identification by antibody conjugation, and a C-terminal 
6xHis-tag for immobilized metal ion affinity chromatography purification and for the 




Figure 20 .  The pET101/D-TOPO vector contains two covalently bound topoisomerase 
for simplified gene insertion and a C-terminal V5 epitope and 6xHis-tag.  Gene expression is 
regulated by the T7/lac promoter.  
 
In order to add the recombinant attributes mentioned above, the 
pET101D/TOPO vector was elected for subsequent cloning of Bacillus licheniformis 
1,3-1,4 β-glucanase (Figure 21).  
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Figure 21 . The C-terminal His-tag, pET101/D-TOPO-β-glucanase vector construct. 
Insertion of the Bacillus licheniformis 1,3-1,4 β-glucanase gene into the pET101/D vector for 
immobilized biocatalysis. Note the presence of two Aat II restrictions sites upon β-glucanase 
insertion. 
 
The forward oligonucleotide employed for β-glucanase PCR amplification added 
the start codon (ATG) to β-glucanase since the template β-glucanase gene from the 
pD62-β-glucanase vector contained a signal peptide for extracellular transport (see 
Introduction) which was not needed.  Also a 5´ CACC nucleotide sequence was added 
to the forward primer for in-frame TOPO insertion.  
The reverse oligonucleotide employed for β-glucanase PCR amplification 
removed the template stop-codon in order to continue transcription of the V5 epitope 
and 6xHis-tag. The exact oligonucleotide sequences and predicted annealling 
temperatures can be found in the “Primers List” section. 
The gene corresponding to β-glucanase was PCR amplified using a blunt-end 
polymerase for subsequent TOPO insertion. Once the optimum amplification conditions 
(Figure 22) were ascertained, the TOPO-β-glucanase gene PCR product was agarose 
gel extracted. 
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Figure 22.   Optimum PCR amplification conditions of TOPO-β-glucanase.  Lane 1 DNA 
Molecular Weight Marker III, Lane2 Tm=45oC, Lane 3 Tm=45.5oC, Lane 4 Tm=46.7oC Lane 5 
Tm=48.2oC, Lane 6 Tm=50.5oC, Lane 7 Tm=53.4oC, Lane 8 Tm=56.7oC, Lane 9 Tm=59.6oC, 
Lane 10 Tm=61.8oC, Lane 11 Tm=63.4oC, Lane 12 Tm=64.60C, Lane 13 Tm=65oC.Note the 
optimum PCR amplification conditions were considered to have an annealing temperature of 
63.40C (Lane11).  
 
The agarose gel extracted TOPO-β-glucanase PCR product was incubated with 
the pET101D/TOPO vector following the Invitrogen pET Directional TOPO Expression 
Kits Manual protocol for gene insertion. Subsequently, DH5α E. coli cells were 
transformed with the reaction mixture and transformant colonies were grown, harvested 
and their DNA purified.  The DNA was then restriction digested with the Aat II 
restriction enzyme for confirmation of gene insertion and correct orientation (observe 
pET101 vector map shown above). For correct insert orientation a 1022 bp fragment 
and a 5376 bp fragment are created after digestion whereas for incorrect insert 
orientation a 638 bp fragment and a 5760bp fragment are produced (Figure 23). 
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Figure 23 .  1% Agarose gel with ethidium bromide staining of Aat II restriction digested 
TOPO transformant colonies dsDNA. Here, in lanes 8, 11, 13, 14, and 15 the correct gene 
insertion and orientation can be observed. 
 
After confirmation of correct β-glucanase gene insertion and orientation, the 
final pET101D/TOPO-β-glucanase nucleotide sequence was verified by the Big Dye 
Terminator Sequencing reaction v2.0. 
 
1.2.  β-glucanase C-terminal His-tag characterization  
Once the proper nucleotide sequence was attained, a congo red activity assay 
was conducted in order to verify the hydrolytic activity of β-glucanase after the addition 
of a V5 epitope and 6xHis-tag. The congo red activity assay is a quick and easy 
method for verification of hydrolytic enzymatic activity.  Congo red binds carbohydrate 
polymers however it does not bind to low molecular weight oligomers.  Therefore if 
depolymerization of β-glucan occurs, the condo red will leave depolymerized halos 
corresponding to β-glucanase hydrolytic activity (Figure 24). More information on the 
“Congo red activity assay” can be found in the “Methods” section. 
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Figure 24.   Congo red plate assay. Agar plate with 1mg β-glucan, stained with congo 
red and counter stained with 100mM acetic acid. Quadrant 1 pET101-β-glucanase induction 
time 0 intracellular soluble 10uL, Quadrant 2 15uL phosphate buffer, Quadrant 3 pET101D-No 
insert 6h induction with 1mM IPTG intracellular soluble 10uL, Quadrant 4 pET101-β-glucanase 
2 hours induction time 0.2mM IPTG intracellular soluble 10uL, Quadrant 5 pET101-β-glucanase 
2 hours induction time 0.5mM IPTG intracellular soluble 10uL, Quadrant 6 pET101-β-glucanase 
2 hours induction time 1.0mM IPTG intracellular soluble 10uL, Quadrant 7 pET101-β-glucanase 
4 hours induction time 0.2mM IPTG intracellular soluble 10uL, Quadrant 8 pET101-β-glucanase 
4 hours induction time 0.5mM IPTG intracellular soluble 10uL, Quadrant 9 pET101-β-glucanase 
4 hours induction time 1.0mM IPTG intracellular soluble 10uL.  Note: Hydrolase activity (halo) 
was detected at all time points of pET101-β-glucanase induction. 
 
Hydrolytic activity corresponding to β-glucanase was confirmed by observation of 
depolymerized β-glucan halos stained with Congo red. 
A pilot recombinant expression was performed to for subsequent enzyme 
purification.  The pilot expression consisted of transforming chemically competent 
BL21DE3 E. coli cells with the pET101-β-glucanase vector and subsequently 
inoculating 100 mL of lysogeny broth with a single transformant colony.  Next, the 
culture was grown overnight (37oC 250rpm), until the stationary growth phase was 
reached. The next morning β-glucanase expression was induced with IPTG at varying 
final concentrations (0.05, 0.2, 0.5, and 1mM). Time point aliquots were taken and the 
intracellular soluble fraction was analyzed by PAGE with Coomassie staining (Figure 
25 and 26 below).  
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Figure 25.  pET101/D-TOPO-β-glucanase pilot expression analysis of the intracellular 
soluble fraction by PAGE with Coomassie staining.  Lane1 Low range marker, Lane 2 pET101-
No-insert 0h induction (negative control), Lane 3 pET101-No-insert 6h induction 1.0mM IPTG 
(negative control II), Lane 4 pET101-β-glucanase 0h induction, Lane5 pET101-β-glucanase 2h 
induction 0.05mM IPTG, Lane6 pET101-β-glucanase 4h induction 0.05mM IPTG, Lane7 
pET101-β-glucanase 6h induction 0.05mM IPTG, Lane8 pET101-β-glucanase 2h induction 
0.2mM IPTG, Lane9 pET101-β-glucanase 4h induction 0.2mM IPTG, Lane10 pET101-β-
glucanase 6h induction 0.2mM IPTG. 
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Figure 26 .  pET101/D-TOPO-β-glucanase pilot expression analysis of the intracellular 
soluble fraction by PAGE with Coomassie staining. Red Arrow marks β-glucanase production.  
Lane 1 pET101-No-insert 6h induction 1.0mM IPTG (negative control), Lane 2 Low range 
marker, Lane 3 pET101-β-glucanase 2h induction 0.5mM IPTG, Lane4 pET101-β-glucanase 4h 
induction 0.5mM IPTG, Lane 5 pET101-β-glucanase 6h induction 0.5mM IPTG, Lane 6 pET101-
β-glucanase 2h induction 1.0mM IPTG, Lane 7 pET101-β-glucanase 4h induction 1.0mM IPTG, 
Lane 8 pET101-β-glucanase 6h induction 1.0mM IPTG, Lane 9 blank, and Lane10 pET101-β-
glucanase 6h induction 1.0mM IPTG insoluble fraction. 
 
Upon analysis of β-glucanase expression, the expression conditions which 
produced the largest amount of intracellular soluble protein occurred with 0.5mM IPTG 
after 6 hours of induction.  Also, two forms of β-glucanase of different molecular 
weights seemed to appear overtime (which will be discussed in more detail later).  
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Consequently, it seemed that in Figure 26 lane 10 that the two forms of the insoluble β-
glucanase ran a little slower due to the differences in salt concentrations between the 
soluble and insoluble aliquots. 
Once expression conditions were sufficiently set, a pilot His-tag affinity 
chromatography purification was performed. The pilot purification consisted of 
expressing β-glucanase with the aforementioned best expression conditions, followed 
by resuspending the cellular pellet in Binding Buffer (20mM Tris-HCl, 0.5M NaCl pH 
8.0). Next, the cells were ruptured by sonication and the intracellular soluble and 
insoluble fractions separated by centrifugation. The intracellular soluble fraction was 
subsequently charged onto a pre-equilibrated 1 mL HiTrap™ chelating HP column. 
Finally, a linear Elution Buffer (20mM Tris-HCl, 0.5M NaCl, 0.5M Imidazol pH 8.0) 
gradient was applied for selective elution of the recombinant β-glucanase protein.   The 
resulting purified fractions can be seen below in Figure 27. 
 
1       2         3        4       5        6        7         8 9      10
 
Figure 27.   14% PAGE with Coomassie staining of pET101D-β-glucanase pilot affinity 
purification. Lane 1 Low Range Marker, Lane 2 Positive Control (previously purified β-
glucanase), Lane 3 intracellular soluble protein sample, Lane 4 column flow-through fraction, 
Lane 5 and 6 primary elution peak pertaining to non-specifically bound proteins, Lanes 7, 8, and 
9 secondary elution peak pertaining to β-glucanase, Lane 10 insoluble pellet. Note that 
presence of three distinct molecular weight proteins present in the secondary elution peak. 
 
As seen in the figure above, the secondary elution peak (lanes 7, 8, and 9) do 
not contain a pure protein product but rather 3 different proteins of varying molecular 
weight. Two of these three protein bands can also be seen to increase with time in the 
previous pilot expression polyacrylamide gel. 
In order to confirm the identity of these three protein bands seen in the 
secondary elution peak, a β-glucan zymogram was realized [110].  First, duplicate 14% 
polyacrylamide gels of the β-glucanase pilot purification were made containing β-
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glucan.  Then one gel was stained with Coomassie (Figure 28) while the other gel was 
processed to ascertain hydrolytic activity by the zymogram method (Figure 29). Lastly, 
the two gels were superimposed in order to identify protein bands positive for hydrolytic 
activity (Figure 30). Please see the methods section for more details on zymograms.  
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Figure 28 . Zymogram polyacrylamide gel with Coomassie staining. Lane 1  low range 
protein standards, Lane 2 previously purified β-glucanase (positive control), Lane 3 protein 
sample, Lane 4 column flow-through, Lanes 5 and 6 primary elution peak, Lanes 7, 8, and 9 
secondary elution peak, Lane 10 insoluble pellet. 
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Figure 29 . Zymogram polyacrylamide gel with congo red staining. Lane 1  low range protein 
standards, Lane 2 previously purified β-glucanase (positive control), Lane 3 protein sample, 
Lane 4 column flow-through, Lanes 5 and 6 primary elution peak, Lanes 7, 8, and 9 secondary 
elution peak, Lane 10 insoluble pellet. Note hydrolase activity detected for the positive control, 
precharge, and secondary elution peaks. 
 
Results and Discussion  
44 
1      2      3       4      5        6       7          8  9        10
 
Figure 30 . Zymogram overlay of the polyacrylamide gel with Coomassie and Congo red 
staining. Lane 1  low range protein standards, Lane 2 previously purified β-glucanase (positive 
control), Lane 3 pre-charge, Lane 4 flow-through, Lanes 5 and 6 primary wash peak, Lanes 7, 
8, and 9 secondary elution peak, Lane 10 insoluble pellet. Note in lanes 7, 8, and 9 hydrolytic 
activities for both protein bands are observed. 
 
In the zymogram overlay, high amounts of hydrolytic activity can be seen in the 
elution peak fractions so much in fact that the whole lane trail was voided of β-glucan 
polymers, the result of enzymatically active β-glucanase traveling through the gel. 
However, it can be noted that the two protein bands seen in the secondary elution peak 
have hydrolytic activity. 
In an effort to separate the two isoforms of pET101D-β-glucanase observed 
during the previous His-tag purification, the linear imidazole elution gradient was 
decreased by half.  The resulting purified fractions can be seen in the following gel 
electrophoresis (Figure 31).   
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Figure 31 .  14% PAGE with Coomassie staining of pET101D-β-glucanase purification 
with decreased imidazole elution gradient slope. Lane 1, previously purified β-glucanase 
(positive control), Lane 2 low range protein standards, Lane 3-7 secondary elution peak 
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fractions pertaining to low molecular weight β-glucanase, Lanes 8-10 tertiary elution peak 
fractions pertaining to high molecular weight β-glucanase. With sequential fraction collection it 
can be observed the delayed elution of the higher molecular weight β-glucanase isoform. 
 
As seen above, the lower molecular weight isoform eluted before the higher 
molecular weight isoform.  This shorter elution time is possibly the result of proteolytic 
processing of part of the C-terminal His-tag. That is, loss of some Histidine residues 
results in less affinity for the HiTrap™ column which corresponds to a shorter elution 
and lower molecular weight. 
The eluted fractions of the decreased imidazole gradient slope His-tag 
purification were pooled into three aliquots. One aliquot containing exclusively low 
molecular weight β-glucanase, another with mixed high and low molecular weight β-
glucanase, and lastly one aliquot containing exclusively high molecular weight β-
glucanase.  The three aliquots were subsequently dialyzed into 87mM phosphate, 
6.5mM citric buffer pH7.2 with 100µM CaCl2 and assayed for hydrolase activity by the 
“Congo red activity assay” (Figure 32).  
 
 
Figure 32.  Congo red plate β-glucan hydrolase activity assay. For the three aliquots of 
the pooled purified fractions (High, Low, and Mixed molecular weight β-glucanase), hydrolase 
activity was detected (red circles) whereas no hydrolase activity was detected in the negative 
control (bottom right). 
 
Since hydrolytic activity of both the high and low molecular weight isoforms 
were observed, it was decided to precisely measure the molecular weight of both 
samples in order to understand exactly which amino acids were being lost due to 
proteolytic processing.  Therefore, Matrix Assisted Laser Desorption /Ionization - Time 
Of Flight (MALDI-TOF) mass spectrometry was employed.  The protein samples sent 
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for analysis and the resulting MALDI-TOF chromatograms can be seen below (Figures 
33 and 34). 
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Figure 33.   SDS-PAGE Low and high molecular weight β-glucanase samples sent for 
MALDI-TOF. Lanes 1-3 blank, Lane 4 low range protein standards, Lane 5 low molecular weight 
β-glucanase, Lane 6 blank, Lane 7 high molecular weight β-glucanase, Lane 8 blank, Lane 9 
mixed molecular weight β-glucanase, Lane 10 blank. The hand-drawn 21.5 and 31 with arrows 
mark the 21.5 kD and 31 kD protein standards. 
 
 
Figure 34.  MALDI-TOF chromatograms of high and low molecular weight β-glucanase 
isoforms. The top chromatogram shows the molecular weight of 28034.214 Daltons for the high 
molecular weight β-glucanase sample. The lower chromatogram shows a molecular weight of 
20870.069 Daltons for the low-molecular weight β-glucanase sample. 
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The theoretical molecular weight of the pET101D-β-glucanase was 28026.1 
Daltons which corresponds to the high molecular weight sample. However, the low 
molecular weight sample was 7164 Daltons less than the expected full-length 
theoretical weight.  A loss of 7164Da is as if 53 amino acids or 21% of the total protein 
length was lost (using an average amino acid molecular weight of 135Da). The MALDI-
TOF molecular weight calculated for the low molecular weight sample does not to be 
correct since no protein band can be observed below the 21.5kD protein standard as 
seen in the SDS-PAGE above (Figure 33). 
While able to confirm that the high molecular weight sample corresponded to 
the full length C-terminal His-tag protein, the exact cause of the lower molecular weight 
sample was not determined.  However, both β-glucanase isoforms were seen to be 
hydrolytically active. 
In order to have a homogeneous β-glucanase fraction for immobilized 
biocatalysis it was decided to change expression vectors.  Rather than expressing β-
glucanase with a C-terminal His-tag, an N-terminal His-tag expression vector was 
elected. 
 
1.3.  β-glucanase N-terminal His-tag experimental design  
In order to eliminate the two β-glucanase isoforms seen while using the 
pET101/D-TOPO vector, a new vector was acquired which carries an N-terminal His-
tag thereby switching the His-tag position from the C-terminal to the N-terminal and a 
Factor Xa protease recognition site for His-tag removal. Other features of the pET16b 
vector by Novagen are similar to that of pET101/D, having aT7/lac promoter for high-
level expression and lac operator sequence immediately downstream of the T7 
promoter for added regulation of basal expression. While also carrying the low-copy 
pBR322 origin of replication to further reduce basal expression levels in the uninduced 
state (Figure 35). 
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Figure 35.   The pET16b expression vector by Novagen carries an N-terminal His-tag 
sequence followed by a Factor Xa protease recognition site and three cloning sites.  Unique 
restiriction sites are shown on the map.  Note that the sequence is numbered by the pBR322 
convention so the T7 expression region is reversed on the circular map. 
 
For insertion of β-glucanase into the pET16b vector, two primers called N-
terminal and C-terminal primers were developed containing unique restriction sites.  
The N-terminal primer added an Xho I restriction site followed by removal of the start 
codon.  The C-terminal primer added a stop codon followed by a Bpu1102I restriction 
site. (Figure 36). Note, upon insertion of the β-glucanase gene into the pET16b vector, 
the T7 reverse primer binding site was altered. Therefore the commercially available T7 
reverse primer is non-functional hence a new primer was designed and designated as 
the pET16b-reverse primer.  
 












T7 Promoter primer 










Figure 36.  The pET16b-β-glucanase-His vector containing N-terminal His-tag and 
Factor Xa site.  Note the flanking Xho I and Bpu1102I restriction sites. 
 
 The β-glucanase gene was subsequently amplified by polymerase chain 
reaction by use of the two aforementioned primers (N- and C-terminal) and template 
dsDNA β-glucanase coding sequence from the previously developed pD62-1,3-1,4- β-
glucanase vector. Following PCR amplification, the gene was agarose gel extracted. 
Next, both the vector and insert were double restriction digested using the Xho I and 
Bpu 1102I restrictions enzymes and agarose gel extracted another time (Figure 37). 
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Figure 37 .  1% Agarose gel of Xho I and Bpu 1102I double digested β-glucanse (Gel I 
lanes 6 and 7) and pET-16b vector (Gel II lanes 7, 8, and 9). 
 
After successful vector and insert double digestion and extraction, both vector 
and insert were mixed and ligated using the T4 ligase. Following ligation, chemically 
competent E. coli cells were transformed and the resulting transformant colonies were 
screened for insertion by PCR using primers (T7 promoter and pET16b-Reverse) 
flanking the insertion site (Figure 38).  
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Figure 38 .  1% agarose gel of flanking primer insertion screen of  transformant 
colonies. Lane 1 positive control (pET16b-∆Loop1-E134A-His in DH5α E. coli cells), lane 2 DNA 
molecular weight marker III, Lanes 3-7 transformant colonies, Lanes 8-10 blank.  Note gene 
insertion events in lanes 5 and 7 were detected. 
 
Colonies screened positive for β-glucanase insertion were subsequently bulked 
up for DNA purification and nucleotide sequenced. Two spontaneous nucleotide 
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mutations were detected. One nucleotide mutation (cytosine to adenine) was found to 
be near the center of the β-glucanase sequence, specifically changing amino acid 141 
from alanine to glutamate.  While the second nucleotide mutation (guanine to thymine), 
was found to be present in the N-terminal primer binding site resulting in a threonine to 
lysine amino acid change at amino acid number 26. 
Quite surprisingly, upon transformation of E. coli expression cells with the 
spontaneous nucleotide mutation dsDNA and assaying for β-glucan hydrolase activity 
by the “Congo red activity assay” hydrolytic activity was detected (Figure 39). 
 
 
Figure 39 .  Congo red plate assay of pET16b- β-glucanase-His transformant colonies. 
X73 and X75 (top quadrants) are the transformant colonies which tested positive for insertion by 
flanking primer PCR screening; positive control (bottom left quadrant) and negative control 
(bottom right quadrant). Note both X73 and X75 showed β-glucan hydrolytic activity 
(depolymerized halos). 
  
Even though hydrolytically active, oligonucleotides (E141A-sense and E141A-
antisense) and (K26T-sense and K26T-antisense) were designed in order to correct 
the aforementioned mutations. 
A site directed mutagenesis reaction (see Methods section) was performed to 
fix the A141E mutation, followed by Dpn 1 restriction nuclease digestion of the dam 
methylated template dsDNA. Next, chemically competent DH5α E. coli cells were 
transformed with the reaction product, and the resulting transformant colonies were 
bulked up for subsequent DNA purification. Lastly, the DNA from the transformant 
colonies was sequenced using the previously mentioned BigDye® sequencing kit. 
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A transformant colony with the corrected E141A nucleotide sequence was then 
used for the subsequent reparation of the T26K nucleotide mutation, following the 
same procedure as used for the E141A repair. 
 
1.4.  β-glucanase N-terminal-His-tag characterization  
In order to evaluate whether or not the two isoforms observed with the C-
terminal His-tag vector was eliminated, and in order find the expression conditions of 
the pET16b-β-glucanse-His vector construct, two pilot expression studies were 
completed. 
  The first pilot expression consisted of inducing transformed BL21DE3star E. 
coli cells with 1mM IPTG in the stationary growth phase (after overnight growth). Then, 
cellular aliquots were taken at times 0, 2, 4, and 6 hours. Next, the samples were 
centrifuged and the cell pellet resuspended in His-tag Binding Buffer (20mM Tris-HCl, 
0.5M NaCl pH 8.0). Subsequently, the cells were ruptured by sonication and the 
intracellular soluble and insoluble fractions were isolated by centrifugation.  Lastly the 
proteins of the samples were separated by 14% polyacrylamide gel electrophoresis 
(Figure 40). Note the insoluble pellet was solubilized in 10% SDS prior to running. 
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Figure 40 .  14% SDS-PAGE of a stationary growth phase pilot expression study of 
pET16b-β-glucanase-His construct. Gel I intracellular soluble : Lane 1 low range protein 
standard, Lane 2 pET16b-His 6 h induction (negative control), Lane 3 pET16b-β-glucanase-His 
0 h induction, Lane 4 pET16b-B-glucanase-His 2 h induction, Lane 5 pET16b-β-glucanase-His 4 
h induction, Lane 6 pET16b-β-glucanase-His 6 h induction. Gel II insoluble pellet  Lane 1 
pET16b-His 6 h induction (negative control), Lane 2 low range protein standard, Lane 3 
pET16b-β-glucanase-His 0 h induction, Lane 4 pET16b-β-glucanase-His 2 h induction, Lane 5 
pET16b-β-glucanase- His 4 h induction, Lane 6 pET16b-β-glucanase-His 6 h induction.  Note 
that the largest quantity of intracellular soluble N-terminal His-tag protein was observed after 4 
hours of induction, while the largest quantity of insoluble β-terminal His-tag protein was 
observed after 6 hours of induction. 
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The second pilot expression consisted of inducing transformed BL21DE3star E. 
coli cells with 1mM IPTG in the exponential growth phase, either with or without 1% 
glucose in the growth medium.  Addition of glucose was assessed for further 
repression of the Lac promoter until subsequently induced by IPTG.  Cellular aliquots 
were taken at times 0, 2, 4, and 6 hours. Next, the samples were centrifuged and the 
cell pellet resuspended in His-tag Binding buffer (20mM Tris-HCl, 0.5M NaCl pH 8.0). 
Subsequently, the cells were ruptured by sonication and the intracellular soluble and 
insoluble fractions were isolated by centrifugation. Lastly, the proteins of the samples 
were separated by 14% polyacrylamide gel electrophoresis (Figure 41). Note only the 
intracellular soluble fraction was analyzed by SDS-PAGE. 
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Figure 41 .  14% SDS-PAGE of an exponential growth phase pilot expression study of 
intracellular soluble pET16b-β-glucanase-His construct. Lane 1 pET16b-β-glucanase-His 
stationary growth phase 4 h induction (see Figure X above), Lane 2 low range protein standard, 
Lane 3 pET16b-β-glucanase-His (0% Glucose)0 h induction, Lane 4 pET16b-β-glucanase-His 
(0% Glucose) 2 h induction, Lane 5 pET16b-β-glucanase-His (0% Glucose) 4 h induction, Lane 
6 pET16b-β-glucanase-His (0% Glucose) 6 h induction, Lane 7 pET16b-β-glucanase-His (1% 
Glucose) 0 h induction, Lane 8 pET16b-β-glucanase-His (1% Glucose) 2 h induction, Lane 9 
pET16b-β-glucanase-His (1% Glucose) 4 h induction, and Lane 10 pET16b-β-glucanase-His 
(1% Glucose)  6 h induction. Note that there is very little difference between the quantities of 
recombinant protein expressed, using growth medium with or without 1% glucose. Also note 
that the largest quantity of recombinant protein is expressed after 6 h, however, it is less 
plentiful than that seen after 4 hours of induction in the stationary growth phase pilot expression 
(Lane 1). 
 
As seen in the three figures above, no protein isoforms were observed upon β-
glucanase N-terminal His-tag expression.  Also, the largest proportion of intracellular 
soluble pET16b-β-glucanase-E134A-His protein was detected after 4 hours of induction 
using the stationary growth phase transformed BL21DE3star E. coli cells.  However, 
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the largest quantity of insoluble protein was detected after 6 hours of induction using 
also, stationary growth phase BL21DE3star cells. 
It was decided that the expression conditions would consist of growing the cells 
until the stationary growth phase, inducing with 1mM IPTG, and harvesting after 4 
hours of induction.  
Once a homogeneous N-terminal His-tag protein sample was verified, the 
pET16b-β-glucanse-E134A-His glycosynthase vector in which the catalytic nucleophilic 
residue has been removed by mutation to alanine was completed (see Introduction).  
The pET16b-β-glucanse-E134A-His glycosynthase vector was prepared by the 
design of two oligonucleotides (E134A-Sense and E134A-Antisense) for subsequent 
site directed mutagenesis by means of mutating Glutamate 134 to Alanine.  Following 
site directed mutagenesis, the correct nucleotide sequence of the pET16b-β-glucanse-
E134A-His glycosynthase vector was confirmed. 
Also, since in further studies it was noted that the β-glucanase E134S 
glycosynthase mutant had a higher catalytic activity than that of the E134A 
glycosynthase, the pET16b-β-glucanse-E134S-His vector was also completed.  The 
E134S glycosynthase was prepared by the design of two oligonucleotides (E134S-
Sense and E134S-Antisense) for subsequent site directed mutagenesis. The template 
utilized was that of the pET16b-β-glucanse-E134A-His glycosynthase vector. 
Subsequently the correct nucleotide sequence was confirmed. 
Since, both the wild-type N-terminal His-tag vector and the E143A N-terminal 
His-tag vector showed the same expression characteristics, and the E143A 
glycosynthase mutant was to be subsequently used for immobilized biocatalysis,  
further characterization was done exclusively with the E134A vector.  
A Immobilized Metal Affinity Chromatography (IMAC) purification was 
attempted.  This purification consisted of using the aforementioned set expressions for 
a 1 Liter culture.  The cells were centrifuged, and the cell pellet resuspended in His-tag 
Binding Buffer (20mM Tris-HCl, 500mM NaCl pH8.0).  Next, the cells were ruptured by 
sonication and the soluble and insoluble fractions separated by centrifugation.  The 
intracellular soluble fraction was then injected into a precharged Ni2+ Sepharose 
HisTrap HP 5mL column. The column was subsequently washed, and then a linear 
imidazol gradient ranging from 0 to 500mM was applied.  Subsequent elution of the 
bound recombinant protein is shown by chromatogram below (Figure 42). Note that the 
primary elution peak is of nonspecifically bound proteins whereas the secondary elution 
peak is of the pET16b-β-glucanase-E134A-His recombinant protein. 
 





Figure 42 .  Chromatogram of pET16b-β-glucanase-E134A-His affinity chromatography 
purification.  The blue line represents 280nm absorbance units while the green line shows the 
linear imidazole gradient. The elution tube number are shown in red. Note the primary elution 
peak at 24.71 mL is of the non-specifically bound proteins whereas the secondary elution peak 
at 40.26mL is of the recombinantly expressed pET16b-β-glucanase-E134A-His protein. 
 
In order to evaluate the His-tag purification efficiency, samples of each of the 
purification steps were saved for subsequent analysis by SDS-PAGE with Coomassie 
stain (Figures 43 and 44).  
1        2        3        4       5        6       7       8   9       10
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Figure 43 .  14% SDS-PAGE with Coomassie stain of the pET16b-β-glucanase-E134A-
His protein purification shown in the chromatogram above (Gel I). Lane 1 Low range protein 
standard, Lane 2 previously purified protein (positive control), Lane 3 insoluble cell pellet, Lane 
4 protein standard, Lane 5 column flow-through, Lane 6 primary elution peak (tube A4), Lane 7 
primary elution peak (tube A5), Lane 8 primary elution peak (tube A8), Lane 9 secondary elution 
peak (tube A9), Lane 10 secondary elution peak (tube A10). 
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Figure 44 .  14% SDS-PAGE with Coomassie stain of the pET16b-β-glucanase-E134A-
His protein purification shown in the chromatogram above (Gel II). Lane 1 secondary elution 
peak (tube A11), Lane 2 low range protein standard, Lanes 3-10 secondary elution peak (tubes 
A12-B6). 
 
Upon analysis of the aforementioned chromatogram and polyacrylamide gels, it 
was concluded that the gradient slope needed to be decreased by approximately half in 
order to fully separate the primary elution peak of the non-specifically bound proteins 
from that of the secondary elution peak containing the recombinant protein (lanes 8 
and 9 Gel I).   Besides this small change the purification proved to be quite successful. 
A recombinant protein recovery yield of 23 milligrams per liter of culture was attained.  
The purified pET16b-β-glucanase-E134A-His protein was then dialyzed into 
ultra-pure H2O for subsequent storage by lyophilization.  Unlike most other proteins, 
the recombinant protein was 100% soluble in the ultra-pure water, and was 
successfully lyophilized.  Likewise, the lyophilized protein was later solubilized with no 
precipitation or aggregation noted. 
Since the majority of β-glucanase was found to be in the insoluble cell fraction, 
a inclusion body purification and refolding was attempted (see Methods section).  The 
protocol consisted of disruption, wash and isolation of inclusion bodies followed by 
sample solubilization and preparation, preparation of the column, and lastly purification 
and refolding. The protocol calls for 8-0M urea gradient to refold the column-bound 
recombinant protein.  However, column refolding was unsuccessfully due to the 
formation of protein aggregates in the column. Instead, the recombinant protein was 
eluted in its denaturized state and subsequently dialyzed into His-tag Binding buffer 
(20mM Tris-HCl, 0.5M NaCl pH 8.0) in an attempt to refold the protein.   
The first assays of refolding by dialysis were also unsuccessful until it was 
realized that Ca2+ is necessary in the refolding buffer for β-glucanase to properly refold. 
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Ca2+ is necessary since β-glucanase has a calcium binding site, and if this site is left 
vacant the protein becomes highly unstable. Once calcium was added to the dialysis 
buffer (87mM phosphate, 6.5mM citric buffer pH7.2 with 100µM CaCl2), the β-
glucanase protein was refolded 100%. Below is the chromatogram of β-glucanase 
inclusion body purification in a denaturized state (Figure 45) followed by a 
polyacrylamide gel of the subsequently dialysis refolded β-glucanase protein (Figure 
46). 
 















Figure 45 .  Chromatogram of pET16b-β-glucanase-E134A-His insoluble inclusion body 
purification. The blue line represents 280nm absorbance units while the green line shows the 
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Figure 46 .  14% SDS-PAGE with Coomassie stain of the of pET16b-β-glucanase-
E134A-His insoluble inclusion body purification. Lane 1 low range protein standards, Lane 2 
protein sample, Lane 3 column flow-through, Lanes 4-10 recombinant β-glucanase elution peak 
fractions.  Note that the protein sample is almost completely pure β-glucanase with no other 
proteins observed.  Also note that the high molecular weight protein seen in wells 4-7 is the 
result of the sample being so highly concentrated that it aggregated in the presence of the 
PAGE charge buffer, effectively forming β-glucanase dimers as can be noted by the doubling of 
the molecular weight. 
 
After successfully purifying and refolding the insoluble β-glucanase fraction, the 
quantity of recombinant protein was calculated by absorbance at 280nm, resulting in 28 
milligrams of purified protein from a 1 liter culture.   Therefore, both the soluble and 
insoluble fractions of the pET16b-β-glucanase-E134A-His protein purification could be 
successfully. 
In order to insure that the pET16b-β-glucanase-E134A-His protein was properly 
folded, a urea denaturation curve was attempted.  First, the glycosynthase, which was 
thought to be properly folded, was scanned for the wavelength at which the maximum 
emission fluorescence occurred in 0M urea (see Methods section).  The maximum 
emission fluorescence value recorded occurred at 340nm (Figure 47).  Thereby, the 
urea unfolding could be effectively monitored by the decrease in fluorescence at 
340nm. 





























pET16b-B-glucanase-E134A-His phosphate citric pH7.2 CaCl2
 
Figure 47 .  Fluorescence scanning of pET16b-β-glucanase-E134A-His in 0M urea at 
wavelengths from 300 to 500nm. Note the maximum fluorescence intensity occurred at 340nm. 
 
A urea equilibrium denaturation assay was conducted (see Methods section). 
The assay consisted of β-glucanase in 87mM phosphate, 6.5mM citric buffer pH7.2 
with 100µM CaCl2 incubated at 37
oC for 16 hours in the presence of different urea 
concentrations ranging from 0 to 8 molar. Then the sample’s fluorescence intensity was 
analyzed with excitation at 280nm and emission at 340nm. Figure 48, below, shows the 
resulting plotted fluorescence intensity versus urea concentration.  


















Figure 48 . Urea unfolding curve of both intracellular soluble β-glucanase-E134A 
(magenta) and refolded inclusion body β-glucanase-E134A (orange). Note data uniformity and 
singular inflections are recovered. 
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1.5. Analysis of β-glucanase equilibrium urea denaturation 
The stability of the β-glucanase enzyme reported in this study was assumed to 
follow a two-state transition denaturation model.  Unfolding was monitored by 
measuring the dependence of fluorescence in the presence of the denaturant e.g. urea.  
Equilibrium denaturation data were analyzed using the Clarke and Fersht model 
(1993), where the free energy of the unfolded protein in the prescence of denaturant 
(∆GUD) is linearly dependent of the denaturant concentration (Pace 1986),  
 
(1) ∆GUD = ∆GUH2O – m*[D] 
 
 Where GU
H2O is the value of the apparent free energy of unfolding in the 
absence of denaturant, [D] is the concentration of denaturant, and m (=δ∆GU/δ[D]) is 
the slope of the transition.  The equilibrium constant (KU) for unfolding at a given 
denaturant concentration for a two-state model is evaluated from the fluorescence data 
as 
  
(2) KU = (FF – F)/(F – FU)  
 
Where FF and FU are the fluorescence of the folded and unfolded forms, 
respectively, and F the measured fluorescence.  FF and FU are considered to be 
linearly dependent upon denaturant concentration,  
 
(3) FF = αF + βF*[D],  FU = αU + βU*[D] 
 
Where αF and αU are the intercepts and βF and βU the slopes of the baselines at 
low (F) and high (U) denaturant concentrations.  By combining equations 1, 2, and 3, 
the dependence of the measured fluorescence on denaturant concentration is given by: 
 
(4) F = [(αF + βF*[D]) + (αU + βU*[D])*exp{m([D] – [D50%])/RT}]/[1 + exp{m[D] – 
[D50%])/RT}] 
 
Where [D50%] is the concentration of denaturant at which 50% of the protein is 
unfolded.  Fitting the data to equation 4 gives the calculated values for [D50%] and m, 
from which the apparent free energy of unfolding (equation 1) in the absence of 
denaturant is calculated as 
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(5) ∆GUH2O = m*[D50%] 
 
The m values are know to be subject to large standard errors because the 
model assumes that Equation 1 holds over the entire range of urea concentrations,  as 
previously noted by Clarke and Fersht (1993).  Although reasonable accurate values of 
∆GUH2O may be derived, the extrapolations are over too wide a range of denaturant 
conditions so that small errors in the slope m result in large errors in the estimation of 
∆GUH2O. Therefore the intrinsic values of ∆GUH2O noted in the table below are 
estimations at best. The standard error of ∆GUH2O was calculated as follows: 
  
(6) ±SE ∆GUH2O= ∆GUH2O*[(±SEm/m) + (±SE[D50%]/[D50%])] 
 
Where ±SE ∆GUH2O is the standard error of ∆GUH2O and ±SEm is the standard 
error of m and ±SE[D50%] is the standard error of [D50%]. 
 
Protein m (kcal/mol/M)  [D50%] (M) 
Intracellular soluble pET16b-β-glucanase-His 3.37± 0.58  3.80±0.03 
Refolded pET16b-β-glucanase-His 2.90± 0.31  3.68±0.02  
pD62-β-glucanase** 1.20± 0.08  4.68±0.05 
 
Table 3 .  Equilibrium urea denaturation data for intracellular soluble and refolded pET16b-β-
glucanase-E134A in comparison to pD62-β-glucanase.  **Note pD62-β-glucanase denaturation 
data was derived from the work of Jaume Pons, Antoni Planas, and Enrique Querol [111]. 
 
A direct comparison of ∆GUH2O values between pD62-β-glucanase and 
intracellular soluble β-glucanase and refolded inclusion body β-glucanase are 
precluded due to significantly different m values, possibly due to slight differences in 
the experimental conditions.  However,  ([D50%] values show that the N-terminal His-tag 
protein is slightly less stable, probably due to the addition of a Factor Xa recognition 
site and His-tag.  
Even though the pET16b-β-glucanase-E134A is less stable than the pD62-β-
glucanase, the overall differences between the two recombinant enzymes are slight. 
Additionally, it is possible to conclude that the pET16b-β-glucanaseE134A is properly 
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1.6. β-glucanase N-terminal His-tag glycosynthase activit y 
 
As shown in the Introduction, glycosynthases are enzymes which have had 
their catalytic nucleophile removed, rendering them incapable of catalyzing the 
hydrolysis of glycosidic linkages.  But by mimicking the covalent glycosyl-enzyme 
intermediate with an activated glycosyl donor of the opposite anomeric configuration as 
the normal substrate, the glycosynthase can catalyze its transfer to another sugar 
residue.   
Glycosynthase enzymatic studies were initiated by Fluoride Selective Electrode 
Monitoring using pET16b-β-glucanase-E134A (11.2µM final concentration), a fluoride 
activated glycosyl donor G4G4G3G-αF (5mM final concentration), and a glycoside 
acceptor G4G-Mu (5mM final concentration).  Below, the chemical reaction of the two 








































































Figure 49 . Glycosynthase (E134A) catalyzed reaction of G4G4G3G-αF and G4G-Mu. 
Note fluoride liberation as the reaction progresses. 
 
All reactions were carried out in 87mM phosphate, 6.5mM citric buffer pH7.2 
with 100µM CaCl2.  Kinetics of fluoride release were monitored with a fluoride selective 
electrode (Figure 50) while sodium fluoride standards for calibration curves were 
prepared under the same experimental conditions. The negative control, both the 
alpha-fluoride donor and acceptor saccharides in the reaction mixture using the same 
reaction conditions but without enzyme, measures spontaneous hydrolysis of the 
fluoride donor. 
 





















Figure 50 .  Glycosynthase activity studies of pET16b-β-glucanase-E134A-His 
monitored by fluoride liberation. The negative control was alpha-fluoride donor and acceptor 
saccharides without enzyme. Note the evolution of saccharide products overtime is consistent 
with the liberation of fluoride by the E134A-His enzymatic activity. 
 
 The specific activity of pET16b-β-glucanase-E134A v/[E] = 0.3 s-1 at saturating 
5 mM donor and acceptor concentration was similar to that observed previously with 
the untagged enzyme [109]. Therefore, the addition of an N-terminal His-tag had no 
effect of enzyme specific activity. 
Since pET16b-β-glucanase-E134A showed glycosynthase activity, continuous 
oligosaccharide synthesis, with mixed β-1,3- and β-1,4-linkages by immobilized 
biocatalyst methods, was subsequently confirmed in a proof of concept work 
(Sellabona and Faijes, personal communication).  Further in-depth characterization of 
immobilized pET16b-β-glucanase-E134A glycosynthase activity is currently underway. 
 
1.7.  Native β-glucanase experimental design  
In order to develop a β-glucanase vector construct lacking the Factor Xa 
protease recognition site and His-tag peptide sequences, but controlled by aT7/lac 
promoter for high-level expression and lac operator sequence immediately downstream 
of the T7 promoter for added regulation of basal expression and also carrying the low-
copy pBR322 origin of replication for further reduction of basal expression levels in the 
uninduced state, the pET16b-β-glucanase-No-His vector was completed. 
The pET16b-β-glucanase-No-His vector was developed using the pET16b 
vector by Novagen as seen in the aforementioned pET16b-β-glucanase-His vector 
section (Figure 35). To construct the pET16b-β-glucanase-No-His vector, 
oligonucleotides were designed that added unique restriction sites flanking the β-
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glucanase gene and which likewise removed the pET16b vector Factor Xa and His-tag 
nucleotide sequences.   
Specifically, the N-terminal primer (pET16b-No-His-N-term primer) added an 
alanine to the N-terminal β-glucanase sequence in order to conserve the unique Nco I 
restriction site for subsequent cloning.  Since the wild-type Bacillus licheniformis β-
glucanase contains an alanine upstream of the β-glucanase gene, coding for the last 
amino acid of the signal peptide, the addition of alanine was considered to be optimal. 
Therefore, the alanine addition is as if one amino acid of the Bacillus licheniformis 
signal peptide was still present.  
Since the C-terminal region of both the pET16b-β-glucanase-His and the 
pET16b-β-glucanase-No-His vectors are homologous, the C-terminal primer designed 
for the pET16b-β-glucanase-His vector containing the Bpu1102 I restriction site could 
be used for both constructions.  
Once the N- and C-terminal oligonucleotides were received a polymerase chain 
reaction was carried out in order to assess the optimum primer annealing temperature 
by use of a thermal gradient ranging from 45 to 65oC (Figure 51). 
 
1    2    3    4    5    6    7    8    9  10   11  12  13  14   15   16
 
Figure 51 .  Optimum annealing temperature PCR of the N- and C-terminal primers for 
subsequent pET16b-β-glucanase-No-His cloning. Lane 1 DNA Molecular Marker III, Lanes 2-13 
PCR thermal gradient products ranging from 45oC to 65oC, Lane 14 DNA Molecular Marker III, 
and Lanes 15, 16 blank.   Note that amplification occurred throughout the temperature range. 
However in lane 13 (Tm = 65oC) a cleaner PCR product was observed.   
 
After attaining the optimum annealing temperature for β-glucanase PCR 
amplification (Tm = 65oC),   β-glucanase was subsequently bulked up by PCR 
amplification, double restriction digested with Blp I and Nco I and agarose gel extracted 
(Figure 52). 
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Figure 52 .  1% agarose gel of β-glucanase PCR amplification using the pET16b-β-
glucanase-No-His N- and C-terminal primers. Lane 1 DNA Molecular Marker III, Lanes 2-5 β-
glucanase.No-His amplification product Blp I and Nco I restriction digested. 
 
Likewise, the pET16b vector was double restriction digested using the same 
restriction enzymes as were used for digestion of β-glucanase (Blp I and Nco I). 
Subsequently the digested vector was agarose gel extracted (Figure 53). 
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Figure 53 .  1% agarose gel of double restriction digested pET16b vector for 
subsequent β-glucanase insertion. Lane 1 non-digested pET16b dsDNA, Lane 2 Xho I Blp I 
previously digested and agarose gel extracted pET16b vector, Lane 3 DNA Molecular Marker 
III, and Lanes 4-6 Blp I and Nco I restriction digested pET16b vector. 
 
The vector and insert were mixed and ligated using T4 Ligase. Subsequently, 
the reaction mixture was used to transform chemically competent DH5α E. coli cells.  
The transformant colonies were selected by ampicillin resistance and the surviving 
colonies screened for insertion by PCR (see Methods section) using primers flanking 
the insertion site (specifically the N- and C-terminal No-His primers). The reaction 
mixture was separated by a 1% agarose gel and subsequently stained with ethidium 
Results and Discussion  
66 
bromide. Colonies positive for insertion showed a PCR product corresponding to the 
molecular weight of β-glucanase (Figure 54). 
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Figure 54 .  1% agarose gel with ethidium bromide staining of gene insertion 
transformant colony screening.  Lane 1 pET16b vector (negative control), Lane 2 DNA 
Molecular Marker III, Lane 3 pET16b-B-glucanase-His (positive control) Lanes 4-8 PCR 
products of pET16b-β-glucanase-No-His transformant colonies 1-5, Lanes 9 and 10 blank. Note 
lanes 4, 5, and 6 are positive for β-glucanase insertion while lanes 7 and 8 are negative for 
insertion. 
 
The colonies positive for insertion were bulked up for DNA purification and 
subsequently nucleotide sequenced. Nucleotide sequencing showed that the pET16b-
β-glucanase-No-His vector was acquired. 
As noted in the N-terminal His-tag characterization section, the β-glucanase 
E134S glycosynthase mutant has a higher catalytic activity than that of the E134A 
glycosynthase; therefore the pET16b-β-glucanse-E134S-No-His vector was also 
completed.  The E134S glycosynthase was prepared by using the same two 
oligonucleotides (E134S-Sense and E134S-Antisense) implemented for pET16b-β-
glucanase-E134S vector construction. A subsequent site directed mutagenesis was 
carried out using the pET16b-β-glucanse-No-His vector as template and the two 
aforementioned oligonucleotides. Subsequently ,the correct nucleotide sequence was 
confirmed allowing for future expression and kinetic studies. 
 
1.8.  Native β-glucanase characterization  
The hydrolytic activity of the β-glucanase-No-His construct was confirmed by 
the “Congo Red activity assay” (see the methods section for more information).  
Chemically competent Bl21DE3 star recombinant expression E. coli cells were 
transformed with the pET16b-β-glucanse-No-His vector.  A single transformant colony 
was then re-plated onto a lysogeny broth agar plate containing ampicillin and β-glucan 
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polysacharrides, and subsequently incubated overnight at 37oC.  The next morning, the 
LB + β-glucan agar plate was stained using Congo red and the depolymerized β-glucan 
halos could be visualized (Figure 55).  
 
 
Figure 55 .  Congo red plate assay of pET16b-β-glucanase-No-His transformant colony. 
pET16b-B-glucanase-No-His transformant colony acted (top right quadrant), pET16b-β-
glucanase-His transformant colonies X73 and X75 (bottom quadrants).  Negative control (top 
left quadrant). Note the pET16b-β-glucanase-No-His transformant colony showed β-glucan 
hydrolytic activity (depolymerized halo). 
 
A pilot recombinant expression studied was completed. A single pET16b-β-
glucanase-No-His Bl21DE3star colony was added to lysogeny broth, containing 
ampicillin and incubated at 37oC with 250rpm overnight until the stationary growth 
phase was reached.  Then the cells were induced with a final concentration of 1mM 
IPTG, and time point aliquots taken; the time point aliquots were centrifuged, the cell 
pellet resuspended in His-tag Binding Buffer, sonicated, and re-centrifuged in order to 
separate the soluble and insoluble fractions.  The soluble fraction was then analyzed 
for recombinant expression by SDS-PAGE with Coomassie staining (Figure 56). 
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Figure 56.  14% SDS-PAGE with Coomassie staining of pET16b-β-glucanase-No-His 
pilot expression.  Lane 1 low range protein standards, Lane 2 pET16b-β-glucanase-No-His 
induction time 0, Lane 3 pET16b-β-glucanase-No-His 2h induction, Lane 4 pET16b-β-
glucanase-No-His 4h induction, Lane 5 pET16b-β-glucanase-No-His 6h induction. Note the red 
box marks recombinant β-glucanase expression.   Also note that the largest quantity of 
intracellular soluble β-glucanase is seen after 4 hours of induction. 
 
The pET16b-β-glucanase-No-His construct was successfully expressed and the 
largest quantity of intracellular protein was observed after four hours of induction, using 
the expression conditions noted above.  No further assays were completed with this 
construct.  However, the pET16b-β-glucanase-No-His vector was shown to be a viable 
expression vector for β-glucanase expression. 
 
In summary, the following vector library was completed: 
 
pET16b-β-glucanase-His 
• N-terminal His-tag 
• Factor Xa protease cleavage site (for removal of His-tag) 
• T7/lac promoter 
Notes: Purified and characterized. 
 
pET16b-β-glucanase-E134A-His 
• N-terminal His-tag 
• Factor Xa protease cleavage site (for removal of His-tag) 
• T7/lac promoter 
Notes: Purified and characterized. 
 
pET16b-β-glucanase-E134S-His 
• N-terminal His-tag 
• Factor Xa protease cleavage site (for removal of His-tag) 
• T7/lac promoter 
Notes: Purified and characterized. 
 
pET101D-TOPO-β-glucanase 
• C-terminal 6xHis-tag  
• C-terminal V5 epitope  
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• T7/lac promoter 
Notes: Formation of isoforms upon expression. 
 
pET16b-β-glucanase-No-His 
• T7/lac promoter 
Notes: Expressed but not characterized. 
 
pET16b-β-glucanase-E134S-His 
• T7/lac promoter 
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CHAPTER 2, Engineering of enzyme specificity: a β-glucanase and XET16A 
chimera.  
Populus tremula x tremuloides xyloglucan endotransglycosylase (PttXET16A) 
and Bacillus licheniformis 1,3-1,4-β-glucanase are both members of Family 16 
carbohydrate active enzymes however, widely differ in activity and substrate specificity.   
Even though 1,3-1,4-β-glucanase and XET16A share a mere 20.5% amino acid 
homology, observations of substantial tertiary structure conservation, the characteristic 
jellyroll β-sandwich of family 16, led to the question of what physical features distinguish 
one enzyme from another.  By creating hybrid enzyme combinations the elucidation of 
critical enzymatic domains and amino acids responsible for specificity and activity will be 
experimentally revealed. Therefore, hybrid enzymes between XET and 1,3-1,4-β-
glucanase were constructed in an effort to identify structural elements which confer both 
activity and specificity. 
 
2.1  ∆Loop1 Design 
The Visual Molecular Dynamics (VMD) program [114] was used to visualize the 3-
Dimensional structure of XET16A and β-glucanase.  By visualization, differences in the 
two structures can be seen leading to possible implications in specificity and activity. The 
3-D structures used for analysis are all from family 16 Carbohydrate Active Enzymes: 
the XET16A Populus tremula x tremuloides structure containing the xyloglucan 
Oligosaccharide (XGO) acceptor (transferase activity), and 1,3-1,4-β-glucanase Bacillus 
licheniformis (hydrolase activity). 
Upon analysis of the 3-D structures, there seemed to be two main areas of 
comparison in which the family 16 glycoside hydrolase lost homology with that of the 
transferase.  These two areas consisted of frontal facial loops and the connecting frontal 
β-strands. 
The largest structural deviation was found to be a frontal facial loop.  This loop 
will be subsequently referred to as loop1 due to it being the first beta turn frontal loop 
found from the N-terminal amino acid sequence. 
The β-glucanase structure contains a loop crossing the face of the enzyme with 
amino acids pointing into the active site and shows possible steric hindrance in the 
acceptance of branched side chain carbohydrate substrates.  Whereas, XET does not 
contain this loop and might be the reason that XET can accept a branched side chain 
substrate while the β-glucanase cannot.  The XET structure contains a β -turn going 
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straight into another β-strand with no amino acids facing the active site.  The 
superimposed 1,3-1,4-β-glucanase and PttXET16A structures are shown below with the 
loop1 regions for both enzymes highlighted (Figure 57).  
 
 
Figure 57.  Loss of 3-dimensional structural homology at the primary loop. The xyloglucan 
oligosaccharide is shown superimposed onto both 3-D structures (blue licorice). Note that the β-
glucanase clearly shows a frontal loop (red) crossing the enzymatic face while XET shows no 
such frontal loop (green).  
 
Further observations of the two 3-dimensional structures showed obvious 
branched substrate steric hindrance when the surface area of β-glucanase was mapped 
with the XET16A xyloglucan oligosaccharide, in the positive subsites, superimposed 
whereas the XET16A structure showed no such oligosaccharide hindrance (Figures 58 
and 59). 
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Figure 58.   PttXET16A 3-dimensional structure with xyloglucan oligosaccharide.  Note 
the open positive subsites (yellow) allowing for branched substrates acceptance into the catalytic 
cleft. 
 




Figure 59.   1,3-1,4-β-glucanase 3-dimensional structure with superimposed xyloglucan 
oligosaccharide.  Note the absence of open positive subsites (yellow and white) allowing for 
branched substrates acceptance into the catalytic cleft. Also note the clear steric hindrance of the 
xyloglucan oligosaccharide (blue licorice) in the catalytic cleft.  
 
3-Dimensional analysis of hypothetical loop1 removal from β-glucanase revealed 
a protein structure with high similarity to that of XET16A. The surface area of β-
glucanase was plotted for all amino acids except those present in loop1 (Figure 60).  
 





Figure 60.   Removal of β-glucanase loop1 surface area for the theoretical opening of the 
enzymatic cleft.  Loop 1 is illustrated by the violet tube surrounded by its surface area plotted 
transparently (black cloud). Note the removal of the loop1 surface area reveals an enzymatic cleft 
similar to that of XET16A. 
 
After extensive 3-dimensional analysis, in order to observe the effects of Loop1 
on specificity, activity, and stability, the decision was made to replace Loop1 of 1,3-1,4-
β-glucanase bacillus licheniformis for that of XET16A. 
There were two designs considered:   
The first replacement design (Option 1) conserved loop amino acid spatial 
alignment and secondary structure.  However, side-chain orientation was lost. That is, 
the side chain orientation was inverted 1800 in the process of conserving the amino acid 
spatial alignment.  In order to conserve the spatially aligned amino acids, the first and 
last amino acids of loop1, showing spatial alignment, were identified in the 3-D 
structures.  
The following table shows the 3-dimensional crystal structure amino acid 
sequences of the spatially aligned regions before and after loop1, the loop1 region for 
XET16A, β-glucanase, and the theoretical structure of the loop1 hybrid.  XET amino 
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acids #16-18 are homologous in spatial alignment, and tertiary structure with β-
glucanase amino acids #18-20, however non-homologous in side-chain orientation.  XET 
amino acids #24-27 are homologous in spatial alignment, and tertiary structure with β-





































Table 4.   Option 1 ∆Loop1 hybrid design: amino acid sequences of the spatially aligned 
regions before and after loop1 and the loop1 region for XET16A, β-glucanase, and the theoretical 
structure of the loop1 hybrid.  The amino acids highlighted in yellow show the start and finish of 
the spatial equivalent loop1 amino acids. Note that in the loop1 deletant hybrid the last amino 
acid of β-glucanase is Lysine20 followed by XET equivalent amino acids, then continuing with β -
glucanase amino acid homology after Serine40. 
 
In order to evaluate the feasibility of the Option 1 loop replacement, an amino 
acid structural analysis was performed using the Cerius package [Cerius² version 3.8 
(1998) © Molecular Simulations], by fixing the spatially homologous amino acids before 
and after the loop1 region and replacing the β-glucanase Loop1 with those of XET16A 
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Figure 61.   Option 1 loop replacement. Note that the presence of a non-planar peptidic 
bond (almost perpendicular) between Serine 40 (β-glucanase) and Histidine 23 (XET). This non-
planar peptidic bond is not repaired by small rotations of the loop. 
 
Upon structural analysis, it was noted that Serine 40 (glucanase) and Histidine 
23 (XET) showed torsional strain in the theoretical simulation.  The peptide bond is 
forced into a 900 angle resulting in a sterically hindered loop.  Even though option 1 
conserved spatial and structural alignment, this design was deemed sterically inoperable 
due to the induced change in side-chain orientation. 
To circumvent the problems encountered in Option 1 (non-planar orientation of 
the His23-Ser24/40 peptide bond), it was necessary to retain an additional β-glucanase 
residue, Val39, in the ∆loop1 hybrid. In this second option, side-chain orientation was 
conserved, 3-dimensional crystal structure spatial homology was not (Table 5). 
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Table 5.  Option 2 ∆Loop1 hybrid design: amino acid sequences of the spatially aligned 
regions before and after loop1 and the loop1 region for XET16A, β-glucanase, and the theoretical 
structure of the loop1 hybrid.  The amino acids highlighted in yellow show the start and finish of 
the spatial equivalent loop1 amino acids. Note the addition of β-glucanase Valine 39 recovers 
side-chain orientation while spatial homology was lost. 
 
In order to asses the feasibility of the theoretical design, a molecular dynamic 
simulation of the Loop1 region was conducted. The details of the simulation are 
described in the “Methods section”.  The torsional strain noted between Serine 40 (β-
glucanase) and Histidine 23 (XET) in Option 1 was removed by the addition of Valine 39 
(β-glucanase) as observed below (Figure 62). 
 





Figure 62.   Option 2 molecular dynamics simulation.  Note that the torsional strain of the 
non-planar peptidic bond seen in Option1 is alleviated by the addition of Valine39 (β-glucanase). 
The addition of Valine 39 restores amino acid side chain orientation homology while amino acid 
spatial alignment is lost.  
 
Once the simulation was conducted, the loop 1 amino acid backbone showed 
little movement and no torsional strain. Phenylalanine 23 was noted to have the most 
liberal side chain movement (more than the other exposed β-glucanase phenylalanines). 
Also observed in the simulation, there is a possible cation-π interaction between the 
side-chains of Lysine 20 and Phenylalanine 23. And Tryptophan 21 could possibly 
interact with the branched substrate acceptance. 
The results obtained suggested that the selected loop 1 amino acid change of 
Option 2 is conformationaly stable, and minimal backbone torsion is induced.  However, 
as noted, Phenylalanine 23 showed increased side chain instability resulting in side 
chain freedom. In the two following snapshots below, the side chain rotation of 
Phenylalanine 23 is shown (Figure 63). 
 
 





Figure 63.   Snapshots of phenylalanine rotation by molecular dynamics simulation. 
Phenylalanine 23, showed increased side chain rotation. 
 
Even though Phenylalanine 23 was observed in the whole protein molecular 
dynamics simulation to have a certain degree of side-chain flexibility resulting in side-
chain rotation, this rotation was considered to be of slight importance.  Therefore 
experimental design of the ∆Loop1 hybrid was initiated. 
 
2.2.  ∆Loop1 experimental design 
Following theoretical modeling analysis of Loop1 substitution, different strategies 
were proposed for the experimental construction of the ∆Loop1 hybrid.  First, the 
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fabrication of the ∆Loop1 gene coding sequence was implemented; followed by sub-
cloning of ∆Loop1 into different expression vectors, specifically the pET101D with C-
terminal His-tag, pET16b with N-terminal His-tag, and pET16b without His-tag vectors. 
More information of these vectors can be found in Chapter 1. 
In order to remove the loop1 of β-glucanase and replace it with loop1 of 
PttXET16A, for construction of the ∆Loop1 coding sequence, the molecular biology 
technique of overlapping extension was implemented.  
Overlapping extension has been previously described as a method for production 
of chimeric genes by combining two DNA fragments, and consists of four primers and 
three PCRs.  In separate PCR reactions, two fragments of a target sequence are 
amplified by using, for each reaction, one universal and one mutagenic primer (in this 
case the mutagenic primer contains the XET loop1 coding sequence). The two 
intermediate PCR products contain a complimentary terminal region in order to form a 
new template DNA by duplexing in a second reaction. During this so-called overlap 
extension the fused product is amplified with the help of the two universal primers.  
Below is the theoretical overlapping extension diagram for removal and replacement of 
loop1 (Figure 64). 
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Figure 64.   Overlapping extension theoretical experimental design diagram. β-glucanase 
gene size is subsequently reduced with loop1 replacement due to XET16A having a considerably 
smaller loop1. 
 
Two mutagenic primers containing both β-glucanase homology and the XET 
homologous Loop1 region needed to be designed for addition of the XET loop1 and the 
complimentary overlapping region for subsequent extension and amplification.  These 
oligonucleotides were called the N-terminal 3´primer and the C-terminal 5´primer (B and 
C respectively).  These primers and their relative position are noted above in the 
theoretical overlapping extension diagram.  
The other two universal primers (A and D) share homology with the β-glucanase 
gene and pET101D vector.  These oligonucleotides were also used for the pET101D-β-
glucanase cloning and their nucleotide sequence is noted in “Primer List” section. 
The N-terminal 3´ primer had a total of 34 nucleotides and was homologous to 
the anti-sense loop1 hybrid strand.  There were 21 nucleotides with homology to the 
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wild-type β-glucanase structure (amino acids 14-20), and 13 nucleotides homologous to 
XET16A loop1.  These 13 nucleotides form the overlapping homologous region with the 
C-terminal 5´primer and would be later used for the overlapping extension reaction.  
The C-terminal 5´ primer had a total of 36 nucleotides and was directed to gene 
orientation.  There were 22 nucleotides with wild-type β-glucanase homology (amino 
acids 39-48), and 14 nucleotides homologous to XET loop1.  These 14 nucleotides 
formed the homologous region with the N-terminal 3´ primer and were later used for the 
overlapping extension reaction.   
Shown below is the loop1 hybrid theoretical nucleotide sequence (sense) with 
the relative position of the overlapping primers (Figure 65). 
                                         
 
Theoretical Loop1 hybrid nucleotide sequence 
 













Yellow=XET loop1 homology 
Red=N-terminal 3´ primer 
Blue=C-terminal 5  ́primer 
Green=region of overlap 
Figure 65.   Loop1 hybrid theoretical nucleotide sequence with the relative position of the 
overlapping primers. 
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Following the overlapping extension primers design, the optimum amplification 
conditions of the two intermediate PCR products was assessed by use of a thermal 
gradient PCR thermocycler. Below the resulting amplification products separated by 1% 
Agarose gel can be observed for both N- and C- terminal intermediate products (Figure 
66 and 67 respectively). 
 
1    2    3   4    5   6    7   8   9   10 11 12 13  14 15 16  17 18 19  20
 
Figure 66.   Optimum amplification annealing temperature of the N-terminal intermediate 
product.  Lane 1 and 2 Blank, Lane 3 1Kb Plus DNA Ladder, Lane 4 Tm=55.0oC,  Lane 5 
Tm=55.5oC, Lane 6 Tm=56.7oC, Lane 7 Tm=58.2oC, Lane 8 Tm=60.5oC, Lane 9 Tm=63.5oC, 
Lane 10 Tm=66.8oC, Lane 11 Tm=69.6oC, Lane 12 Tm=71.9oC, Lane 13 Tm=73.4oC, Lane 14 
Tm=74.6oC, Lane 15 Tm=75.0oC, Lane 16-20 Blank. Note that the theoretical N-terminal 
fragment size is 79 bases, which is very similar to that of the N-terminal 3´ primer (34 bases); 
therefore it is difficult to distinguish between the non-amplified primers and the amplification 
product. Since the amplification band in Lane 5 seemed to be of stronger intensity than that of the 
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Figure 67.   Optimum amplification annealing temperature of the C-terminal intermediate 
product. Lane 1 and 2 Blank, Lane 3 Tm=55.0oC,, Lane 4 Molecular Weight Marker, Lane 5 
Tm=55.5oC, Lane 6 Tm=56.7oC, Lane 7 Tm=58.2oC, Lane 8 Tm=60.5oC, Lane 9 Tm=63.5oC, 
Lane 10 Tm=66.8oC, Lane 11 Tm=69.6oC, Lane 12 Tm=71.9oC, Lane 13 Tm=73.4oC, Lane 14 
Tm=74.6oC, Lane 15 Tm=75.0oC, Lane 16-20 Blank. Note that the theoretical C-terminal 
fragment size is 541 bases, which can be observed in lanes 3 and lanes 5-9. The optimum Tm of 
55.5oC was used for further C-terminal PCR amplifications. 
 
Once the amplification conditions for both the N- and C-terminal intermediate 
PCR products were optimized, both products were bulked-up and agarose gel extracted. 
After extraction of both N- and C-terminal amplification products for construction 
of the loop1 hybrid, the overlapping extension product remained elusive. Multiple 
assaying conditions were tried without success until the root cause of overlapping 
extension failure was found to be insufficient nucleotide overlap. The region of overlap 
was only 12 nucleotides with a 28oC annealing temperature. This small overlap area was 
too unspecific for the subsequent annealing reaction.  Therefore, the region of overlap 
needed to be enlarged by the design of a new primer (N-term-loop1-ext).  The N-
terminal overlap region was elected for enlargement thereby increasing the N-terminal 
intermediate PCR product from 79 nucleotides to a new 98 nucleotide length.  While 
conjointly enlarging the overlap region from 12 nucleotides to 31 nucleotides with a new 
annealing temperature of 79oC.  
Shown in Figure 68 is the loop1 hybrid theoretical nucleotide sequence (sense) 
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Blue=C-Terminal 5  ́primer 
Pink= N-terminal loop1 enlargement primer 
 Green=region of overlap 
Figure 68.   Relative position of the N-terminal Loop1 extension primer and resulting 
overlap region. 
 
Using the previously amplified N-terminal intermediate PCR product, a 
subsequent PCR amplification was carried out using the N-term-loop1-ext primer.  The 
resulting PCR product can be seen below in Figure 69. 
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Figure 69.   2% agarose gel with ethidium bromide staining of N-terminal intermediate 
PCR product amplification using the N-term-loop1-ext primer.  Lanes 1 and 2 blank, Lane 3 1Kb 
Plus DNA Ladder, Lane 4 T7 promoter and N-terminal 3´ primer amplification product (positive 
control), Lane 5 pET101 Forward and N-term-loop1-ext primers (negative control), Lane 6 and N-
term-loop1-ext primer extended N-terminal fragment amplification product, Lane 7 N-terminal 
fragment, Lane 8 1Kb Plus DNA Ladder, Lane 9 and 10 blank.  Note that the N-term-loop1-ext 
amplification product (Lane 6) is of higher molecular weight than that of the N-terminal 
amplification product (Lane 7).  
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Once the extended N-terminal fragment was successfully amplified, the N-
terminal enlarged intermediate PCR product was agarose gel extracted for the 
subsequent overlapping extension reaction with the previously acquired C-terminal 
intermediate PCR product. The final overlapping extension design schematic and 
product are shown below (Figures 70 and 71 respectively). 
 
 
Figure 70.  Final overlapping extension schematic for the ∆Loop1-β-glucanase gene 
coding sequence acquisition. 
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Figure 71.  Lane 1 1Kb Plus DNA Ladder, Lanes 2-13 1:1v/v N-terminal extension 
product: C-terminal product, Lane 14 1Kb Plus DNA Ladder, Lanes15-26 1:2v/v N-terminal 
extension product: C-terminal product, Lane 27 1Kb Plus DNA Ladder, Lane 28 negative control 
1 N-terminal extension product without C-terminal product, Lane 29 C-terminal product without N-
terminal extension product, Lane 30 pET101D vector.  Lane 15 Tm=52.0oC, Lane 16 Tm=52.5oC, 
Lane 17 Tm=53.7oC, Lane 18 Tm=55.2oC, Lane 19 Tm=57.5oC, Lane 20 Tm=60.4oC, Lane 21 
Tm=63.8oC, Lane 22 Tm=66.6oC, Lane 23 Tm=68.8oC, Lane 24 Tm=70.4oC, Lane 25 
Tm=71.6oC, Lane 26 Tm=72.0oC, Note that the overlapping extension product can be only 
observed in Lanes 15-19 Tm=52.0-57.5oC with 1:2v/v N-terminal extension product: C-terminal 
product. 
 
By mixing N- enlarged and C- terminal intermediate PCR products 1:2 (v/v) 
respectively, the overlapping extension product was attained.  Therefore, the final 
∆Loop1 hybrid gene coding sequence could be subsequently sub-cloned into different 
expression vectors for further characterization. The first vector construct which will be 
discussed is the pET101D-∆Loop1, followed by discussion of the pET16b-∆Loop1-No-
His and pET16b-∆Loop1-His constructs respectively. 
 
 2.3.  ∆Loop1 C-terminal His-tag expression and characteriz ation 
The ∆Loop1 hybrid overlapping extension product was sub-cloned into 
pET101D-TOPO vector (containing a C-terminal His-tag) using the TOPO cloning 
procedure. This procedure and the exact characteristics of pET101D vector can be 
observed in the “β-glucanase C-terminal His-tag experimental design” section. 
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Once transformant colonies were received from the TOPO cloning reaction, 
confirmation of gene insertion was accomplished by dsDNA plasmid purification followed 
by restriction digestion with the AatII restriction enzyme. 
The AatII restriction enzyme was used since the TOPO vector without the gene 
insert had only one AatII restriction site and the ∆Loop1 gene another. Therefore when 
the plasmids were restriction digested and the vector contained no gene insert only one 
linear DNA fragment was observed.  However, if the vector contained the ∆Loop1 gene 
and was restriction digested two linear DNA fragments were observed. Using this simple 
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Figure 72.   AatII restriction digest of transformant colony dsDNA for pET101-∆loop1 
vector insertion screening. Lane1 Blank, Lane 2 Molecular weight marker XIV, Lane 3 
pET101D/TOPO vector AatII digested (negative control) Lanes 4-12 transformant colonies 1-9 
AatII digested dsDNA, Lane 13 blank Note insertion events detected in transformant colonies 
1,2,5,8 and 9. 
 
The transformant colonies dsDNA, which tested positive for ∆Loop1 insertion, 
was subsequently nucleotide sequenced for confirmation of proper gene sequence.  A 
single transformant colony dsDNA was elected as the final pET101D-∆Loop1 (C-
terminal His-tag) hybrid construct. 
In order to analyze the expression conditions of the pET101D-∆Loop1 hybrid, 
chemically competent BL21DE3 cells were transformed. Next, LB medium containing 
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ampicillin in an Erlenmeyer flask at 37oC and 250rpm was inoculated with single 
transformant colonies.  One colony was subsequently induced with IPTG during the 
exponential growth phase, while another colony was induced with IPTG during the 
stationary growth phase.  Time point aliquots were taken for both samples and the 
intracellular soluble fraction was analyzed by SDS-PAGE with Coomassie staining 
(Figure 73). 
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Figure 73.   pET101D-∆Loop1-B-glucanase pilot expression by PAGE with Coomassie 
staining. Lane 1 Low Range Molecular Weight Marker, Lane 2 Negative Control pET101D-TOPO 
vector (no insert) stationary growth phase 0 hrs induction, Lane 3 Negative Control pET101D-
TOPO vector (no insert) exponential growth phase 6hrs induction, Lane 4 Negative Control 
pET101D-TOPO vector (no insert) stationary growth phase 6hrs induction Lane 5 Loop1 
stationary growth phase 2hrs induction, Lane 6 Loop1 stationary growth phase 4hrs induction, 
Lane7 Loop1 stationary growth phase 6hrs induction, Lane8 Loop1 exponential growth phase 
2hrs induction, Lane9 Loop1 exponential growth phase 4hrs induction, Lane10 Loop1 exponential 
growth phase 6hrs induction.  
 
The largest quantity of intracellular soluble ∆Loop1 protein was seen to be 
produced after 4 hours of IPTG induction for both exponential and stationary growth 
phase samples.  Since no optical density measurements are necessary for ascertaining 
the stationary growth phase whereas encountering the exponential growth phase is 
optical density measurement intensive, it was decided for future ∆Loop1 expression to 
grow cells until the stationary growth phase was reached and induce for 4 hours.   
After optimization of ∆Loop1 expression conditions, an IMAC pilot purification of 
the polyhistidine-tagged ∆Loop1 protein was attempted using a pre-equilibrated 1mL 
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HisTrap™ HP column.  First, the expressed cells were lysed in binding buffer (20mM 
Tris-HCl, 0.5M NaCl pH8.0) and the lysate cleared of insoluble cellular debris by 
centrifugation followed by filtration through a 0.45µm filter.  Next, the protein sample was 
charged into the column and subsequently washed of non-bound proteins. Lastly, a 0 to 
500mM linear imidazol gradient was applied for selective elution of the His-tagged 
protein. As seen in the following chromatogram (Figure 74), only one elution peak is 
identified whereas normally two peaks should be seen; one peak pertaining to the non-
specifically bound proteins, and the second peak pertaining to the His-tagged 
recombinant protein.   
 






Figure 74.   Chromatogram pertaining to the ∆Loop1 His-tag pilot purification. The red 
arrow letter-number combinations mark elution fractions subsequently analyzed by PAGE. 
Observe the presence of only a primary elution peak at 31.88 minutes (tube B7) with no other 
secondary elution peak noted. 
 
Even though no secondary elution peak was observed, subsequent analysis by 
SDS-PAGE with Coomassie staining (Figure 75) and Western blot with α-His-tag 
antibodies was attempted (Figure 76).  ∆Loop1 recombinant protein was clearly visible in 
the protein sample and also in the primary elution peak.  However, the corresponding 
Western blot only showed a slight quantity of His-tag recombinant protein in the protein 
sample with no other His-tag protein present in the subsequent elution peaks. 
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Figure 75.   SDS-PAGE with Coomassie staining and α-His-tag Western blot pertaining to 
the ∆Loop1 His-tag pilot purification.  Lane1 Low Range Molecular Weight Marker, Lane 2 protein 
sample, Lane 3 flow-through (tube A1), Lane 4 flow-through (tube A2), Lane 5 flow-through (tube 
A3), Lane 6 primary elution peak (tubeB7), Lane 7 Elution fraction (tube E1), Lane 8 Elution 
fraction (tube E8), Lane 9 Elution fraction 2 (tube G9), Lane 10 Elution fraction (tube G11).  
∆Loop1 recombinant protein was only observed in the protein sample and primary elution peak 
fractions by Coomassie staining.   
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Figure 76.   α-His-tag Western blot pertaining to the ∆Loop1 His-tag pilot purification.  
Lane1 Low Range Molecular Weight Marker, Lane 2 protein sample, Lane 3 flow-through (tube 
A1), Lane 4 flow-through (tube A2), Lane 5 flow-through (tube A3), Lane 6 primary elution peak 
(tubeB7), Lane 7 Elution fraction (tube E1), Lane 8 Elution fraction (tube E8), Lane 9 Elution 
fraction 2 (tube G9), Lane 10 Elution fraction (tube G11).  Only α-His-tag recombinant protein was 
observed in the protein sample.   
 
A large fraction of ∆Loop1 eluted in the primary elution peak, which normally 
corresponds to non-specifically bound proteins, and this fraction lacked a His-tag since 
no αHis-tag reaction was observed by Western blot.  No recombinant ∆loop1 protein 
was recovered from multiple His-tag affinity chromatography assays involving a variety 
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of purification conditions.  Also, the loop1 hybrid showed little to no binding of the α-His-
tag antibody, possibly due to proteolytic processing of the C-terminal His-tag. 
Since no recombinant ∆Loop1 protein was able to be purified by His-tag 
chromatography, a pilot ion exchange chromatography was attempted as an alternative 
method for ∆Loop1 purification.  
Ion exchange chromatography of ∆Loop1 was attempted since wild-type β-
glucanase had been shown to be successfully purified using this technique.  Before a 
pilot ion exchange purification could be attempted, the isoelectric point of ∆Loop1 had to 
be identified for efficient ion exchange resin binding.  This was accomplished by 
equilibrating both resin and ∆Loop1 protein to different pHs ranging from pH 5.0 to pH 
9.0. For acidic pHs the cation exchange resin Source™ 30S by GE Lifesciences was 
used while for basic pHs the anion exchange resin Source™ 30Q by GE Lifesciences 
was used.  After the resin and protein for a given pH were equilibrated, the samples 
were mixed and centrifuged.  The supernatant was subsequently extracted and analyzed 
by SDS-PAGE with Coomassie staining. Supernatant samples lacking ∆Loop1 
recombinant protein therefore had efficiently bound ∆Loop1 to the resin (Figure 77).  
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Figure 77.   14% SDS-PAGE with Coomassie staining of supernatant samples for 
efficient ion exchange binding.  Lane1 Low Range Protein Standards, Lane 2 pH 5.0, Lane 3 pH 
5.5, Lane 4 pH 6.0, Lane 5 pH 6.5, Lane 6 pH 7.0, Lane 7 pH 7.5, Lane 8 pH 8.0 Lane 9 pH 8.5, 
and Lane 10 pH9.0. Note in Lane 2 pH 5.0 loop1 recombinant protein was bound to the ion 
exchange resin and therefore cannot be seen in the PAGE. 
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∆Loop1 recombinant protein was efficiently bound to the cation exchange resin 
Sourse S™ at a pH of 5.0. Once the Loop1 binding conditions had been developed, a 
pilot ion exchange elution assay was attempted. 
Elution of ∆Loop1 recombinant protein, bound to the Source S™ ion exchange 
resin, was attempted by increasing salt concentrations (ionic-strength).  First ∆Loop1 
recombinant protein was bound to the ion exchange resin using the aforementioned 
binding conditions. Then the resin was washed free of all un-bound proteins, and 
increasing salt concentration aliquots were added to the resin.  After addition of the 
buffer containing salt, the resin was spun down and the supernatant analyzed by SDS-
PAGE with Coomassie staining. Supernatant showing elution of Loop1 protein defined 
the approximate salt concentration needed for efficient elution (Figure 78). 
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Figure 78.   ∆Loop1 pilot ion exchange elution assay analysis by SDS-PAGE with 
Coomassie staining. Lane 1 pH 5.0 non-bound protein of recombinant sample (flow-through), 
Lane 2 Low Range Protein Standards, Lane 3 58mM NaCl, Lane 4 88mM NaCl, Lane 5 130mM 
NaCl, Lane 6 197mM NaCl, Lane 7 296mM NaCl, Lane 8 444mM NaCl, Lane 9 6667mM NaCl, 
Lane 10 1M NaCl. Note that with the addition of 88mM NaCl recombinant loop1 elutes nicely from 
the Source S™ resin. 
 
∆loop1 recombinant protein eluted from the Source S™ cation exchange resin 
with 88mM NaCl. Therefore, Loop1 protein could be efficiently bound to the ion 
exchange resin at pH 5.0 and efficiently eluted with a salt concentration of approximately 
88mM.  
After the preliminary binding and elution conditions of Loop1 ionic exchange 
purification were identified, the purification of recombinantly expressed Loop1 protein 
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was attempted. pET101D-∆Loop1-β-glucanase transformed BL21DE3 cells were 
inoculated into 1 liter of Lysogeny broth containing ampicillin and incubated overnight at 
37oC 250 rpm.  The next morning, recombinant expression was induced by the addition 
of IPTG (final concentration 1mM) and after 4 hours of induction, the cells were 
harvested.  Next, the cells were lysed by sonication, centrifuged, and the intracellular 
soluble fraction dialyzed into 10mM sodium acetate pH 5.0. Following dialysis, the 
protein sample was charged onto pre-equilibrated Source S™ resin, the resin washed, 
and a linear gradient of 0 to 200mM NaCl elution buffer applied.  The resulting 
chromatogram and SDS-PAGE can be seen below (Figures 79 and 80). 
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Figure 79.   Chromatogram of ∆Loop1 ion exchange purification with a linear 200mM 
NaCl gradient. The flow-through fraction can be seen at the 2.30mL A280 peak whereas the 
primary elution peak corresponding to non-specifically bound proteins can be seen at 16.17mL 
and the secondary elution peak corresponding to Loop1 protein can at the 25.65mL peak. Note 
that Loop1 eluted with approximately 100mM NaCl which is in accordance with the 
aforementioned pilot ion exchange assay conditions. 
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Figure 80.   14% SDS-PAGE with Coomassie staining of the ∆Loop1 ion exchange 
purification with linear NaCl gradient. Lane1 insoluble pellet, Lane 2 previously purified ∆loop1 
recombinant protein (positive control), Lane 3 low range protein standards, Lanes 4 and 5 flow-
through, Lane 6 primary wash peak, and Lanes7-10 ∆Loop1 Elution peak. Note in Lanes 7-10 the 
presence of purified loop1 recombinant protein. 
 
Approximately 5mg/L of pET101D-∆Loop1 recombinant protein was successfully 
purified by ion exchange chromatography. Therefore, utilization of this purification 
technique allowed further studies of ∆Loop1 to be carried out. 
In order to verify proper enzyme folding, a urea unfolding assay was completed 
using previously purified loop1 protein. The assay conditions utilized for urea unfolding 
were the same as those described in the “Analysis of β-glucanase equilibrium urea 
denaturation” section. The assay consisted of Loop1 recombinant protein in 
phosphate/citric buffer pH7.2 with 100µM CaCl2 incubated at 37
0C for 16 hours in the 
presence of different urea concentrations ranging from 0 to 8 molar. Then the sample’s 
fluorescence intensity was analyzed with an emission wavelength of 340nm. Figure 81, 
below, shows the resulting plotted fluorescence intensity versus urea concentration.  
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Figure 81.   Urea unfolding assay of recombinant pET101D-∆Loop1-β-glucanase protein. 
Note data uniformity and a singular inflection point. 
 
Upon analysis of the ∆Loop1 equilibrium urea denaturation data, utilizing the two 
state model equations previously described in the “Analysis of β-glucanase equilibrium 
urea denaturation” section, it was found that the ∆Loop1 hybrid had m and [D50%] similar 
to those of the previously investigated pD62- β-glucanase-C61A mutant [111].  As shown 
in the following table (Table 6), the slopes of both the ∆Loop1 hybrid and C61A mutant 
are almost identical whereas a slight deviation can be seen for the [D50%] values.  The 
∆GUH2O values show large deviations (data not shown) probably because the 
extrapolations are over too wide a range of denaturant conditions so that small errors in 
the slope m result in large errors in the estimation of ∆GUH2O. 
 
Protein m (kcal/mol/M)  [D50%] (M) 
pET101D-∆Loop1-β-glucanase  3.38± 0.44 2.82±0.04 
pD62-β-glucanase-C61A** 3.93± 0.26 1.73±0.02  
pD62-β-glucanase** 1.20± 0.08  4.68±0.05 
Table 6.   ∆Loop1 equilibrium urea denaturation data and its comparison with the 
previously studied C61A mutant and wild type β-glucanases. **Note pD62- β-glucanase 
denaturation data was derived from the work reported in Pons et al.  [111]. 
 
The conclusions drawn from the analysis of the ∆Loop1 equilibrium urea 
denaturation data are that ∆loop1 recombinant protein is properly folded (data uniformity 
and singular inflection point). 
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A direct comparison of ∆GUH2O values between pD62-β-glucanase and 
intracellular soluble ∆Loop1 are precluded due to significantly different m values, 
possibly due to slight differences in the experimental conditions.  However, [D50%] values 
show that that the largest β-glucanase primary loop stability contributor is Cysteine 61. 
Therefore the removal of Loop1 is similar in stability to that of removing a key Loop1 
amino acid Cys 61 which forms a disulphide bond with Cys32 in the wt β-glucanase.  
After proper folding of ∆loop1 was assured, enzyme kinetic assays were 
conducted. Substrates for both wild-type β-glucanase, and wild-type XET were 
attempted in the loop1 construct. Xyloglucan, β-glucan, and G4G3G-Mu substrates were 
assayed.  However no enzymatic activity was detected for all substrates assayed. 
Since the pET101D-∆loop1 construct was only purified by ion exchange 
chromatography and never by His-tag affinity chromatography, the expression vector 
was changed.  Rather than continuing to purify ∆loop1 by ion exchange, a purification 
method inconsistent with the addition of a recombinant C-terminal His-tag, the ∆loop1 
construct was swapped to the pET16b vector.  Using the pET16b vector two vector 
configurations were assembled. One vector configuration produced ∆loop1 with an N-
terminal His-tag. And the other vector configuration produced ∆loop1 in its native state 
while under aT7/lac promoter system.  First the experimental design of the native ∆loop1 
under theT7/lac promoter system (pET16b-∆Loop1-No-His) will be discussed. 
 
2.4.  Native ∆Loop1 design and expression 
Two oligonucleotides were designed for fabrication of the pET16b-∆Loop1-No-
His construct.  One primer, N-terminal, shared restriction site homology (Nco I) with the 
pET16b vector, upstream of the affinity tags.  Therefore by restriction digest of the 
pET16b vector the affinity tags were removed and ∆Loop1 could be inserted in their 
place. The second primer (C-terminal) also shared restriction site homology (Bpu 1102I) 
with the pET16b vector while adding a stop codon to the ∆Loop1 gene coding sequence.  
The stop codon was added since the template DNA used for PCR amplification of 
∆Loop1 was the pET101D-∆loop1 and this vector contained a C-terminal His-tag, and 
therefore needed to be removed. 
Since both the N- and C-terminal nucleotide sequences (at least for the given 
primer length) of ∆Loop1 and β-glucanase are homologous, the oligonucleotides used 
for insertion of the ∆Loop1 gene into the pET16b vector are the same as those used for 
insertion of β-glucanase into the pET16b vector.  Further details of these primers, 
Results and Discussion  
 101 
pET16b-No-His-N-term and C-terminal Primers, can be found in the “Native β-glucanase 
experimental design” and “Primer List” sections. Moreover, the pET16b-vector 
characteristics can be found in the “β-glucanase N-terminal His-tag experimental design” 
section. 


















Figure 82.   The pET16b-loop1-No-His-tag vector map. Note the unique flanking 
restriction sites Bpu 1102I and Nco I which were used for ∆Loop1 insertion. 
 
After designing the oligonucleotides for insertion of the loop1 gene into the 
pET16b vector, ∆loop1 was amplified by PCR and doubled-digested with the Nco I and 
Bpu 1102I  restriction enzymes.  Likewise, the pET16b vector was double digested with 
the same restriction enzyme pair. Following PCR amplification and double digestion, 
both products were extracted from a 1% agarose gel.  Shown in Figure 83 are the two 
double digested DNA products before agarose gel extraction. 
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Figure 83.  1% Agarose gel with ethidium bromide staining of the Nco I and Blp I double 
digested ∆loop1 PCR product and pET16 vector. Lanes1-5 loop1 PCR product, Lane 6 molecular 
weight maker, Lanes 7-9 pET16b vector. 
 
Once both vector and insert were extracted, in the presence of T4 ligase, the 
products were mixed in a 1:3 vector to insert molar ratio respectively. Chemically 
competent cells were transformed with the ligase product.  Subsequently, transformant 
colonies were screened for insertion by flanking T7 oligonucleotide PCR amplification.  
Two screening methods were employed in parallel. One method used purified 
transformant dsDNA for the PCR while the other used freshly picked transformant cells 
directly added into the PCR mixture (Figure 84). Transformant colonies positive for 
∆Loop1 insertion showed a PCR amplification product of 714 bases while transformant 
colonies lacking loop1 insertion show amplification of 113 bases.  
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Figure 84.  1% Agarose gel with ethidium bromide staining of transformant colony PCR 
pET16b-∆loop1-No-His insertion screening. Lane 1 positive control purified pET101-∆loop1 
dsDNA, Lane 2 positive control pET101-∆loop1 DH5α colony, Lane 3 molecular weight marker, 
Lane 4 transformant colony #1 dsDNA, Lane 5 transformant colony #2 dsDNA, Lane 6 
transformant colony #3 dsDNA, Lane 7 transformant colony #4 dsDNA, Lane 8 transformant 
colony #5 dsDNA, Lane 9 transformant colony #6 dsDNA, Lane 10 transformant colony #7 DH5α 
cells, Lane 11 transformant colony #8 DH5α cells, Lane 12 transformant colony #9 DH5α cells, 
Lane 13 transformant colony #10 DH5α cells, Lane 14 transformant colony #11 DH5α cells, Lane 
15 transformant colony #12 DH5α cells.  Note that insertion events were detected in Lanes 8 and 
9.  Also, note that the positive control in Lane 2 for the pET101-∆loop1 DH5α colony was 
negative therefore insertion events in Lanes 10-15 are inconclusive. 
 
As shown above, the positive control of the freshly picked transformant colonies 
directly added into the PCR mixture was negative; therefore the results of transformant 
colonies 7-12 were inconclusive.  However, the positive control for the purified 
transformant dsDNA worked correctly and insertion events were detected in 
transformant colonies #5 and #6. Subsequent nucleotide sequence analysis of the 
transformant colonies positive for Loop1 insertion showed that the predicted nucleotide 
sequence was correct. 
Next, a pilot expression assay was attempted in E. coli BL21DE3-Star expression 
cells. Chemically competent BL21DE3 cells were transformed with the pET16b-∆loop1-
No-His-tag vector. Next, LB medium containing ampicillin in an Erlenmeyer flask at 37oC 
and 250rpm was inoculated with single transformant colonies.  After growing the colony 
overnight, the next morning, during the stationary growth phase, recombinant expression 
was induced with IPTG (1mM final concentration).  Time point aliquots were taken and 
the intracellular soluble fraction was analyzed by SDS-PAGE with Coomassie staining 
(Figure 85). 
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Figure 85.  pET16b-∆Loop1-No-His-tag pilot expression. Analysis of the intracellular 
soluble fraction by 14% SDS-PAGE with Coomassie staining. Lane 1 Low Range Protein 
Standards Lane 2, pET16b negative control 6hrs IPTG induction, Lane 3, pET16b-∆loop1-No-His 
0hrs IPTG induction, Lane 4 pET16b-∆loop1-No-His 2hrs IPTG induction, Lane 5 pET16b-
∆loop1-No-His 4hrs IPTG induction, Lane 6 pET16b-∆loop1-No-His 6hrs IPTG induction. Note 
that within the red box the Loop1 recombinant protein is shown. Also note that the largest quantity 
of Loop1 protein is expressed after 4hrs of IPTG induction. 
 
Analysis of the pilot expression assay showed that pET16b-∆loop1-No-His 
recombinant protein was successfully expressed in the soluble fraction and the largest 
quantity of protein was present after 4hrs of IPTG induction. 
No protein purification or enzyme kinetics were completed with this construct.  At 
the same time as the pET16b-∆loop1-No-His construct was being made, a N-terminal 
His-tag vector was made.  Since recombinant protein purification is simplified and 
immobilized biocatalysis is possible with a His-tag, subsequent experiments were only 
conducted with the pET16b-∆loop1-His vector. 
 
2.5.  ∆Loop1 N-terminal His-tag design and expression 
In order to add an N-terminal His-tag to the ∆loop1 gene, two primers were 
designed.  The N-terminal primer added an Xho I restriction site, extra nucleotides for 
efficient restriction enzyme cleavage, and removed the start codon for addition of an N-
terminal His-tag.  The C-terminal added a Bpu1102 I  (Blp I) restriction site, stop codon, 
and extra nucleotides for efficient restriction site cleavage. Details of these primers, N-
terminal and C-terminal Primers, can be found in the “Primer List” section.  The vector 
map for the pET16b-∆Loop1-His plasmid is shown below (Figure 86). 
 















T7 Promoter primer 








Figure 86.  The pET16b-∆Loop1-His vector map.  Note the presence of the unique 
∆Loop1 flanking restriction sites (Bpu1102 I and Xho I) used for subsequent gene insertion. 
 
Following the primer design for N-terminal His-tag addition the Loop1 gene was 
amplified by PCR using the unique primer pair and subsequently double restriction 
digested by Xho I and Blp I. At the same time the pET16b vector was also double 
restriction digested with the same restriction enzymes.  Shown below are the Loop1 
gene amplification product after double digestion and the pET16b vector after double 
digestion and before agarose gel extraction in a 1% agarose gel with ethidium bromide 
staining (Figure 87). 
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Figure 87.  ∆Loop1 amplification product and pET16b vector after double restriction 
digestion and before agarose gel extraction in a 1% Agarose gel with ethidium bromide staining. 
Lanes 1-5 ∆Loop1 amplification product, Lane 6 molecular weight marker, Lanes 7-9 pEt16b 
vector, Lane 10 blank. 
 
Once both vector and insert were extracted, in the presence of T4 ligase, the 
products were mixed in a 1:3 vector to insert molar ratio. Chemically competent cells 
were transformed with the ligase product. The dsDNA from the transformant colonies 
was subsequently purified and analyzed for insertion by flanking primer (T7 promoter 
and pET16b reverse primers) PCR.  Colonies positive for Loop1 insertion showed an 
800 base pair product whereas colonies negative for insertion showed no PCR product 
formation (Figure 88). 
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Figure 88.  Transformant colony screening by flanking primer PCR. Product separated in 
a 1% Agarose gel and stained with ethidium bromide. Lane 1 pET101D-∆Loop1 dsDNA PCR 
product (positive control), Lane 2 pET16b-∆Loop1-No-His dsDNA PCR product, Lane 3 molecular 
weight marker, Lanes 4-11 transformant colonies 1-8 dsDNA PCR product, Lane 12 molecular 
weight marker, Lane 13 blank.  Note lane 6 (transformant colony #3) is positive for insertion. 
 
The colony which was positive for Loop1 insertion was subsequently nucleotide 
sequenced, and the correct predicted nucleotide sequence was attained.  
 
Following confirmation of the correct pET16b-∆Loop1-His nucleotide sequence, 
three distinct expression conditions were assayed: 
1. Stationary growth phase induction. 
2. Exponential growth phase induction. 
3. Reduced temperature induction. 
 
 
Stationary growth phase induction:  The pilot expression assay consisted of 
transforming chemically competent E. coli BL21DE3-star cells with the pET16b-∆loop1- 
His-tag vector. Next, LB medium containing ampicillin in an Erlenmeyer flask at 37oC 
and 250rpm was inoculated with single transformant colonies.  After growing the colony 
overnight, the next morning, during the stationary growth phase, recombinant expression 
was induced with IPTG (1mM final concentration).  Time point aliquots at different 
induction times ( 0, 2, 4, and 6h) were taken and the intracellular soluble fraction and 
insoluble fraction were analyzed by SDS-PAGE with Coomassie staining and Western 
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blot.  The Western blot was carried out by utilizing mouse-α-His-tag primary antibodies 
and HRP-conjugated-rabbit-α-mouse secondary antibody.  (Figures 89 and 90 below). 
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Figure 89.   Pilot expression of pET16b-∆Loop1-His vector construct. Lane 1 low range 
protein standards, Lane 2 pET16b vector  6 hrs induction (negative control), Lane 3 intracellular 
soluble pET16b-∆Loop1-His 0 hrs induction, Lane 4 intracellular soluble pET16b-∆Loop1-His 2 
hrs induction, Lane 5 intracellular soluble pET16b-∆Loop1-His 4 hrs induction, Lane 6 
intracellular soluble pET16b-∆Loop1-His 6 hrs induction. Lane 7 insoluble pellet pET16b-∆Loop1-
His 0 hrs induction, Lane 8 insoluble pellet pET16b-∆Loop1-His 2 hrs induction, Lane 9 insoluble 
pellet pET16b-∆Loop1-His 4 hrs induction, Lane 10 insoluble pellet pET16b-∆Loop1-His 6 hrs 
induction,  Note it is difficult to discern the optimum expression time for the intracellular soluble 
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Figure 90.   Pilot expression of pET16b-∆Loop1-His vector construct analysis by Western 
blot. Lane 1 low range protein standards, Lane 2 pET16b vector  6 hrs induction (negative 
control), Lane 3 intracellular soluble pET16b-∆Loop1-His 0 hrs induction, Lane 4 intracellular 
soluble pET16b-∆Loop1-His 2 hrs induction, Lane 5 intracellular soluble pET16b-∆Loop1-His 4 
hrs induction, Lane 6 intracellular soluble pET16b-∆Loop1-His 6 hrs induction. Lane 7 insoluble 
pellet pET16b-∆Loop1-His 0 hrs induction, Lane 8 insoluble pellet pET16b-∆Loop1-His 2 hrs 
induction, Lane 9 insoluble pellet pET16b-∆Loop1-His 4 hrs induction, Lane 10 insoluble pellet 
pET16b-∆Loop1-His 6 hrs induction. Note the largest quantity of intracellular soluble pET16b-
∆Loop1-His protein is noted after 4 hrs of induction (Lane 5). 
 
After analysis of the pilot expression assay, it was possible to conclude that the 
largest quantity of intracellular soluble protein was produced after 4 hours of induction.  
Since such a small quantity of intracellular soluble protein was detected during stationary 
phase expression, two more pilot expression assays were subsequently attempted: 
 
Exponential growth phase and reduced temperature in duction :  Both pilot 
expression assays were carried out in parallel as follows: chemically competent E. coli 
BL21DE3-star cells were transformed with the pET16b-∆loop1-His vector. Next, one 
Erlenmeyer flask containing LB medium and ampicillin at 25oC and 250rpm was 
inoculated with a single transformant colony while the second Erlenmeyer flask, with the 
same reagents, but at 37oC was inoculated.  After both colonies reached the exponential 
growth phase, recombinant expression was induced with IPTG. Time point aliquots were 
taken and both the intracellular soluble and insoluble fractions were subsequently 
analyzed by SDS-PAGE (Figures 91 and 92). 
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Figure 91.   SDS-PAGE analysis of the pET16b-∆Loop1-His intracellular soluble fractions 
for exponential growth phase induction and reduced temperature induction.  Lane 1 low range 
protein standards, Lane 2, previously purified ∆Loop1 protein (positive control), Lane 3 pET16b 
6hr induction time (negative control), Lane 4 pET16-∆Loop1 reduced temperature 0hr induction 
time, Lane 5 pET16-∆Loop1 reduced temperature 3hr induction time, Lane 6 pET16-∆Loop1 
reduced temperature 6hr induction time, Lane 7 pET16-∆Loop1 exponential growth 0hr induction 
time, Lane 8 pET16-∆Loop1 exponential growth 3hr induction time, Lane 9 pET16-∆Loop1 
exponential growth 6hr induction time, Lane 10 low range protein standards. Note that the 
previously purified ∆Loop1 protein (positive control) showed dimer formation. Also note the 
relative absence of intracellular soluble ∆Loop1 protein. 
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Figure 92.   SDS-PAGE analysis of the pET16b-∆Loop1-His intracellular soluble fractions 
for exponential growth phase induction and reduced temperature induction.  Lane 1 previously 
purified ∆Loop1 protein (positive control), Lane 2, low range protein standards, Lane 3 pET16b 
6hr induction time (negative control), Lane 4 pET16-∆Loop1 reduced temperature 0hr induction 
time, Lane 5 pET16-∆Loop1 reduced temperature 3hr induction time, Lane 6 pET16-∆Loop1 
reduced temperature 6hr induction time, Lane 7 pET16-∆Loop1 exponential growth 0hr induction 
time, Lane 8 pET16-∆Loop1 exponential growth 3hr induction time, Lane 9 pET16-∆Loop1 
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exponential growth 6hr induction time, Lane 10 low range protein standards. Note that the 
previously purified ∆Loop1 protein (positive control) showed dimer formation.  Also, note the 
highly reduced quantity of insoluble ∆Loop1 protein present in comparison with the pET16b-
∆Loop1-His pilot stationary phase expression. 
 
Since the pET16b-∆Loop1-His reduced temperature induction and exponential 
growth induction pilot expression experiments showed little to none intracellular soluble 
and insoluble ∆Loop1 protein, it was decided to use the stationary growth phase 
expression conditions for further pET16b-∆Loop1-His characterization. 
Once the pET16b-∆Loop1-His expression conditions were decided upon, a His-
tag affinity chromatography purification of the intracellular soluble fraction was 
attempted. 
A 1 liter LB medium with ampicillin Erlenmeyer flask was inoculated with a single 
pET16b-∆Loop1-His transformed Bl21DE3-star colony.  The culture was grown 
overnight, until stationary growth phase was reached, and induced with IPTG (1mM final 
concentration). After 4 hours of induction, the cells were harvested and lysed in Binding 
buffer (20mM Tris-HCl, 0.5M NaCl pH8.0). The soluble and insoluble fractions were 
separated by centrifugation and subsequent filtration (0.45µm). Next, the intracellular 
soluble protein was charged onto a pre-equilibrated 5mL HiTrap™ HP column and 
subsequently washed. Then a 0 to 500mM linear imidazol gradient was applied and the 
elution fractions collected (Figure 93).  Analysis of the elution fractions was 
accomplished by SDS-PAGE with Coomassie staining (Figures 94 and 95). 
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Figure 93.   Chromatogram the pET16b-∆Loop1-His immobilized metal affinity 
chromatography. Blue line represents A280 protein elution while the green line represents the 
applied linear imidazol gradient. Note the presence of two elution peaks upon application of the 
imidazol gradient, the 1o elution peak corresponds to non-specifically bound proteins while the 2o 
elution peak pertains to ∆Loop1 elution. 
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Figure 94.   Elution Fractions corresponding to the aforementioned ∆Loop1 affinity 
purification.  Lane 1 low range protein standards, Lane 2 previously purified Loop1 protein 
(positive control), Lane 3 intracellular soluble protein sample, Lane 4 flow-through, Lanes 5-10 
primary elution peak fractions.  Note in lanes 8-10 there was possible elution of ∆Loop1 protein in 
the primary elution peak. 
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Figure 95.  Elution fractions corresponding to the aforementioned ∆Loop1 affinity 
purification. Lane 1 previously purified Loop1 protein (positive control), Lane 2 low range protein 
standards, Lanes 3-10 secondary elution peak corresponding to ∆Loop1 protein elution.  Note the 
relative singular elution of ∆Loop1 recombinant protein in the secondary elution peak. 
 
The elution fractions pertaining to ∆Loop1 recombinant protein were pooled, and 
the quantity of ∆Loop1 protein was calculated.  Approximately 600µg of ∆Loop1 protein 
was recovered from a 1 liter LB culture. Since such a small quantity of ∆Loop1 protein 
was recovered from the intracellular soluble fraction, refolding and purification of the 
insoluble fraction was subsequently attempted. 
The minimum urea concentration needed for solubilization of the insoluble 
∆Loop1 fraction needed to be ascertained. This was accomplished by adding different 
concentrations of urea (1.7 to 8M) to the insoluble pellet and subsequently analyzing the 
solubilized protein by PAGE (Figure 96).  
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Figure 96.   Analysis of the minimum urea concentration needed for solubilization of the 
insoluble ∆Loop1 protein fraction.  Lane 1 intracellular soluble fraction, Lane 2 low range protein 
standards, Lane 3 8M urea, Lane 4 6.4M urea, Lane 5.1M urea, 4.1M urea, 3.3M urea, 2.6M 
urea, 2.1M urea, 1.7M urea.  Note the largest quantity of ∆Loop1 protein was solubilized in 8M 
urea (lane 3). 
 
The largest quantity of ∆Loop1 protein, from the insoluble fraction, was 
solubilized in 8M urea therefore; subsequent refolding experiments were carried out by 
first solubilizing ∆Loop1 protein in Binding Buffer with 8M urea. Once the ∆Loop1 
solubilization conditions were ascertained, on-column refolding was attempted by first 
capturing ∆Loop1, in its denatured state, on a IMAC column and subsequently applying 
a linear urea gradient from 8 to 0M in order to slowly refold the ∆Loop1 protein. 
Following the refolding step, a linear imidazol gradient from 0 to 500mM was applied 
(Figure 97). The corresponding elution fractions were subsequently analyzed by SDS-
PAGE (Figure 98). 
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Figure 97.   Chromatogram of ∆Loop1 column refolding and elution.  Note the presence 
of a single A280 peak at 182.18 mL (tube C6) before application of the imidazol gradient, and no 
subsequent elution peaks in the imidazol gradient. 
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Figure 98.  14%PAGE pertaining to the column refolding chromatogram elution fractions.  
Lane 1 protein sample, Lane 2 low range protein standards, Lane 3 tube C6 (peak at 182.18 mL), 
Lanes 4-9 tubes G2-G7 (end of imidazol gradient fractions) Lane 10 elution fraction from 
application of 8M urea + 500mM imidazol. Note that the ∆Loop1 formed aggregates in the column 
and was only eluted by re-solubilization in urea and with addition of 500mM imidazol. 
 
No ∆Loop1 protein was eluted after attempted on-column refolding. Only by 
adding 8M urea and 500mM Imidazol the ∆Loop1 protein, which had aggregated in the 
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column, was effectively eluted. Therefore, on-column refolding of ∆Loop1 was 
unsuccessful. 
Following multiple unsuccessful assays of on-column refolding, denatured 
purification of ∆Loop1 was attempted for further de novo refolding assays.  
In order to further assess ∆Loop1 refolding, ∆Loop1 was purified in a denatured 
state.  First, the insoluble ∆Loop1 fraction was solubilized in 20mM Tris-HCl, 8M urea, 
500mM NaCl, pH 8.0 and subsequently bound to the IMAC column.  Next, a 0 to 500mM 
linear imidazol elution gradient was applied.  The resulting chromatogram and 
subsequent analysis of elution fractions by SDS-PAGE with Coomassie staining are 
shown (Figures 99 and 100). 
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Figure 99.   Chromatogram of denatured ∆Loop1 IMAC purification. Note the presence of 
three A280 elution peaks upon application of the linear imidazol gradient at 21.44, 63.02, and 
82.42 mL. 
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Figure 100.   Analysis of purification fractions by SDS-PAGE.  Lane 1 protein sample, 
Lane 2 low range protein standards, Lane 3 flow-through (1.76 mL), Lane 4 primary elution peak 
(21.44 mL), Lane 5-7 secondary elution peak (63.02 mL), Lanes 8-10 tertiary elution peak (82.42 
mL).  Note that both the secondary and tertiary elution peaks pertain to ∆Loop1 protein. 
 
Analysis of the denatured ∆Loop1 purification revealed that ∆Loop1 protein was 
successfully purified in a denatured state. The presence of two distinct elution peaks 
pertaining to ∆Loop1 might be due to proteolytic processing of the His-tag resulting in 
distinct ∆Loop1 populations which have different affinities for the IMAC column. 
 Following purification of ∆Loop1, in a denatured state, the elution fractions 
pertaining to ∆Loop1 were pooled and the quantity of protein calculated. For a 1 liter LB 
culture 89 mg of purified denatured ∆Loop1 protein was recovered.  Therefore, 148 
times more protein was purified by denatured ∆Loop1 purification than by purification of 
the intracellular soluble fraction. 
Subsequent dialysis of the pooled ∆Loop1 denatured fractions into phosphate/ 
citric buffer pH7.4 with 100µM CaCl2 resulted in 17 mg of soluble ∆Loop1 with 72 mg of 
insoluble ∆Loop1 due to extensive precipitation upon dialysis.  Therefore, 23% of the 
denatured ∆Loop1 was resolubilized. 
In an attempt to maximize the resolubilization rate of ∆Loop1, a reducing agent, 
β-mercaptoethanol was added to the dialysis/resolubilization buffer. The reducing agent 
was added to minimize dimer production caused by disulfide bond formation between 
proteins.  As seen in Figure 101, a 5mM final concentration of β-mercaptoethanol totally 
eliminated ∆Loop1 dimer formation. 
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Figure 101.   Elimination of previously purified ∆Loop1 protein dimer formation by addition 
of β-mercaptoethanol.  Lane 1 low range protein standards, Lane 2 15µL ∆Loop1 protein without 
β-mercaptoethanol, Lane 3 7µL ∆Loop1 protein without β-mercaptoethanol, Lane 4 4µL ∆Loop1 
protein without β-mercaptoethanol, Lane 5 2µL ∆Loop1 protein without β-mercaptoethanol, Lane 
6 15µL ∆Loop1 protein with β-mercaptoethanol, Lane 7 7µL ∆Loop1 protein with β-
mercaptoethanol, Lane 8 4µL ∆Loop1 protein with β-mercaptoethanol, Lane 9 2µL ∆Loop1 
protein with β-mercaptoethanol, Lane 10 blank. Note addition of β-mercaptoethanol totally 
eliminated ∆Loop1 dimer formation. 
 
Since β-mercaptoethanol was observed to totally eliminate protein dimer 
formation, β-mercaptoethanol was subsequently added to the dialysis/resolubilization 
buffer after denatured ∆Loop1 purification.  Addition of β-mercaptoethanol (5mM final 
concentration) elevated the resolubilization rate from 23 to 40%.  Therefore, in all further 
purification procedures β-mercaptoethanol was added to the dialysis/resolubilization 
buffer. 
 
2.6.  ∆Loop1 N-terminal His-tag characterization 
2.6.1.  Urea equilibrium denaturation 
In order to insure the proper folding of both the intracellular soluble and 
resolubilized pET16b-∆Loop1-His recombinant protein, a urea equilibrium denaturation 
assay was attempted using the aforementioned conditions noted in the “Analysis of β-
glucanase equilibrium urea denaturation” section. The assay consisted of ∆Loop1 in 
6.5mM citric acid 87mM Na2HPO4 pH7.2 with 100µM CaCl2 incubated at 37
oC for 16 
hours in the presence of different urea concentrations ranging from 0 to 8 molar. Then 
the sample’s fluorescence intensity was analyzed with excitation at 280nm and emission 
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at 340nm. Figure 102, below, shows the resulting plotted fluorescence intensity versus 
urea concentration for both the intracellular soluble purified (blue) and resolubilized 
(green) ∆Loop1 protein. 
 
 
Figure 102.   Urea equilibrium denaturation assay of both intracellular soluble purified 
(blue) and resolubilized (green) ∆Loop1 protein.  Note data uniformity and singular inflections are 
recovered. 
 
Since both intracellular soluble purified and resolubilized ∆Loop1 protein showed 
high data uniformity, it was considered that both samples were identically folded 
independently of the purification technique. Therefore, in subsequent discussions the 
resolubilized ∆Loop1 protein will be referred to as “refolded” ∆Loop1 protein. 
The same assumptions and equations utilized for the calculations of “Analysis of 
β-glucanase equilibrium urea denaturation” were applied for analysis of the ∆Loop1 
recombinant protein. In the table below, both the intracellular soluble purified and 









∆loop1 N-terminal His-tag 2.92± 0.72  3.04±0.07 8.86±2.42 
∆loop1 N-terminal His-tag “refolded” 2.12± 0.64  3.24±0.11 6.87±2.10 
Table 7.   Comparison of intracellular soluble purified and refolded ∆Loop1 protein. Note that all 
calculated values are within the range of standard error. 
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By considering both ∆Loop1 protein samples equal, and averaging the generated 
data points, the averaged ∆Loop1 equilibrium urea denaturation was compared with the 
averaged pET16b-β-glucanase-E134A-His data points as seen below in the following 
graph (Figure 103). 
 
 
Figure 103.   Comparison of ∆Loop1 N-terminal His-tag protein (red) with that of β-
glucanase-N-terminal His-tag (black). Note the slightly decreased inflection point and increased 
slope of the ∆Loop1 protein. 
 
Analysis of the pET16b-∆Loop1-His recombinant protein stability, in comparison 
with that of pET16b-β-glucanase-His protein, reveals that the ∆Loop1 is slightly less 
stable than the wild-type enzyme.  However, the pET16b-∆Loop1-His construct shows a 









∆Loop1N-terminal His-tag 2.42 ±1.32  3.13±0.08 7,58±4.32 
∆Loop1 C-terminal His-tag  3.38± 0.44 2.82±0.04 9.53±1.36 
β-glucanase-N-terminal His-tag 3.07±0.74  3.74±0.02 11.50±2.8 
Table 8.  Comparison of urea equilibrium denaturation values for pET16b-∆Loop1-His, 
pET101D-∆Loop1, and wild-type enzyme.  
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2.6.2.  Hydrolase / transferase activity assays 
After confirmation of pET16b-∆Loop1-His recombinant protein proper folding, the 
natural substrates and enzymatic activities (transferase / hydrolase) for XET and 1,3-1,4-
β-glucanase were assessed using different enzyme kinetic methods.  
Observation of xyloglucan transferase activity relied on the addition of low 
molecular weight xyloglucan oligosaccharides to high molecular weight xyloglucan 
polysaccharides.  If ∆Loop1 transferase activity existed, the high molecular weight 
polysaccharides would decrease in size as the low molecular weight oligosaccharides 
increased in size.   
This evolution of size can be observed by the addition of a chemical dye which 
can bind to the polymer substrate, but not the low molecular weight oligomers.  
Therefore by following the loss of Iodine intensity at 590nm, as the average molecular 
weight decreases, transferase or hydrolase activity can be observed (see Methods 
section). 
The transferase activities of duplicate pET16b-∆Loop1-His samples (final 
concentration 9.8µM) with xyloglucan (final concentration 375µg/mL) and xyloglucan 
oligosaccharides (final concentration 440µg/mL) were monitored over 7 days at 37oC as 
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Figure 104.  pET16b-∆Loop1-His xyloglucan transferase activity assay with xyloglucan 
(final concentration 375µg/mL) and xyloglucan oligosaccharides (final concentration 440µg/mL). 
The two ∆Loop1 samples (final concentration 375µg/mL) are marked in red and green 
respectively while the negative control is marked in black. Note that over the course of 7 days no 
transferase activity was detected for both ∆Loop1 samples. 
 
No xyloglucan transferase activity for pET16b-∆Loop1-His was ever detected 
even though multiple assays involving differing enzyme and substrate concentrations 
were tried. Since no xyloglucan transferase activity, was detected xyloglucan hydrolase 
was assayed. 
In order to assess xyloglucan hydrolytic activity of pET16b-∆Loop1-His the 
reducing sugar Dinitrosalicylic acid (DNS) assay was utilized (see “Methods” section).  
3,5-Dinitrosalicylic acid (DNS) is an aromatic compound that reacts with reducing sugars 
and other reducing molecules to form 3-amino-5-nitrosalicylic acid, which absorbs light 
strongly at 540 nm.  Therefore, when an enzyme hydrolyzes polysaccharides, reducing 
sugars are formed which in turn react with the DNS agent forming a compound which 
can be easily monitored at 540nm. pET16b-∆Loop1-His recombinant protein (4.5 µM 
final concentration)  in 6.5mM citric acid 87mM Na2HPO4 pH7.2 with 100µM CaCl2 was 
incubated with xyloglucan (2mg/mL final concentration) over a period of 30 hours at 
37oC and time point aliquots taken. The positive control consisted of Aspergillus niger 
Cellulase A which can hydrolyze branched carbohydrates (final concentration 50nM). 
The negative control was 1,3-1,4-β-glucanase (20µM final concentration). Dinitrosalicylic 
acid was subsequently added to the time point aliquots and their absorbance at 540 
nanometers read (Figure 105). 





















Figure 105.   DNS xyloglucan reducing ends assay of pET16b-∆Loop1-His hydrolytic 
activity.  ∆Loop1 (4.5 µM final concentration) time points are shown in blue, the negative control 
in pink, and the positive control in red. Note the negative control (1,3-1,4-β-glucanase 20µM final 
concentration and the ∆Loop1 sample have the same absorbance values overtime whereas the 
positive control (Cellulase A 50nM final concnetration) reached a maximum absorbance of 
approximately 0.475 in the first hour. 
 
No xyloglucan hydrolase activity for pET16b-∆Loop1-His was ever detected even 
though multiple assays involving differing enzyme and substrate concentrations were 
tried.  After confirmation of no ∆Loop1 xyloglucan hydrolytic activity, 1,3-1,4 β-glucanase 
substrates were assayed for Loop1 enzymatic activity. 
The pET16b-∆Loop1-His recombinant protein (4.5 µM final concentration) was 
assayed for hydrolytic activity using the natural substrate for 1,3-1,4 β-glucanase, β-
glucan (2mg/mL final concentration).  The enzymatic activity assay was carried out using 
the previously described DNS reducing ends methods with time point aliquots taken over 
60 minutes. In the figure below the change in absorbance at 540 nm for pET16b-
∆Loop1-His and the change in absorbance for the negative control (no enzyme) was 
plotted (Figure 106).  
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y = 0,0033x + 0,1181
R2 = 0,9806
















Figure 106.   DNS β-glucan reducing ends assay of pET16b-∆Loop1-His hydrolytic 
activity. ∆Loop1 time point absorbance values, tendency line, tendency line equation, and R2 
value are marked in red whereas the negative control time point absorbance values, tendency 
line, and tendency line equation are marked in blue. 
 
As shown above, pET16b-∆Loop1-His recombinant protein does have slight β-
glucan hydrolytic activity. However, when comparing ∆Loop1 to wild-type β-glucanase a 
large difference in hydrolytic activity is observed. In the following figure, pET16b-
∆Loop1-His β-glucan hydrolytic activity is compared to wild-type pET16b-β-glucanase-
His (Figure 107).  The pET16b-β-glucanase-His recombinant protein (final concentration 
50nM) was 250x less concentrated than the pET16b-∆Loop1-His sample. 
 












Negative Control Loop1 Positive control
 
Figure 107.  DNS β-glucan reducing ends assay of pET16b-∆Loop1-His hydrolytic activity 
in comparison with wild-type pET16b-β-glucanase-His. ∆Loop1 time point absorbance values and 
tendency line are marked in red whereas the negative control time point absorbance values and 
tendency line are marked in black. The positive control, pET16b-β-glucanase-His time point 
absorbance values are marked in green.  Note the β-glucanase protein sample reached the 
maximum absorbance value in approximately 15 minutes. 
 
Even though the pET16b-β-glucanase-His recombinant protein sample had a 
concentration 250x less than that of pET16b-∆Loop1-His, β-glucanase was still able to 
hydrolyze all of the β-glucan polysaccharides in less than 15 minutes whereas after 1 
hour ∆Loop1 had only hydrolyzed approximately 16% of the polysaccharides. The 
∆Loop1 specific activity was calculated to be approximately 0.1% that of wild-type β-
glucanase. This large reduction in β-glucan hydrolytic activity is the result of the removal 
of the β-glucanase primary loop since the protein was shown to be properly folded. 
In order to ascertain the hydrolytic activity of pET16b-∆Loop1-His using a low-
molecular-mass chromogenic substrate, which had been previously shown to be highly 
active in the wild-type β-glucanase enzyme, Glcβ4Glcβ3Glc-MU (where MU is 4-
methylumbelliferyl) enzyme kinetics were attempted (see Methods section). The enzyme 
kinetics were performed by following changes in UV absorbance due to the release of 4-
methylumbelliferone. 
Reactions were initiated by addition of substrate to a preincubated mixture of 
∆Loop1 enzyme (final concentration 18.5µM) in 6.5mM citric acid 87mM Na2HPO4 pH7.2 
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with 100µM CaCl2 at 30
oC and the absorbance changes at 365 nm for G4G3G-MU (final 
concentration 11.6mM) release of 4-methylumbelliferone; ∆ε365=5136 M-1* cm-1 were 


















Figure 108.   pET16b-∆Loop1-His recombinant protein G4G3G-MU hydrolysis kinetics. 
∆Loop1 change in absorbance over time points, are marked in black whereas the negative 
control (no enzyme) change in absorbance over time points are marked in pink. Note the no 
difference between the negative control and Loop1 samples. 
 
As seen above, there is no difference between the negative control and pET16b-
∆Loop1-His sample.  
In conclusion, β-glucan ∆Loop1 hydrolytic enzyme activity was confirmed; 
however, no hydrolytic activity for xyloglucan or G4G3G-MU was observed. Next, the 
glycosynthase activity of the nucleophile-less ∆Loop1 enzyme was assayed. 
 
2.6.3.  Glycosynthase activity 
For assessment of the glycosynthase activity of ∆Loop1, the catalytic 
nucleophile first needed to be mutated to alanine.  Such a mutant enzyme has severely 
disabled hydrolytic catalysis and cannot cleave normal substrates.  However, when 
presented with an activated sugar of the 'wrong' anomeric configuration, such as a 
glycosyl fluoride, the glycosynthase can catalyze the condensation of sugar residues, 
synthesizing a glycoside. The newly formed glycoside, being a poor substrate for the 
mutant enzyme, can accumulate to essentially quantitative yields. 
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Mutation of the catalytic nucleophile to alanine was accomplished by site-
directed mutagenesis.  The site directed mutagenesis consisted of designing two 
complementary oligonucleotides containing the nucleotides which were wanted to be 
mutated, in this case changing glutamate for alanine, and sufficient nucleotides 
complementary to the template DNA for specific and efficient binding.  Specific details of 
the primers used (E134A sense and E134 antisense primers) can be found in the 
“Primers List” section.  After designing the site directed mutagenesis primers, template 
dsDNA (pET16b-∆Loop1-His) and polymerase were mixed and the site directed 
mutagenesis reaction carried out using a thermocycler (see Methods section).  Following 
completion of the site-directed mutagenesis reaction, template DNA was digested with 
the restriction endonuclease Dpn I, and the resulting product used to transform 
chemically competent E. coli cells.  Next, transformant colonies had their DNA extracted 
and purified. The purified transformant DNA was subsequently nucleotide sequenced for 
confirmation of the correct nucleotide sequence thereby creating the pET16b-∆Loop1-
E134A-His vector construct. 
Once the correct nucleotide sequence was confirmed, the pET16b-∆Loop1-
E134A-His vector construct was used to transform E. coli Bl21DE3 expression cells. The 
pET16b-∆Loop1-E134A-His recombinant protein was purified using the aforementioned 
pET16b-∆Loop1-His expression and purification techniques.  After pET16b-∆Loop1-
E134A-His recombinant protein purification, glycosynthase enzymatic activity assays 
could begin. 
The first glycosynthase activity assessed was by use of High Performance Liquid 
Chromatography (see “Methods” section).  The pET16b-∆Loop1-E134A-His recombinant 
protein (final concentration 21.9µM) in 6.5mM citric acid 87mM Na2HPO4 pH7.2 with 
100µM CaCl2 was incubated with G4G-PNP (final concentration 7.8mM) and G4G3GαF 
(final concentration 1.75mM) at 35oC and time point aliquots taken over 2 hours. In the 
following figure, the chromatograms for the positive control (pD62-β-glucanase E134A 
final concentration 15µM) after 5 minutes of reaction time and the time 0 and time 2hr for 
∆Loop1-E134A are shown (Figure 109). 
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Figure 109.   Chromatogram of the HPLCE glycosynthase activity assay. The ∆Loop1-
E134A time 0 chromatogram is shown in pink, the ∆Loop1-E134A time 2hrs chromatogram in 
yellow, and the pD62-β-glucanase E134A positive control chromatogram in blue.  Note only 
glycosynthase product formation was detected for the positive control. 
 
After 2 hours of reaction time, the ∆Loop1-E134A, using the G4G3GαF and 
G4G-PNP substrates, showed no glycosynthase product formation.  However the 
positive control showed glycosynthase product formation after 5 minutes.  Therefore, it 
was concluded that the ∆Loop1-E134A was ineffective for glycosynthase activity for the 
aforementioned substrates.   
Once no glycosynthase activity was detected for the substrates which had been 
shown to be catalyzed by the 1,3-1,4-β-glucanase-E134A, a glycosynthase activity 
assay involving a xyloglucan oligosaccharide fluoride activated donor and β-glucan 
oligosaccharide acceptor was attempted. 
Enzymatic studies of pET16b-∆Loop1-E134A-His (final concentration 8.5uM) 
were initiated using a fluoride activated glycosyl donor XXGαF (final concentration 5mM) 
in the presence of a G4G-Mu glycoside acceptor (final concentration 25.5mM) at 35oC 
(final volume 500µL). Sodium fluoride standards for calibration curves were prepared in 
the same experimental conditions (6.5mM citric acid 87mM Na2HPO4 pH7.2 with 100µM 
CaCl2 at 35
oC). The chemical hydrolysis negative control consisted of the alpha-fluoride 
donor and acceptor saccharides in the reaction mixture using the same reaction 
Results and Discussion  
 129 
conditions but without enzyme while the enzymatic hydrolysis negative control consisted 
of the alpha-fluoride donor and ∆Loop1 enzyme without acceptor. As the enzymatic 
reaction progressed and polysaccharide product was formed, fluoride ions were 
liberated from the glycosyl donor. The liberation of these fluoride ions was monitored by 
Fluoride Selective Electrode Monitoring (see Methods section). The resulting graph is 
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Figure 110.   pET16b-∆Loop1-E134A-His glycosynthase activity of XXGαF and G4G-MU 
followed by fluoride liberation. ∆Loop1 red, chemical hydrolysis black, and enzymatic hydrolysis 
green. Note no difference in the rate of fluoride liberation was noted between the ∆Loop1-E134A 
and negative control samples. 
 
No glycosynthase activity was ever noted with the ∆Loop1-E134A enzyme even 
though multiple assays, conditions, and substrates were tried. In order to “fine-tune” the 
∆Loop1 enzyme, in an effort to gain glycosynthase activity, further 3-dimensional 
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CHAPTER 3, Engineering of the negative subsites β-strands of the enzymatic 
cleft 
 
3.1. “Scaffold” hybrid protein design 
In order to refine the ∆Loop1 hybrid protein structure for negative subsite branched 
substrate acceptance and enzymatic activity, further structural analysis of the native 
Populus tremula x tremuloides xyloglucan endotransglycosylase and Bacillus licheniformis 
1,3-1,4-β-glucanase was initiated.   
First, the negative subsite β-strands were identified for both PttXET16A and β-
glucanase as shown in the following (Figure 111). 
 
 
Figure 111 . Negative subsite β-glucanase (left) β-strands (brown) and PttXET16A (right) β-
strands (magenta)  involved in substrate binding. Catalytic motif amino acids are marked in red. 
 
Having identified the XET16A and β-glucanase negative subsite β-strands, the β-
glucanase amino acids previously shown to be integral in substrate binding, by work our 
laboratory [112, 113], were annotated for further comparison with the equivalent XET16A 
amino acids (Figure 112). 
 




Figure 112 . The 1,3-1,4-β-glucanase X-ray crystallography 3-D structure with β-glucan 
hexasaccharide substrate and interacting negative subsite amino acids. 
 
Theses annotated β-glucanase negative subsite amino acids, which interact with 
the substrate, were considered integral for β-glucan binding.  Therefore it was highly 
probable that these amino acids could obstruct or interfere with branched substrate 
binding. 
In order to compare the evolutionary divergence of these key negative subsite 
amino acids for β-glucan binding, an amino acid sequence alignment of XET16A and β-
glucanase was conducted. Comparison of amino acids present in the negative subsite β-
strands showed remarkably few differences.  In the following tables, the negative subsite 
amino acids for both XET16A and β-glucanase are compared (Tables 9, 10, and 11). 
 
 
Results and Discussion  
 
 135 
Strand -III Side Chain Analysis
Strand -3 ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓
B-glucanase Lys58 Phe Asp Cys Gly Glu Asn Arg Ser Val Gln Thr Tyr70
XET Gly42 Thr Gly Thr Gln Ser Lys Gly Ser Tyr51
 
Table 9 . Negative -III β-strand side amino acid side chain analysis. Arrows facing upwards 
represent amino acids protruding into the enzymatic face while arrows facing downwards represent 
buried amino acid. Amino acids highlighted in yellow have been shown to be integral for β-
glucanase substrate binding. Amino acids within the dark border are on the enzymatic face. Amino 
acid side-chains protruding into the enzymatic face for β-glucanase (top) and XET (bottom) are 
illustrated.  Differences in amino acid side-chains are annotated within red boxes. Note for the -3 β-
strand there are three amino acids which show evolutionary divergence. 
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Strand -II Side Chain Analysis
Strand -2 ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓
B-glucanase Asn185 Trp Leu Asn Met Met Ile Lys Gly177
XET Asn175 Trp Leu Ser Ser Tyr Ile Lys Met167
 
Table 10 . Negative -II β-strand side amino acid side chain analysis. Arrows facing upwards 
represent amino acids protruding into the enzymatic face while arrows facing downwards represent 
buried amino acid. Amino acids highlighted in yellow have been shown to be integral for β-
glucanase substrate binding. Amino acids within the dark border are on the enzymatic face. Amino 
acid side-chains protruding into the enzymatic face for β-glucanase (top) and XET (bottom) are 
illustrated.  Differences in amino acid side-chains are noted within red boxes. Note for the -2 β-
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Strand -I Side Chain Analysis
Strand -1 ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓
B-glucanase Ile87 Val Ser Ser Phe Phe Thr Tyr Thr95
XET Thr70 Val Thr Ala Phe Tyr Leu Ser77
 
Table 11. Negative -I β-strand side amino acid side chain analysis. Arrows facing upwards 
represent amino acids protruding into the enzymatic face while arrows facing downwards represent 
buried amino acid. Amino acids highlighted in yellow have been shown to be integral for β-
glucanase substrate binding. Amino acids within the dark border are on the enzymatic face. Amino 
acid side-chains protruding into the enzymatic face for β-glucanase (top) and XET (bottom) are 
illustrated.  Differences in amino acid side-chains are noted within red boxes. Note for the -1 β-
strand there are three amino acids which show evolutionary divergence. 
 
Since a total of 8 amino acids protruding into the negative subsites enzymatic face 
showed evolutionary divergence between XET16A and β-glucanase, these amino acids 
where thought likely candidates for subsequent mutation in order to restore/activate 
negative subsite branched substrate acceptance and enzymatic activity. Once these 8 
amino acids showing evolutionary divergence were encountered, their relative structural 
position for β-glucanase and XET16A were overlaid in order to observe the exact effect 
these side-chains have on overall enzymatic structure and possible branched substrate 
acceptance. These amino acids are shown in the following figures below (Figures 113 and 
114).  
 




Figure 113 . 3-Dimensional structural overlay of XET16A (white) and β-glucanase (brown). 
β-glucanase negative subsite amino acids showing evolutionary divergence are shown in yellow 
while XET16A amino acids are shown in red. Note that the β-glucanase amino acids show, on 









Figure 114 . 3-Dimensional structural overlay of XET16A (white) and β-glucanase (brown). 
β-glucanase negative subsite amino acids showing evolutionary divergence are shown in yellow 
while XET16A amino acids are shown in red. Note that the β-glucanase amino acids show, on 
average, more protrusion into the enzymatic face than those of XET16A. 
 
Following identification of the PttXET16A and β-glucanase evolutionary divergent 
negative subsite amino acids, amino acid sequence alignment comparisons of 16 
lichenases and 26 xyloglucan endotransglycosylases were completed.  The sequence 
alignments were completed in order to identify lichenases which contained XET like amino 
acids and transferases which contained β-glucanase like amino acids. Therefore, if other 
lichenases contained XET-like amino acids or vice versa then these amino acids could be 
considered to not be critical for branched substrate acceptance or enzymatic activity. The 
full sequence alignments can be found in the “Alignments” section, whereas in the 
following tables the β-strand amino acid alignments are summarized (Tables 12, 13, and 
14). 




Transferase Amino Acid 
sequences which are 
homologous to β-
glucanase0/160/162/16
Hydrolase Amino Acid 









contain a.a. alignments 
homologous with  β-
glucanase (bacillus 
licheniformis)nonoyes
Other hydrolases contain 
a.a. alignments 
homologous with  
PttXET16A
QGGamino acidRECamino acid
PttXET16A Strand -IIIBacillus licheniformis β-glucanase Strand -III
 
Table 12 . Summarized -III β-strand amino acid sequence alignments for Bacillus 
licheniformis 1,3-1,4-β-glucanase and PttXET16A. The Bacillus licheniformis 1,3-1,4-β-glucanase 
amino acid sequence is compared to 15 other lichenase sub-family members whereas the 
PttXET16A amino acid sequence is compared to 25 other xyloglucan transferase sub-family 
members. Note that only the β-glucanase cystein amino acid residue had other hydrolases 
containing amino acid alignments homologous to XET16A.  And only 2 of 16 lichenases had amino 
acids homologous to XET16A in the β-glucanase cystein position. Also note that not one 
transferase had amino acids similar to that of β-glucanase. 
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Table 13 . Summarized -II β-strand amino acid sequence alignments for Bacillus 
licheniformis 1,3-1,4-β-glucanase and PttXET16A. The Bacillus licheniformis 1,3-1,4-β-glucanase 
amino acid sequence is compared to 15 other lichenase sub-family members whereas the 
PttXET16A amino acid sequence is compared to 25 other xyloglucan transferase sub-family 
members. Note that not one lichenase amino acid was similar to PttXET16A, and not one 
transferase amino acid was similar to β-glucanase. 
 
 
































homologous with  
PttXET16A
SYAamino acidYFSamino acid
PttXET16A Strand -IBacillus licheniformis β-glucanase Strand -I
 
Table 14 . Summarized -I β-strand amino acid sequence alignments for Bacillus 
licheniformis 1,3-1,4-β-glucanase and PttXET16A. The Bacillus licheniformis 1,3-1,4-β-glucanase 
amino acid sequence is compared to 15 other lichenase sub-family members whereas the 
PttXET16A amino acid sequence is compared to 25 other xyloglucan transferase sub-family 
members. Note that only the β-glucanase serine amino acid residue had other hydrolases 
containing amino acid alignments homologous to XET16A.  And only 4 of 16 lichenases had amino 
acids homologous to XET16A in the β-glucanase cystein position. Also, note that only the 
PttXET16A alanine amino acid residue had other xyloglucan transferases containing amino acids 
similar to that of β-glucanase. And only 3 of 26 tranferases had amino acids homologous to β-
glucanase in the PttXET16A alanine position. 
 
Since only 2 negative subsite amino acid positions showed xyloglucan transferase 
and lichenase homology it was considered that all of the evolutionary divergent amino 
acids noted were critical for branched substrate acceptance and enzymatic activity.  
Therefore rather than leaving the 2 β-glucanase amino acids, which showed sub-family 
homology with PttXET16A wild-type, it was decided to mutate all 8 evolutionary divergent 
amino acids to the equivalent PttXET16A amino acids.  
The subsequent resulting enzyme was named “Scaffold” since it was considered 
that this new enzyme would be the platform for further mutagenic refinement in an effort to 
attain a protein structure for negative subsite branched substrate acceptance and 
enzymatic activity. Therefore in the following sections, “Scaffold” will refer to the ∆Loop1 
enzyme with the 8 aforementioned β-glucanase amino acids mutated to the homologous 
PttXET16A amino acids. 




3.2. Construction of Scaffold gene for expression 
In order to mutate the 8 β-glucanase evolutionary divergent amino acids to those 
homologous to PttXET16A, a multiple site directed mutagenesis reaction was carried out. 
Traditional site-directed mutagenesis methods rely on the mutation of only one site 
at a time and efficiencies drop drastically when more than three sites are targeted 
simultaneously. Therefore multiple site directed mutagenesis method developed by 
Andreas Seyfang and Jean Huaqian Jin [111] was employed for simultaneously mutating the 
8 β-glucanase evolutionary divergent amino acids to those homologous to XET16A (see 
“Methods” section). 
  In this method, two terminal tailed primers each with a unique nucleotide tail are 
simultaneously annealed to template DNA together with the set of mutagenic primers in 
between. Following synthesis of the mutant strand by primer extension and ligation with T4 
DNA polymerase and T4 ligase, the unique mutant strand-specific tails of the terminal 
primers are used as anchors to specifically amplify the mutant strand by high-fidelity 
polymerase chain reaction.  Shown are the relative positions of the mutagenic primers for 
the three negative subsite β-strands and the two terminal tailed primers with the unique 
nucleotide tails.  Also, the theoretical strand synthesis and amplification steps are show 
(Figure 115). 
 
Figure 115 .  The multiple site directed mutagenesis theoretical mutanagenic strand 
synthesis and amplification steps with the relative positions of the three negative subsite β-strands 
mutagenic primers (-1,-2, and-3) and the two terminal tailed primers (Forward and Reverse) with the 
unique 25 nucleotide tails (green). Note the unique nucleotide tails correspond to the M13 Forward 
and Reverse primers, which were subsequently used for strand amplification. 




Once the multiple site directed mutagenesis method was selected for 
simultaneously mutating the 8 β-glucanase amino acids to those of XET16A, mutagenic 
primers and terminal tailed primers were subsequently designed. 
Since the previous optimum expression conditions, involving the ∆Loop1 enzyme, 
were with the pET16b vector, it was decided to clone the Scaffold gene into the same 
vector.  Upon insertion into the pET16b vector, the Scaffold would contain a N-terminal 
His-tag, aT7/lac promoter for high-level expression, and lac operator sequence 
immediately downstream of the T7 promoter for added regulation of basal expression. 
While also carrying the low-copy pBR322 origin of replication to further reduce basal 
expression levels in the uninduced state. The theoretical linear Scaffold gene map for 
vector insertion with annotated unique restriction sites, β-strand positions, and mutagenic 
amino acids are shown (Figure 116).  Immediately following, the circularized Scaffold gene 






C61G E63G R65Q M180Y N182SS90A F92Y Y94S
 
Figure 116 . The ∆Loop1-Scaffold linear gene map for insertion with unique restriction sites 
and relative ∆Loop1 and β-strand positions. 
 

































Figure 117 .  The theoretical circularized pET16b-Loop1-Scaffold-His vector map. 
 
In order to mutate the evolutionary divergent β-glucanase amino acids to those 
homologous to XET16A, the -III β-strand had to have three codons mutated (C61G, E63G, 
and R65Q).  For mutagenesis of these three -III β-strand codons, a total of 5 nucleotides 
needed to be replaced. Also, the -III β-strand mutagenic primer needed to be 5´-
phosphorylated for subsequent T4 ligation.  The resulting oligonucleotide was called the 
“Strand -3 primer”. 
The -II β-strand had to have two codons mutated (M180Y and N182S). For 
mutagenesis of these two -II β-strand codons, a total of 4 nucleotides needed to be 
replaced. Also, the -II β-strand mutagenic primer needed to be 5´-phosphorylated for 
subsequent T4 ligation.  The resulting oligonucleotide was called the “Strand -2 primer”. 
The -I β-strand had to have three codons mutated (S90A, F92Y, and Y94S). For 
mutagenesis of these three -I β-strand codons, a total of 3 nucleotides needed to be 
Results and Discussion  
 
 146 
replaced. Also, the -I β-strand mutagenic primer needed to be 5´-phosphorylated for 
subsequent T4 ligation. The resulting oligonucleotide was called the “Strand -1 primer”.  
The forward terminal primer contained 21 nucleotides homologous to the terminal 
∆Loop1 gene sequence and a unique 20 nucleotide tail for specific amplification of the 
mutagenic product, using the complementary anchor primer. Also, the forward terminal 
primer was 5´-phosphorylated for subsequent T4 ligation. The resulting oligonucleotide 
was called the “Scaffold forward primer”. 
The reverse terminal primer contained 26 nucleotides homologous to the terminal 
∆Loop1 gene sequence and a unique 23 nucleotide tail for specific amplification of the 
mutagenic product, using the complementary anchor primer. Since the reverse terminal 
primer was located at the far 5´ side of the gene sequence no 5´-phosphorylation was 
necessary. The resulting oligonucleotide was called the “Scaffold reverse primer”. 
The first anchor primer, for specific amplification of the mutagenic product, was 
complementary to the 5’ end of the “Scaffold forward primer” and contained 21 
nucleotides. These 21 nucleotides were derived from the commercially available M13 
forward primer and were unique to the Scaffold gene. The resulting oligonucleotide was 
called the “M13 forward primer”. 
The second anchor primer, for specific amplification of the mutagenic product, was 
complementary to the 5’ end of the “Scaffold reverse primer” and contained 23 
nucleotides. These 23 nucleotides were derived from the commercially available M13 
reverse primer and were unique to the Scaffold gene. The resulting oligonucleotide was 
called the “M13 reverse primer”. 
More information of the aforementioned primers such as annealing temperatures 
and exact nucleotide sequences can be found in the “Primer List” section. 
After design of the aforementioned primers, the oligonucleotides were synthesized 
at a 50nmol scale and cartridge purified by the manufacturer (Stab Vida, Portugal). 
Mutagenic, terminal, and anchor primers were individually dissolved. Next, Strand -I, 
Strand -II, and Strand -III primers and Scaffold Forward and Reverse primers were pooled. 
After pooling of the multiple site directed mutagenesis primers denatured double-stranded 
template DNA was prepared from pET16b-∆Loop1-His plasmid DNA.  Following 
preparation of the pooled primers and ssDNA template, three sets of extension and 
ligation assays were carried out for mutant strand synthesis (See step I Figure 115 above).   
The first set of conditions assayed (reactions I to IV) were based on the 
bibliographic conditions of Andreas Seyfang and Jean Huaqian Jin [115] while changing the 
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reaction buffer and with or without additional ATP, the second set of assay conditions (V to 
VIII) used an altered pooled primer concentration while changing the reaction buffer and 
with or without additional ATP, the third set of assay conditions (IX and X) used the 
bibliographic primer concentrations while subsequently ethanol precipitating the annealing 
and ligation products (Table 15).  
YesSequential T4 polymerase and T4 LigaseX
NoT4 Ligase and T4 PolymeraseIXEthanol Precipitation
NoT4 Polymerase w/o additional ATPVIII
NoT4 Polymerase w/ additional ATPVII
NoT4 Ligase and T4 PolymeraseVI
NoT4 LigaseVAltered Primer Conc.
NoT4 Polymerase w/o additional ATPIV
NoT4 Polymerase w/ additional ATPIII
NoT4 Ligase and T4 PolymeraseII
NoT4 LigaseIBibliographic Conditions
ProductBufferReactionConditions
Multiple site-directed mutagenesis Scaffold Extensi on and Ligation Conditions
 
Table 15 . Multiple site-directed mutagenesis Scaffold extension and ligation conditions. Reactions 
I-IV used the bibliographic conditions noted in the Andreas Seyfang and Jean Huaqian Jin paper 
[111] however with different buffer combinations and ATP concentrations.  Reactions V-VII used a 
higher  primer concentration than noted in the bibliographic conditions while repeating the same 
buffer combinations as in reactions I-IV.  Reaction IX was conducted in different buffer combinations 
and used ethanol precipitation to concentrate the extension and ligation product for subsequent 
amplification. Reaction X was sequentially extended with T4 polymerase, the product ethanol 
precipitated, redissolved in T4 ligase buffer, and subsequently ligated with T4 ligase. Note only 
reaction X was positive for Scaffold product development. 
 
The annealing and ligation reaction, which proved successful, consisted of first 
extending the mutagenic primers with T4 polymerase (in T4 polymerase buffer), ethanol 
precipitating the product, drying the pellet, then resuspending the product in T4 ligase 
buffer and ligating with T4 ligase (Reaction X).  The exact multiple site-directed 
mutagenesis protocol implemented can be found in the “Methods” section.  The resulting 
extension and ligation Scaffold product can be seen in the following agarose gel below 
(Figure 118).   
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Figure 118 .  2% agarose gel with ethidium bromide staining of the multiple site-directed 
mutagenesis Scaffold extension and ligation product for reaction X. Lane 1 100bp DNA ladder, 
Lanes 2-4 Reaction X Scaffold extension and ligation product, Lanes 5 and 6 blank. Note the slight 
extension and ligation product present in lanes 2-4 corresponding to the theoretical molecular 
weight of the multiple site-directed mutagenesis Scaffold product (625bp). 
 
In order to attain sufficient Scaffold gene product for subsequent double restriction 
digestion and insertion into the pET16b vector a Scaffold PCR amplification was carried 
out (see step II Figure 115 above). The resulting Scaffold amplification product is shown 
(Figure 119). 
1      2     3     4     5      6
 
Figure 119 .  2% agarose gel of Scaffold PCR amplification for subsequent double restiction 
digestion and insertion. Lane 1 blank, Lane 2, 3uL 100bp DNA ladder, Lane 3 1uL 100bp DNA 
ladder, Lane 4 Scaffold amplification product, Lanes 5 and 6 blank. 
 
After bulk up of the Scaffold gene product, the scaffold gene was double restriction 
digested with Xho I and Blp I, and subsequently agarose gel extracted. Following gel 
Results and Discussion  
 
 149 
extraction, the scaffold gene was mixed with the previously double digested pET16b 
vector, and ligated with T4 ligase. Next, chemically competent E. coli DH5α cells were 
transformed with the ligation product and the resulting transformant colonies screened for 
Scaffold insertion by flanking primer PCR.  In the following table, the different Scaffold 














Primary Amplification I 3:1 90:30 No 75 0
II 3:1 45:15 No 0 0
III 6:1 90:15 No 1 0
Negative Control N/A 0:30 No 30 N/A
IV 6:1 90:15 Yes 2 0
V 3:1 45:15 Yes 20 2*
VI 4:1 60:15 Yes 6 0
VII 12:1 90:7.5 Yes 7 0
Negative Control I N/A 0:15 Yes 1 N/A
Negative Control II No ligase added 0:15 Yes 3 N/A
VIII 6:1 90:15 Yes 4 0
IX 3:1 90:30 Yes 11 0
X 1:1 30:30 Yes 6 0
Negative Control N/A 0:30 Yes 13 0
* For the two gene insertion events, one was invert ed in the vector and the other had two nucleotide e rrors: a nucleotide deletion at 
the XhoI restriction site and one codon (R65Q) rema ined wild type
Primary Amplification and 
Vector Dephosphorylation




Table 16 . ∆Loop1-Scaffold gene insertion into the pET16b vector screening. The primary 
amplification conditions refer to a single Scaffold gene product PCR amplification after the multiple 
site directed mutagenesis extension and ligation reaction.  Vector dephosphorylation refers 5´ 
dephosphorylation of the pET16b vector in order to prevent self ligation. Lastly, the secondary 
amplification conditions refer to a re-amplification of the primary Scaffold gene PCR product. Note 
that only two Scaffold gene insertion events were observed, and of theses two insertions, one 
insertion was inverted in the vector and the other insertion had two nucleotide errors: a nucleotide 
deletion at the Xho I restricition site and one codon (R65Q) remained wild type. 
 
The following shows pET16b-∆Loop1-Scaffold insertion screening by flanking PCR 
for the first ten transformant colonies recovered from ligation reaction V (Figure 120).   
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Figure 120 . 1% Agarose gel of Scaffold gene insertion into the pET16b vector screening by 
flanking primer PCR. Lane 1 positive control (pET16b-∆Loop1His), Lane 2 DNA molecular weight 
marker III, Lanes 3-12 transformant colonies I-X, and Lane 13 blank. Note colonies II and III (lanes 
3 and 4) are positive for insertion events; however, only colony III has the proper molecular weight 
corresponding to the Scaffold gene. 
 
Since the only viable pET16b-∆Loop1-Scaffold insertion transformant colony 
recovered contained two nucleotide errors (a nucleotide deletion at the Xho I restriction 
site and one codon (R65Q) remained wild type), it was decided to repair these errors 
rather than continue screening for a non-erroneous insertion transformant colony.   
The two aforementioned nucleotide errors reported in the pET16b-∆Loop1-Scaffold 
were repaired by design of two distinct sets of complementary oligonucleotides for 
subsequent site directed mutagenesis using an adapted QuikChange® Site-directed 
mutagenesis procedure (see Methods section). One primer set effectively repaired the 
nucleotide deletion found at the Xho I restriction site while the other primer set changed 
the wild-type β-glucanase -I β-strand codon to the complementary codon of XET16A 
(R65Q). More information on these primers can be found in the “Primers List” section. The 
scaffold reparation was completed by sequential site directed mutagenesis, and 
subsequently nucleotide sequenced for confirmation of correctness. 
Upon final nucleotide sequencing of the pET16b-∆Loop1-Scaffold construct, a 
complete histidine codon present in the His-tag region was found to be deleted.  This 
codon deletion was considered to be non-critical since 9 histidine residues of the His-tag 
were still present; therefore this codon deletion was never repaired. 




3.3. Scaffold expression 
Once the correct nucleotide sequence of the pET16b-∆Loop1-Scaffold vector was 
confirmed, intracellular soluble expression and purification studies were initiated.   
First, the expression conditions of Scaffold needed to be experimentally set before 
purification could begin.  Therefore, two distinct expression conditions were assayed for 
the largest intracellular soluble Scaffold protein yield. One assay induced Scaffold 
production in the stationary growth phase while the second assay induced Scaffold 
production in the exponential growth phase.  
A:  Stationary phase induction:  a single previously transformed E. coli 
BL21DE3star colony was grown overnight in LB medium containing ampicillin at 37oC and 
250rpm.  The next morning, the culture was induced with IPTG (1mM final concentration). 
Then, cellular aliquots were taken at times 0, 2, 4, and 6 hours. Next, the samples were 
centrifuged and the cell pellet resuspended in Binding Buffer (20mM Tris-HCl, 0.5M NaCL 
pH 8.0). Subsequently, the cells were ruptured by sonication and the intracellular soluble 
and insoluble fractions were isolated by centrifugation. Lastly, the proteins of the samples 
were separated by 14% SDS-PAGE (Figure 121). Note, the insoluble pellet was 
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Figure 121 .  14% SDS-PAGE of a stationary growth phase pilot expression study of 
intracellular soluble (gel I) and insoluble (gel II) pET16b-β-glucanase-E134A-His construct. Scaffold 
protein marked within red box. Gel I Intracellular soluble fraction:  Lane 1 low range protein 
standard, Lane 2 pET16b-His 6 h induction (negative control), Lane 3 induction 0 h, Lane 4 
induction 2 h, Lane 6 induction 4 h, Lane 6 induction 6 h.  Gel II Insoluble fraction: Lane 1 
pET16b-His 6 h induction (negative control), Lane 2 low range protein standard, Lane 3 induction 0 
h, Lane 4 induction 2 h, Lane 6 induction 4 h, and Lane 6 induction 6 h.  Note that the largest 
quantity of intracellular soluble pET16b-∆Loop1-Scaffold was observed after 4 hours of induction 
while the largest quantity of insoluble pET16b-∆Loop1-Scaffold was observed after 6 hours. 
 
For stationary phase induction, the largest quantity of intracellular soluble pET16b-
∆Loop1-Scaffold was observed after 4 hours of induction while the largest quantity of 
insoluble pET16b-∆Loop1-Scaffold was observed after 6 hours. 
 
B: Exponential phase induction:  consisted of inducing transformed BL21DE3star 
E. coli cells with 1mM IPTG in the exponential growth phase at 37oC and 250rpm, either 
with or without 1% glucose in the growth medium. 1% Glucose was added to the growth 
medium for further repression of basal Scaffold expression. Cellular aliquots were taken at 
times 0, 2, 4, and 6 hours. Next, the samples were centrifuged and the cell pellet 
resuspended in Binding Buffer. Subsequently, the cells were ruptured by sonication and 
the intracellular soluble and insoluble fractions were isolated by centrifugation. Lastly the 
proteins of the samples were separated by 14% polyacrylamide gel electrophoresis 
(Figure 122). Note only the intracellular soluble fraction was analyzed by SDS-PAGE. 
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Figure 122 .  14% SDS-PAGE of the pET16b-∆Loop1-Scaffold construct exponential growth 
phase pilot expression. Lane 1 low range protein standards, Lane 2 stationary growth phase 
pET16b-∆Loop1-Scaffold after 4 hours of induction (positive control). Lane 3 pET16b-Scaffold (0% 
Glucose) 0 h induction, Lane 4 pET16b-Scaffold (0% Glucose) 2 h induction, Lane 5 pET16b-
Scaffold (0% Glucose) 4 h induction, Lane 6 pET16b-Scaffold (0% Glucose) 6 h induction, Lane 7 
pET16b-Scaffold (1% Glucose) 0 h induction, Lane 8 pET16b-Scaffold (1% Glucose) 2 h induction, 
Lane 9 pET16b-Scaffold (1% Glucose) 4 h induction, and Lane pET16b-Scaffold (1% Glucose)  6 h 
induction. Note that there is very little difference between the quantities of recombinant protein 
expressed, using growth medium with or without 1% glucose. Also note that the largest quantity of 
recombinant protein is expressed after 6 h, however, it is less plentiful than that seen after 4 hours 
of induction in the stationary growth phase pilot expression (Lane 2). 
 
As seen in the two figures above, the largest proportion of intracellular soluble 
pET16b-∆Loop1-Scaffold protein was detected after 4 hours of induction using the 
stationary growth phase transformed E. coli BL21DE3star cells.  However, the largest 
quantity of insoluble protein was detected after 6 hours of induction using also, the 
stationary growth phase BL21DE3star cells. 
Since the largest quantity of intracellular soluble Scaffold protein was seen after 
four hours of induction, it was decided to set the expression conditions as growing the cells 
until the stationary growth phase, inducing with 1mM IPTG, and harvesting after 4 hours of 
induction.   
 
3.4 Scaffold purification 
Next, 4 distinct Immobilized Metal Affinity Chromatography (IMAC) Scaffold 
intracellular soluble linear imidazol gradient, one-step, two-step, and insoluble purification 
procedures respectively were evaluated for their effectiveness: 
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Linear Imidazol Gradient Purification :  This purification used the aforementioned 
optimized expression conditions for a 1 Liter culture.  The cells were centrifuged, and the 
cell pellet resuspended in Binding Buffer (20mM Tris-HCl, 500mM NaCl pH8.0).  Next, the 
cells were ruptured by sonication and the soluble and insoluble fractions separated by 
centrifugation.  The intracellular soluble fraction was then injected into a precharged Ni2+ 
Sepharose HisTrap HP 5mL column. The column was subsequently washed and a linear 0 
to 500mM imidazol gradient applied.  Subsequent elution of the bound recombinant protein 
is shown by chromatogram in the figure below (Figure 123).  Note that the primary elution 
peak (28.35mL) is of nonspecifically bound proteins whereas the secondary peak 
(198.75mL) is the pET16b-∆Loop1-Scaffold recombinant protein.  Immediately following 
the pilot purification chromatogram the resulting purified fractions analyzed by SDS-PAGE 
are shown (Figure 124). 
 
 ElutionOnly5mLHisTrap(1168006642)001:11_UV  ElutionOnly5mLHisTrap(1168006642)001:11_Conc
 ElutionOnly5mLHisTrap(1168006642)001:11_Fractions  ElutionOnly5mLHisTrap(1168006642)001:11_Inject
 ElutionOnly5mLHisTrap(1168006642)001:11_Logbook
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Figure 123 . pET16b-∆Loop1-Scaffold recombinant protein pilot affinity His-tag purification 
chromatogram. The absorbance at 280nm blue line and the elution gradient (green line) are shown.  
The primary elution peak of nonspecifically bound proteins is observed at 28.35mL whereas the 
secondary elution peak of pET16b-∆Loop1-Scaffold recombinant protein is observed at 198.75mL. 
Note that the area of the secondary elution peak is broad rather than high.  
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Figure 124.   14% SDS-PAGE of pET16b-∆Loop1-Scaffold pilot purification fractions.  Lane 
1 low range protein standards, Lane 2 protein sample, Lane 3 primary elution peak of 
nonspecifically bound proteins (28.35mL), Lanes 4-10 secondary elution peak pertaining to Scaffold 
protein 198.75mL. Note, no scaffold protein is observed in the primary elution peak, and only 
scaffold recombinant protein can be observed in the secondary elution peak.  Also note that the 
Scaffold protein is relatively dilute in the secondary elution peak. 
 
Since the secondary elution peak, pertaining to recombinant Scaffold protein, was 
over a wide volume range (≈60mL), resulting in dilute scaffold fractions, the imidazol slope 
gradient was increased in an effort to elute the scaffold protein over less volume thereby 
concentrating the protein.  The resulting chromatogram and purified fractions analyzed by 
SDS-PAGE are shown below (Figures 125 and 126). 
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Figure 125 . Chromatogram of Scaffold purification with increased imidazol slope gradient. 
The nonspecifically bound proteins primary elution peak is observed at 38.93mL whereas the 
pET16b-∆Loop1-Scaffold recombinant protein secondary peak is observed at 132.41mL. 
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Figure 126 .  14% SDS-PAGE of pET16b-∆Loop1-Scaffold increased imidazol slope 
purification fractions. Lane 1 low range protein standards, Lane 2 insoluble cell pellet, Lane 3 
protein sample, Lane 4 column flow-through, Lanes 5-6 nonspecifically bound protein primary 
elution peak (38.93mL) Lanes 7-10 Scaffold protein elution peak (132.41mL).  Note the large 
quantity of Scaffold protein present in the insoluble cell pellet fraction. And also note the more 
highly concentrated Scaffold protein elution peak. 
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After optimizing the linear imidazol gradient slope for affinity His-tag purification of 
pET16b-∆Loop1-Scaffold recombinant protein, a simplified and time conserving one-step 
purification method was developed. 
 
One-Step Purification : The one-step purification method consisted of disrupting the 
previously expressed and harvested E. coli cells in the presence of binding buffer 
containing imidazol (20mM Tris-HCl, 0.5M NaCl, 75mM Imidazol pH8.0).  The binding 
buffer imidazol concentration was sufficiently high to prevent the non-specifically bound 
proteins seen in the aforementioned linear imidazol gradient chromatogram from binding to 
the column but low enough to allow concurrent binding of the recombinant Scaffold 
protein.   Once the E. coli cells were disrupted, the intracellular soluble fraction was 
separated from the insoluble fraction and the intracellular soluble fraction charged onto a 
pre-equilibrated Sepharose HisTrap HP 5mL column.  Subsequently, 500mM Imidazol was 
applied for elution of the bound Scaffold protein.  The resulting chromatogram and purified 
fractions analyzed by SDS-PAGE are shown below (Figures 127 and 128). 
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Figure 127 . Chromatogram of the one-step Scaffold purification. The application of the 
elution buffer concentration is marked in light green, while the protein absorbance units are marked 
in blue. Note the linear increase in column pressure with time (dark green).  The sudden drops in 
column pressure were due to a manual reduction of the flow rate, however even with the flow rate 
reduced the column pressure still continued to rise. 
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Figure 128 .  14% PAGE of pET16b-∆Loop1-Scaffold one-step purification fractions. Lane 1 
protein sample, Lane 2 low range protein standards, Lane 3 column flow-through, Lanes 4-10 one-
step elution fractions pertaining to recombinant Scaffold protein. 
 
As shown in the aforementioned chromatogram the column pressure increased 
over time. This increase in column pressure was found to be the result of the scaffold 
recombinant protein precipitating in the column.  The imidazol present in both the binding 
and elution buffers had a destabilizing effect on the Scaffold protein which likewise caused 
column obstruction.  Therefore, the one-step purification procedure was considered to be 
inoperable due to the longer Scaffold was exposed to imidazol, the more Scaffold protein 
that precipitated.  Since exposure to imidazol destabilized the recombinant Scaffold 
protein, a two-step purification procedure of intermediate simplicity was initiated. 
 
Two-step Purification : The two-step recombinant protein procedure was initiated in order 
to reduce the time in which the Scaffold protein was exposed to imidazol while 
simultaneously simplifying the purification procedure in respect to a linear gradient. 
Another benefit of the two-step procedure is that the recombinant protein is eluted over a 
small volume thereby resulting in a highly concentrated protein fraction.  
The two-step purification procedure was similar to the linear imidazol gradient 
purification procedure except that rather than applying a linear imidazol gradient, the 
column was washed with 75mM Imidazol for elution of the nonspecifically bound proteins 
and the Scaffold protein eluted with 500mM Imidazol.  The resulting chromatogram and 
purified fractions analyzed by SDS-PAGE are shown below (Figures 129 and 130). 
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Figure 129 .  pET16b-∆Loop1-Scaffold two-step protein purification chromatogram. The 
primary elution peak of nonspecifically bound proteins were eluted at 15.23min with 15% elution 
buffer while the secondary elution peak of recombinant Scaffold protein eluted at 66.13min with 
100% elution buffer. 
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Figure 130 . 14% PAGE of pET16b-∆Loop1-Scaffold two-step purification fractions. Gel I 
Lane 1 low range protein standards, Lane 2 insoluble cell pellet, Lane 3 protein sample, Lane 4 
column flow-through, Lanes 5-8 primary elution peak of nonspecifically bound proteins (15.23min), 
Gel II Lane 1 low range protein standards, and Lanes 2-9 secondary elution peak fractions 
pertaining to recombinant scaffold protein. Note it seems that a small quantity of Scaffold protein 
can be observed in the primary elution peak (Gel I Lanes 5 and 6) while the majority and highly 
concnetrated Scaffold protein can be observed in solely three secondary elution peak fractions (Gel 
II lanes 3, 4, and 5).  
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In the intracellular soluble two-step purification procedure, a small portion of 
recombinant protein was incorrectly eluted in the primary elution peak.  Also, the 
secondary elution peak pertaining to the Scaffold protein was slightly less pure than that 
attained with the linear imidazol gradient.  However, the procedure had a short execution 
time, was relatively simple, and eluted a highly concentrated Scaffold sample.  
Since such a large proportion of recombinant Scaffold protein was observed in the 
insoluble fraction, a inclusion body purification and refolding assay was conducted.  
 
Insoluble Scaffold Purification :  This protocol was similar to that used in Chapter 2.5  
∆Loop1 N-terminal His-tag design and expression. The protocol consisted of disrupting the 
previously expressed cells, washing and isolating the inclusion bodies followed by 
solubilizing the inclusion bodies in 8M urea. Next, purifying the recombinant protein, in a 
denatured state, by IMAC with a 2-step imidazol gradient, and subsequently refolding the 
purified fractions by dialysis. The resulting chromatogram and subsequent analysis of 
elution fractions by SDS-PAGE with Coomassie staining are shown below (Figures 131 
and 132). 
 
 Trevor2steps(1174398577)002:10_UV  Trevor2steps(1174398577)002:10_Conc  Trevor2steps(1174398577)002:10_Fractions
 Trevor2steps(1174398577)002:10_Inject






  0  50 100 150 200 ml
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 B12 B11 B10 B9 B8B7 B5 B3 B1 C2 C4 C6 C8 C10 C12 D11 D9 D7











B - 6-B5.. 1-C2
 
Figure 131 . Chromatogram of Scaffold inclusion body two-step purification.  Note –the non-
uniform secondary elution peak pertaining to recombinant Scaffold protein. 
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Figure 132 . 14% PAGE with Coomassie staining of Scaffold inclusion body two-step 
purification aliquots. Gel I Lane 1 low range protein standards, Lane 2 insoluble fraction, Lane 3 
resolubilized protein sample, Lane 4 column flow-through, Lanes 5-10 primary elution peak fraction 
tubes A5-A9.  Gel II Lane 1 secondary elution peak tube B7, Lane 2 low range protein standards, 
Lanes 3-10  secondary elution peak tubes B6, B5, B4, B3, B2, B1,C1 and C2 Note that in the 
column flow-through fraction a large quantity of Scaffold protein is present (Gel I); therefore the 
column was effectively saturated with protein, and that the primary elution peak should have 
contained only non-specifically bound proteins however Scaffold protein is present (Gel I). 
 
Although, Scaffold protein was detected in both the column flow-through and 
primary elution peak fractions, the secondary elution peak contained a large quantity of 
recombinant Scaffold (≈47mg per 1L culture).  Upon dialysis into phosphate/citric buffer 
(87mM NaH2PO4, 6.5mM Citric, 100uM CaCl2 pH 7.4), 45mg of recombinant Scaffold 
remained soluble with ≈2mg forming precipitate.  Since ≈2mg of Scaffold protein 
precipitated upon dialysis, the ratio of Scaffold resolubilization was ≈96%.  Therefore, 
45mg of Scaffold protein per 1 liter culture could be successfully inclusion body purified 
and resolubilized by the aforementioned method.  
After analysis of the four distinct Scaffold purification methods, the intracellular 
linear imidazol gradient was observed to give the purest Scaffold fraction (less co-eluted 
contaminant proteins); however, the two-step purification method was decided upon for 
further biochemical characterization studies due to its relative simplicity, time saving 
characteristics, and elution of highly concentrated Scaffold protein. Therefore, in the 
following Scaffold sections the recombinant Scaffold protein was purified by the two-step 
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3.5. Scaffold characterization 
3.5.1.  Urea equilibrium denaturation  
In order to insure that the pET16b-∆Loop1-Scaffold protein was properly folded, a 
urea denaturation curve was executed. First, intracellular soluble Scaffold purified by the 
two-step purification procedure was scanned for the wavelength at which the maximum 
emission fluorescence occurred in phosphate/citric buffer pH7.2 with 100µM CaCl2 and 0M 
urea. The maximum emission fluorescence value recorded occurred at 340nm. Thereby, 
the urea unfolding could be effectively monitored by the decrease in fluorescence at 
340nm. 
A urea equilibrium denaturation assay was executed. The assay consisted of 
purified Scaffold protein in phosphate/citric buffer pH7.2 with 100µM CaCl2 incubated at 
37oC for 16 hours in the presence of different urea concentrations ranging from 0 to 8 
molar. Then the sample’s fluorescence intensity was analyzed with an excitation of 280nm 
and emission wavelength of 340nm. The resulting plotted fluorescence intensity versus 
urea concentration for the Scaffold, ∆Loop1, and β-glucanase-E134A pET16b constructs 
are compared below (Figure 133).  
 
Figure 133 .  Comparison of Scaffold (green), ∆Loop1 (red), and β-glucanase-E134A 
(black) pET16b urea denaturation curves. Note the singular inflection points and data uniformity of 
the Scaffold protein. Also, note the slightly decreased urea concentration needed for Scaffold 
denaturation in comparison with the other two samples. 
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The pET16b-∆Loop1-Scaffold protein showed single inflection points and data 
uniformity; therefore it was considered that the protein was properly folded and could be 
compared to the other previously developed fusion proteins. 
The same assumptions and equations utilized for the calculations of pET16b-β-
glucanase and ∆Loop1 equilibrium urea denaturation analysis were applied for analysis of 
the Scaffold recombinant protein. In the table below, the Scaffold protein is compared to 









Scaffold N-terminal His-tag 2.27±0.23  2.78±0.03 6.30±1.4 
∆loop1 N-terminal His-tag 2.42 ±1.32  3.13±0.08 7.58±4.3 
β-glucanase-E134A N-terminal His-tag 3.07±0.74  3.74±0.02 11.50±2.8 
Table 17 . Comparison of urea equilibrium denaturation values for Scaffold N-terminal His-
tag, ∆loop1 N-terminal His-tag, and β-glucanase-E134A N-terminal His-tag. The m and [D50%] 
values for both Scaffold and Loop1 are similar, whereas in comparison with β-glucanase a 1M urea 
concentration denaturation shift is noted. 
 
Analysis of the Scaffold N-terminal His-tag recombinant protein stability, in 
comparison with that of ∆loop1 N-terminal His-tag, reveals that the Scaffold construct is 
only slightly less stable.  However,  Scaffold denatures at approximately 1M less of urea 
than the β-glucanase-E134A N-terminal His-tag construct. 
After confirmation of Scaffold N-terminal His-tag recombinant protein proper 
folding, enzyme kinetic assays were attempted. First, the hydrolytic activity of Scaffold with 
both the natural PttXET16A and β-glucanase substrates will be discussed followed by 
Scaffold-E134A glycosynthase activity with synthetic PttXET16A and β-glucanase 
substrates. 
 
3.5.2.  Scaffold hydrolytic activity  
In order to assess the Scaffold hydrolytic activity, three polysaccharide substrates 
were studied respectively.  
1. Xyloglucan: the natural polysaccharide substrate of xyloglucan 
endotransglycosylase. 
2. β-glucan: the natural polysaccharide substrate of 1,3-1,4-β-glucanase. 
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3. Cellulose: a linear β-1,4 polysaccharide, which mimics the un-branched 
backbone of xyloglucan.  
 
 For Scaffold xyloglucan hydrolytic activity, Scaffold was incubated with high 
molecular weight xyloglucan polysaccharides.  If hydrolase activity was present, the high 
molecular weight polysaccharides would decrease in size. This evolution of size could be 
observed by the addition of Iodine, a chemical dye which can bind to the polymer substrate 
while conversely lacking the ability to form a complex with low molecular weight oligomers 
[47, 67].  Therefore by following the loss of Iodine intensity, as the average molecular weight 
decreases, the hydrolase activity of Scaffold could be observed (see “Methods” section).  
Scaffold enzyme (final concentration 15µM) was incubated with xyloglucan (final 
concentration 1mg/mL) in 87mM Na2HPO4 6.5mM Citric acid, 100µM CaCl2 pH7.4 at 37
oC 
and time point aliquots were taken over 65 hours. The positive control consisted of 
Aspergillus niger Cellulase A which can inherently hydrolyze both branched and linear β-
1,4 carbohydrates (final concentration 50nM). The negative control was pET16b-β-
glucanase (final concentration 20µM). The enzymatic reaction was stopped by immersion 
of the time point aliquots in a dry-ice ethanol bath. Following completion of the enzymatic 
assay, iodine was added to the time point aliquots and the absorbance at 590nm read.  

















Scaffold Negative control Positive control
 
Figure 134 .  Colorimetric xyloglucan hydrolase activity assay. Scaffold green, β-glucanse 
negative control (red), and Aspergillus niger Cellulase A positive control (black).  Note the positive 
control completely hydrolyzed the xyloglucan polysaccharides in less than 1 hour whereas no 
hydrolytic activity was detected for the Scaffold sample over 65 hours. 
 
No xyloglucan hydrolytic activity was detected for the ∆Loop1-Scaffold enzyme 
over the course of 65 hours.  
Scaffold β-glucan hydrolytic activity was assessed by the DNS reducing ends 
assay (see “Methods” section).  ∆Loop1-Scaffold (32µM) was incubated with β-glucan (2 
mg/ml), The positive control reaction consisted of pET16b-β-glucanase (15nM) while the 
negative control was phosphate citric buffer with β-glucan. All assays were run in 87mM 
Na2HPO4 6.5mM Citric acid, 100µM CaCl2 pH7.4 at 37°C for 1 hour with time point aliquots 
taken every 5 minutes. The enzymatic reaction was stopped by immersion of the time 
point aliquots in a dry-ice ethanol bath. Reducing sugars were measured using the 
dinitrosalicylic acid (DNS) reagent and the absorbance read at 530nm (Figure 135). 
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Figure 135 . β-glucan DNS reducing ends hydrolase activity assay. Scaffold (red), no 
enzyme negative control (black), and pET16b-β-glucanase positive control (green). Note the 
positive control completely hydrolyzed the β-glucan polysaccharides in approximately 20 minutes 
whereas no hydrolytic activity was detected for the Scaffold sample. 
 
No β-glucan hydrolytic activity was detected for the ∆Loop1-Scaffold enzyme over 
1 hour.   
Scaffold cellulose hydrolytic activity was also determined by the DNS reducing 
ends assay (see Methods section).  ∆Loop1-Scaffold (59uM) was incubated with cellulose 
(0.75 mg/ml). The positive control reaction consisted of Aspergillus niger Cellulase A, 
which can readily hydrolyze cellulose.  The negative control was pET16b-β-glucanse 
(30µM). All assays were run in 87mM Na2HPO4 6.5mM Citric acid, 100µM CaCl2 pH7.4 at 
37°C for 96 hours with time point aliquots taken at  6, 25, and 96 hours. The enzymatic 
reaction was stopped by immersion of the time point aliquots in a dry-ice ethanol bath. 
Reducing sugars were measured using the dinitrosalicylic acid (DNS) reagent and the 
absorbance read at 530nm (Figure 136). 
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Figure 136 . Cellulose DNS reducing ends hydrolase activity assay. Negative control 
(pET16b-β-glucanse). Note the positive control (Aspergillus niger Cellulase A) completely 
hydrolyzed the cellulose polysaccharides in approximately 6 hours whereas no hydrolytic activity 
was detected for the Scaffold sample. 
 
No cellulose hydrolytic activity was detected for the ∆Loop1-Scaffold enzyme 
over 96 hours. 
Therefore, all attempts of enzymatic hydrolysis using both the natural substrates 
of xyloglucan endotransglycosylase and 1,3-1,4-β-glucanase were unsuccessful with the 
Scaffold enzyme. 
 
3.5.3.  Scaffold glycosynthase activity 
Scaffold design has modified the structure of the negative subsites to become a 
XET-like donor site (that is, to accept branched substrates) whereas positive subsites 
remain β-glucanase-like (that is, to accept linear substrates).  Since there is no natural 
substrate which consist of ½ xyloglucan and ½ β-glucan, mimicking the ∆Loop1-Scaffold 
binding pocket, Scaffold enzymatic activity was assessed using the glycosynthase 
methodology with hybrid synthesized substrates e.g. a branched xyloglucan 
ologisaccharide donor and linear β-glucan oligosaccharide acceptor.  
The pET16b-∆Loop1-Scaffold-E134A glycosynthase vector was prepared by the 
design of two oligonucleotides (E134A-Sense and E134A-Antisense) for subsequent site 
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directed mutagenesis by means of mutating Glutamate 134 to Alanine (see Methods 
section).  
Upon confirmation of the correct nucleotide sequence, enzymatic studies of 
∆Loop1-Scaffold-E134A were initiated with three distinct donor-acceptor combinations: 
1. XXGαF + G4G-Mu (xyloglucan-like donor and β-glucan-like acceptor). 
2. XXXGαF + G4G3G-Mu (both an extended xyloglucan-like donor and β-
glucan-like acceptor). 
3. G4G4G3GαF + G4G-Mu (both β-glucan-like donor and acceptor) 
 
The XXGαF + G4G-Mu Scaffold glycosynthase reaction was initiated using 
Scaffold (final concentration 26µM) incubated with a fluoride activated glycosyl donor 
XXGαF (final concentration 25.5mM) in the presence of a G4G-Mu glycoside acceptor 
(final concentration 25.5mM) at 35oC (final volume 500µL). Sodium fluoride standards for 
calibration curves were prepared in the same experimental conditions (6.5mM citric acid 
87mM Na2HPO4 pH7.2 with 100µM CaCl2 at 35
oC). As the enzymatic reaction progressed 
and polysaccharide product was formed, fluoride ions were liberated from the glycosyl 
donor. The liberation of these fluoride ions was monitored with a fluoride ion sensor 
(Figure 137). Note that the chemical hydrolysis negative control (negative control 1) 
consisted of the alpha-fluoride donor and acceptor saccharides in the reaction mixture 
using the same reaction conditions but without enzyme while the enzyme catalyzed self 
condensation negative control (negative control 2) consisted of the alpha-fluoride donor 
and ∆Loop1-Scaffold enzyme without acceptor . 
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Figure 137 .  XXGαF + G4G-Mu Scaffold-E134A glycosynthase assay. Negative control 1 
chemical hydrolysis, Negative control 2 enzyme catalyzed self condensation. Note no Scaffold 
glycosynthase activity was detected over 1 hour. 
 
No glycosynthase activity was detected for the ∆Loop1-Scaffold enzyme with the 
XXGαF + G4G-Mu substrates.  In an attempt to completely occupy all negative and 
positive subsites, a glycosynthase activity assay using the oligosaccharides, XXXGαF and 
G4G3G-Mu was initiated. 
The reaction consisted of ∆Loop1-Scaffold-E134A (final concentration 26µM) with 
the fluoride activated glycosyl donor XXXGα F (final concentration 25mM) in the presence 
of a G4G3G-Mu glycoside acceptor (final concentration 24mM) at 35oC (final volume 
500µL). The same fluoride selective electrode monitoring and experimental conditions as 
those described above were employed (see Methods section).  The liberation of these 
fluoride ions was monitored and the resulting graph shown below (Figure 138). No positive 
control enzymatic reaction for this experiment was conducted since no enzyme in our 
enzyme bank was present which can glycosylate the two aforementioned substrates.  The 
negative control 1 reaction consisted of the alpha-fluoride donor and acceptor saccharides 
in the reaction mixture using the same reaction conditions but without enzyme, while 
negative control 2 reaction consisted of the alpha-fluoride donor with enzyme, but without 
acceptor saccharides. 
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Figure 138.  XXXGαF + G4G3G-Mu Scaffold-E134A glycosynthase assay.  Negative 
control chemical hydrolysis. Note no Scaffold glycosynthase activity was detected over 1 hour. 
 
No glycosynthase activity was detected for the ∆Loop1-Scaffold enzyme with the 
XXXGαF + G4G3G-Mu substrates.  In conclusion, no hybrid glycosynthase activity was 
observed for combinations of xyloglucan oligosaccharide donor and β-glucan 
oligosaccharide acceptor molecules. 
Lastly, a glycosynthase activity assay involving substrates shown to be excellent 
donor and acceptor molecules, for the nucleophile-less 1,3-1,4-β-glucanase-E134A 
construct, G4G4G3GαF + G4G-Mu respectively was initiated.  
∆Loop1-Scaffold-E134A (final concentration 26µM) with the fluoride activated 
glycosyl donor G4G4G3GαF (final concentration 25.5mM) and G4G-Mu glycoside 
acceptor (final concentration 25.5mM) at 35oC (final volume 500µL) was assayed using the 
same fluoride selective electrode monitoring and experimental conditions as those 
described above. The liberation of these fluoride ions is shown below (Figure 139). Note 
that the negative control consisted of the alpha-fluoride donor and acceptor saccharides in 
the reaction mixture using the same reaction conditions but without enzyme while the 
positive control consisted of pET16b-β-glucanase-E134A (final concentration 18µM) with 
alpha-fluoride donor and acceptor. 
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Figure 139 .  G4G4G3GαF + G4G-Mu Scaffold glycosynthase assay.  Positive control 
pET16b-β-glucanase-E134A. Negative control chemical hydrolysis. Note no Scaffold glycosynthase 
activity was detected over 1 hour while the positive control showed synthesis of saccharides. 
 
No hydrolase or glycosynthase enzymatic activity was ever detected for the 
∆Loop1-Scaffold enzyme.  A summary of the glycosynthase assays executed with the 
distinct donor and acceptor substrates, concentrations, and activity are shown below 
(Table 18).  
 






XXGαF (25.5mM) G4G-Mu (25.5mM) 26µM No 
XXXGαF (25mM) 
G4G3G-Mu 
(24mM) 26µM No 
G4G4G3GαF (25.5mM) G4G-Mu (25.5mM) 26µM No 
Table 18.  Scaffold-E134A glycosynthase reactions assayed with donor and acceptor 
substrates, concentrations, and enzymatic activity. 
 
Since no enzymatic activity was observed, substrate binding calorimetry 
experiments were initiated in order to assess whether or not the Scaffold enzyme was 
capable of binding a series of carbohydrate substrates. 
 
3.5.4.  Isothermal titration calorimetry  
Isothermal titration calorimetry (ITC) is a biophysical technique used to determine 
the thermodynamic parameters of biochemical interactions. When substances bind, heat is 
either generated or absorbed. Measurement of this heat allows accurate determination of 
binding association constants (KA), reaction stoichiometry (n), change in enthalpy ( ∆H) 
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and change in entropy ( ∆S), thereby providing a complete thermodynamic profile of the 
molecular interaction in a single experiment.  In ITC, a syringe containing a “ligand” 
solution is titrated into a cell containing a solution of the “macromolecule” at constant 
temperature. When the ligand is injected into the cell, the two materials interact, and heat 
is released or absorbed in direct proportion to the amount of binding.  As the 
macromolecule in the cell becomes saturated with the ligand, the heat signal diminishes 
until only background heat of dilution is observed.  In this study, the binding of substrate 
molecules to the ∆Loop1-Scaffold enzyme was analyzed.  
All calorimetry experiments were carried out using the Microcal® VP-ITC 
calorimeter that uses a cell feedback network (CFB) to differentially measure and 
compensate for heat produced or absorbed between the sample and reference cell at 
25oC while all enzymes and substrates were dissolved in 20mM Tris-HCl, 0.5M NaCl, 
pH7.5 (see “Methods” section).  
First, natural substrate polysaccharides for both xyloglucan endotransglycosylase 
and 1,3-1,4-β-glucanase, xyloglucan and β-glucan respectively, were assayed for Scaffold 
binding. As a positive control the pET16b-β-glucanase-E134A nucleophile-less mutant, 
was employed since the E134A mutant lacks catalytic activity, but substrate binding to β-
glucan is equal to that of the wild-type enzyme.  The negative control consisted of pET16b-
β-glucanase-E134A with xyloglucan polysaccharides. Shown below are the ITC binding 
thermograms for the Scaffold enzyme with β-glucan and xyloglucan and the β-glucanase-
E134A with β-glucan and xyloglucan (Figure 140). 
 




Figure 140 . ITC binding thermograms of polysaccharide substrates.  Top left β-glucanase-
E134A with β-glucan (positive control). Top right, β-glucanase-E134A with xyloglucan (negative 
control). Bottom left Scaffold with β-glucan. Bottom right Scaffold with xyloglucan. Note Scaffold 
shows slight binding to both β-glucan and xyloglucan polysaccharides whereas β-glucanase-E134A 
only shows binding to β-glucan. 
 
The binding calorimetry data suggests that the Scaffold enzyme has a hybrid 
binding signature and can weakly bind both xyloglucan and β-glucan polysaccharides.  
Further isothermal calorimetry of Scaffold binding to both xyloglucan and β-glucan 
oligosaccharides was performed in order to understand why the Scaffold-E134A 
glycosynthase activity for hybrid donor and acceptor substrates was negligible. 
Using the same conditions as those described above binding of, the β-glucanse 
oligosaccharide substrate, G4G4G4G-OMe, and the PttXET16A oligosaccharide 
substrates XXXG and LLXG were assayed.  Since the G4G4G3G tetrasaccharide had 
been previously shown to be an excellent β-glucanase-E134A substrate, β-glucanase-
E134A with G4G4G3G was used as a positive control.  Below, the Scaffold 
oligosaccharide and β-glucanase-E134A oligosaccharide binding thermograms are shown 
(Figure 141). 




Figure 141 .  ITC binding thermograms of oligosaccharide substrates.  Top left β-gluanase-E134A 
with G4G4G3G tetrasaccharide (positive control). Top right Scaffold with XXXG oligosaccharide.  
Bottom left Scaffold with G4G4G4G-OMe. Bottom right Scaffold with LLXG.  Note Scaffold shows 
slight binding to the G4G4G4G-OMe substrate. 
 
The ITC data suggests Scaffold can weakly bind G4G4G4G-OMe, an excellent 1,3-
1,4-β-glucanse substrate, however no binding was noted for the xyloglucan-like 
oligosaccharides. 
In conclusion, the Scaffold enzyme showed a hybrid binding signature, by being 
able to bind both β-glucan and xyloglucan, whereas the wild-type xyloglucan 
endotransglycosylase and 1,3-1,4-β-glucanase cannot. Therefore the Loop1 and β-strand 
modifications did in fact change the enzyme’s specificity for polysaccharides, however 
conjointly inactivated enzymatic hydrolysis.  
No thermodynamic parameters are calculated since the thermograms show weak 
binding, and current date should be considered preliminary; a deeper calorimetric analysis 
is required. 




3.6. Scaffold X-ray structure analysis 
In an effort to understand exactly what were the structural consequences of 
Loop1 removal and mutation of the negative subsite β-strands, and to also provide a basis 
for detailed structure–function studies, the crystal structure of ∆Loop1-Scaffold, 
heterologously expressed in E. coli, has been determined.   
The starting point for X-ray crystallography is a highly pure and homogeneous 
protein sample for the formation of an adequate crystal with no significant internal 
imperfections.  Therefore, intracellular soluble recombinant Scaffold was first purified by 
the aforementioned linear imidazol gradient procedure.  Subsequently, a second 
purification step of gel filtration was developed for further acquisition of a homogeneous 
sample.   
 
3.6.1.  Gel Filtration 
After Scaffold purification, the aliquots pertaining to recombinant Scaffold were 
pooled and concentrated to ≈1.5mL by Amicon regenerated cellulose Centriprep® 
Centrifugal Filter Device MWCO 10,000Da.  Following Scaffold protein concentration, the 
Scaffold protein was injected (1 mL/min) into a Binding Buffer (20mM Tris-HCl 0-5M NaCl 
pH 8.0) pre-equilibrated High Load 16/60 prep grade column with pre-packed Superdex™ 
75 resin. The resulting chromatogram and Elution fractions analyzed by SDS-PAGE with 
silver staining are shown below (Figure 142 and 143). 
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Figure 142 .  Chromatogram of recombinant Scaffold gel filtration. The protein elution 
peak pertaining to Scaffold is shown in blue at 21.35mL; the void volume is annotated by the 
conductivity peak (brown). Note the slight loss of symmetry at the leading edge the protein elution 
peak. 
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Figure 143 . 14% SDS-PAGE with silver staining of the Scaffold gel filtration elution 
fractions.  Lane 1 low range protein standards, Lane 2 elution fraction at 28mL, Lane 3 elutin 
fraction at 25mL, Lane 4 elution fraction at 20mL, Lane 5 elution fraction at 18mL, Lane 6 blank, 
Lane 7 elution fraction at 15mL, Lane 8 blank, Lane 9 elution fraction at 12mL (loss of symmetry), 
and Lane 10 blank.  Note in lane 9 two isforms of Scaffold protein can be observed. 
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The Scaffold protein sample was concluded to be sufficiently pure of co-purified 
contaminant proteins for X-ray crystallography however; the presence of two Scaffold 
isoforms (seen in the loss of symmetry at the leading edge of the gel filtration elution peak) 
effectively inhibited proper protein crystallization. Therefore, analysis of Scaffold isoform 
formation was initiated.  Previously purified and gel filtrated Scaffold protein was incubated 
at 4oC for 1 week and subsequently re-gel filtrated to see whether or not the 
chromatogram signature had changed.  Upon re-gel purification, the chromatogram 
signature changed from almost-symmetrical elution peak shown above to that shown 
below (Figure 144).  Also, the elution fractions analyzed by SDS-PAGE with Coomassie 










0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 ml
F2 A2 A4 A6 A8 A10 A12 B2 B4 B6 B8 B10 B12 C2 C4 C6 C8 C10 C12 D2 D4 D6 D8 D10 D12 Waste
B8 B10 B12 C2 C4  
Figure 144 .  Chromatogram of the re-gel filtered Scaffold protein sample after a one 
week incubation at 4oC.  Note the total loss of peak symmetry, and the distinguishable presence of 
two protein peaks. 
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Figure 145 .  14% PAGE with Coomassie staining of the re-gel filtered Scaffold protein 
sample after one week incubation at 4oC.  Lane 1 Scaffold protein (positive control), Lane 2 low 
range protein standards, Lane 3 elution aliquot tube B8, Lane 4 elution aliquot tube B10, Lane 5 
elution aliquot tube B11, Lane 6 elution aliquot tube B12, Lane 7 elution aliquot tube C1, Lane 8 
elution aliquot tube C2, Lane 9 elution aliquot tube C3, and Lane 10 elution aliquot tube C4. Note in 
lanes 3, 4 and 5 two isoforms of Scaffold protein are clearly visible. 
 
Confirmation of isoform formation over time resulted in scientific investigation 
along two separate paths, one N-terminal sequencing of the lower molecular weight 
isoform in order to understand exactly which amino acids were being lost, and two 
continuing enzymatic research by purifying the Scaffold protein immediately before use in 
order to limit isoform formation overtime. 
N-terminal sequencing of the low molecular weight Scaffold isoform revealed 21 
amino acids of the N-terminal were hydrolyzed resulting in a molecular weight difference of 
2532.7Da. The low molecular weight isoform consisted of a total His-tag loss while leaving 
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Figure 146.   N-terminal hydrolysis of pET16b-∆Loop1-Scaffold-His protein sample. 
 
Since the amino acid hydrolyzed was methionine 21, two methods for obtaining a 
homogeneous recombinant Scaffold sample were employed.   
1. Mutation of the methionine to a less reactive amino acid, in this case 
alanine was considered (M21A).   
2. Utilization of the protease Factor Xa for total removal of the His-tag 
peptide from the Scaffold protein was considered.  
 
3.6.2.  M21A 
In order to mutate methionine 21 to alanine two mutagenic primers were designed 
for subsequent site-directed mutagenesis.  More information on these primers can be 
found in the “Primer List” section.  After successful M21A site-directed mutagenesis and 
confirmation of the correct nucleotide sequence, the M21A construct was expressed and 
purified for analysis of isoform formation. 
The pET16b-∆Loop1-Scaffold-M21A vector construct was expressed using the 
aforementioned expression conditions for the pET16b-∆Loop1-Scaffold construct.  
Following Scaffold expression, the M21A construct was affinity chromatography purified by 
“Scaffold linear imidazol gradient purification” procedure. The resulting chromatogram and 
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elution fractions analyzed by SDS-PAGE with Coomassie staining for the Scaffold-M21A 
linear imidazol gradient affinity purification are shown below (Figures 147 and 148). 
 
 ElutionOnly5mLHisTrap(1193411547)001:10_UV  ElutionOnly5mLHisTrap(1193411547)001:10_Conc
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Figure 147 . Chromatogram of the pET16b-∆Loop1-Scaffold-M21A recombinant protein 
linear imidazol gradient purification. The primary elution peak pertaining to nonspecifically bound 
proteins is found at 34.92mL while the secondary elution peak pertaining to Scaffold-M21A protein 
is found at 119.56mL. Note the asymmetric nature of the secondary elution peak.  




Figure 148 . 14%SDS-PAGE with Coomassie staining of the pET16b-∆Loop1-Scaffold-
M21A linear imidazol gradient purification elution fractions. Lane 1 low range protein standards, 
Lane 2 blank, Lane 3 protein sample, Lane 4 blank, Lane 5 column flow-through, Lane 6 blank, 
Lane 7 primary elution peak, Lane 8 blank, Lane 9 secondary elution peak pertaining to Scaffold-
M21A, and Lane 10 blank. Note a homogeneous Scaffold-M21A protein fraction was recovered 
(Lane 9). 




Even though the secondary elution peak pertaining to Scaffold-M21A 
recombinant protein was asymmetric, the resulting analysis by SDS-PAGE showed that a 
homogeneous Scaffold-M21A fraction was recovered.  Following affinity purification the 
Scaffold-M21A protein sample was subsequently gel filtrated using the previously 
developed Scaffold gel filtration method. The resulting chromatogram and elution fractions 
analyzed by SDS-PAGE with silver staining are shown below (Figures 149 and 150). 
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Figure 149 . Chromatogram of pET16b-∆Loop1-Scaffold-M21A gel filtration. The elution 
peak pertaining to Scaffold-M21A recombinant protein can be found at 77.63mL. Note the slight 
loss of symmetry at the leading elution peak edge (tube B8). 
 
Results and Discussion  
 
 182 




Figure 150 .  14% PAGE with silver staining of the elution peak pertaining to Scaffold-
M21A recombinant protein.  Lane 1 low range protein standard, Lane 2 blank, Lane 3 tube B5, Lane 
4 blank, Lane 5 tube B6, Lane 6 blank, Lane 7 tube B7, Lane 8 blank, Lane 9 tube B8, and Lane 10 
blank.  Note all tubes show a homogeneous Scaffold-M21A protein fraction. 
 
While both the secondary elution peak of the linear imidazol gradient affinity 
purification and gel filtration fractions showed slight asymmetry, the Scaffold-M21A protein 
was observed to be homogeneous by PAGE with Coomassie staining (not shown). 
However, by PAGE with silver staining contaminant proteins are observed (Figure 150).  
Therefore, mutation of the methionine, which had previously hydrolyzed in the pET16b-
∆Loop1-Scaffold recombinant protein construct, effectively prevented the formation of the 
two previously observed Scaffold isoforms.  The only downside of the pET16b-∆Loop1-
Scaffold-M21A vector construct was that the quantity of Scaffold protein recovered was 
approximately half of that recovered with pET16b-∆Loop1-Scaffold vector (4.5mg versus 
10mg per 1 liter culture). 
 
3.6.3.  Factor Xa digestion  
In parallel of the aforementioned Scaffold-M21A vector construction, expression 
and purification, the utilization of the protease Factor Xa for complete proteolytic removal 
of the Scaffold His-tag was implemented in order to attain a homogeneous protein fraction.  
The Factor Xa protein when incubated with the pET16b-∆Loop1-Scaffold fusion 
protein recognizes and cleaves the Ile-Glu-Gly-Arg-↓-X sequence, where ↓ is the 
cleaveage point. Typically 1mg of fusion protein can be incubated with 10µg of Factor Xa 
for 2.5 hours at 37oC, pH 7.6-8.0. 
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Once a batch of Scaffold protein was affinity chromatography purified, the Scaffold 
protein was incubated with the Factor Xa protease at 37oC.  Immediately upon addition of 
the Factor Xa protease, the Scaffold protein was observed to precipitate.  Upon completion 
of the proteolytic reaction, the soluble and precipitated fractions were separated by 
centrifugation, and the soluble fraction gel filtrated.  The resulting gel filtration 
chromatogram and elution fractions analyzed by SDS-PAGE with silver staining are shown 
(Figures 151 and 152). 
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Figure 151 . Factor Xa digested Scaffold gel filtration chromatogram. Note the slightly 
retarded elution fraction of 79.42 mL, which corresponds to a lower molecular weight Scaffold 
protein, in comparison to the previous gel filtrations.  Also note the presence of the cleaved 
peptides at 98.62mL. 
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Figure 152 .  14% PAGE with silver staining of the elution peak pertaining to Factor Xa 
digested Scaffold recombinant protein. Lane 1 pre-Factor Xa digested Scaffold protein, Lane 2 
blank, Lane 3 low range protein standards, Lane 4 blank, Lane 5 tube B6, Lane 6 blank, Lane 7 
tube B7, Lane 8 blank, Lane 9 tube B3, Lane 10 blank, and Lane 11 tube B8.  Note all elution 
fractions contain homogeneous Scaffold fraction. 
 
Although a homogeneous Scaffold fraction was recovered after Factor Xa 
proteolytic digestion, the recovery yield of soluble protein was quite low.  From 12mg of 
starting Scaffold protein only 3mg remained soluble and could be gel filtered.  Therefore, 
Factor Xa digestion of Scaffold protein for attaining a homogeneous protein fraction was 
considered inoperable due to the elevated price of Factor Xa enzyme and the low recovery 
yields.  Rather than digesting Scaffold protein with Factor Xa for obtaining a homogeneous 
sample, it was decided to either use the pET16b-∆Loop1-Scaffold-M21A vector construct 
or immediately purify pET16b-∆Loop1-Scaffold before use.  
The protein which finally gave crystals of sufficient quality for subsequent diffraction 
came from purifying pET16b-∆Loop1-Scaffold by a linear imidazol gradient followed by 
concentrating the sample to ≈2mL. Next, gel filtration of the sample, and then immediately 
attempting to grow crystals (no dialysis). 
 
3.6.4. Crystallographic analysis  
These recovered Scaffold crystals were diffracted and their X-ray structure 
revealed and the protein 3D structure was solved. Crystallization experiments and 
structure resolution were performed by Barbara Calisto and Dr. Ignasi Fita at the Parc 
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Científic de Barcelona.  In the following table the general crystallographic data 




  Space group 
  Unit Cell Parameters 
      a, b, c (Å) 
      α, β, γ (º) 
  Resolution (Å) 
  Unique reflections 
  Completeness (%) 
  Rmerge (%) 
  <I/σ(I)> 
Refinement statistics 
  Rwork (%)/Rfree (%) 
  No. of protein atoms 
  No. of solvent  molecules 
  No. of Ca2+ atoms 
  Root-mean-square deviations 
     bond lengths (Å) 
     bond angles (º) 




39.6, 54.8, 54.9 















Table 19.  Scaffold crystallographic data collection and refinement statistics. 
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Even though the overall structure of ∆Loop1-Scaffold is a curved β-sandwich 
similar to other enzymes in the glycoside hydrolase family GH16, the removal of Loop1 
and mutation of the β-strands generated a unique enzyme structure (Figure 153). 
 
Figure 153 . Stereo α-Carbon trace of Scaffold. Extended β-strands are shown in yellow, β-
bridges green, turns purple, and coils red. 
 
Three zones of the Scaffold structure were not completely resolved. The first zone 
which was not observed in the crystallographic structure was the N-terminal His-tag and 
Factor Xa protease recognition site due to its high level of disorganization.  
The second zone, found in the Loop2 region, showed only the Cα backbone while 
no amino acid side chains could be observed.  These unobserved amino acid side chains 
were replaced with alanine residue in the final Scaffold X-ray structure.   
The third zone, found in the Loop3 region, was highly disorganized, and therefore 
no crystallographic data was obtained.  In the following figure, the theoretical Scaffold 
amino acid sequence is compared with that obtained through crystallographic resolution 
(Figure 154). 




theoretical        1   MGHHHHHHHH HSSGHIEGRH MLEQTGGSFY EPFNNYNTGL WQKWAFDHVS  
final_struct       1   ---------- ---------- ---QTGGSFY EPFNNYNTGL WQKWAFDHVS  
                                                                  
theoretical       51   MTSLGEMRLS LTSPSYNKFD GGGNQSVQTY GYGLYEVNMK PAKNVGIVSA  
final_struct      28   MTSLGEMRLS LAAASAAAAA GGGNQSVQTY GYGLYEVNMK PAKNVGIVSA  
 
theoretical      101   FYTSTGPTDG TPWDEIDIEF LGKDTTKVQF NYYTNGVGNH EKIVNLGFDA  
final_struct      78   FYTSTGPTDG TPWDEIDIEF LGKDTTKVQF NYYTNGVGNH EKIVNLGFDA  
 
theoretical      151   ANSYHTYAFD WQPNSIKWYV DGQLKHTATT QIPQTPGKIY MSLWNGAGVD  
final_struct     128   ANSYHTYAFD WQPNSIKWYV DGQLKHTATT QIPQTPGKIY MSLWA-----  
 
theoretical      201   EWLGSYNGVT PLYAHYNWVR YTKR  
final_struct     173   ---------- -LYAHYNWVR YTKR  
            
Figure 154 .  Amino acid alignment of the theoretical Scaffold sequence with that derived by 
the crystallographic data. Dashes represent amino acids not observed through crystallographic 
resolution while red highlighted alanines were amino acids whose side chains could not be 
resolved. 
 
A graphical representation of the calculated root mean square deviation RMSD 
values corresponding to both Scaffold subunits A and B with respect to those of wild-type 
















Figure 155.  Calculated root mean square deviations. Scaffold subunit A superimposed 
over wt β-glucanase (green) RMSD = 0.792 Å for 177 equivalent Cα atoms. Scaffold subunit B 
superimposed over wt β-glucanase (blue) RMSD = 0.797 Å for 178 equivalent Cα atoms. Scaffold 
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Note Scaffold residues 21-33 are of the deleted loop and are not comparable with 
the wild-type β-glucanase model; therefore no RMSD can be calculated.  Also, residues 54-
66 (Loop2) suffered a large displacement when compared to the position on the native 
protein so no RMSD was calculated. And Scaffold residues186-201 (subunit A) / 187-201 
(subunit B) show no diffraction density in this region, which is indicative of a disordered 
(Loop3) region; therefore, no RMSD was calculated. 
 
The β-factors are represented in the following structural figure with the lowest β-
factor values represented in blue while the highest β-factor factor values are represent in 
red (Figure 156).  
 
Figure 156 . Structural representation of Scaffold β-factors. Low β-factor values are 
represented in blue while high β-factor factor values are represent in red. 
 
 
3.6.4.1.  Loop1 comparison 
3-Dimensional analysis of the Scaffold structure revealed that the Scaffold Loop1 
region was correctly altered from being homologous to β-glucanase to being homologous 
Results and Discussion  
 
 189 
with PttXET16A.  In the following figures the Scaffold Loop1 region is compared to that of 





Figure 157 .  Structural analysis of Scaffold (white) and 1,3-1,4-β-glucanase (magenta) 
Loop1 regions. Note the presence of the β-glucanase Loop1 region (red arrows) crossing the 
enzymatic face whereas Scaffold contains no such loop.  
 






Figure 158 . Structural analysis of Scaffold (white) and 1,3-1,4-β-glucanase (magenta) 
Loop1 regions. Note the presence of the β-glucanase Loop1 region (red arrows) crossing the 
enzymatic face whereas the Scaffold Loop1 region crosses directly to back of the enzyme.  
 
As seen in the previous two figures, the Scaffold Loop1 region was effectively 
altered from the β-glucanase Loop1-like structure, which crosses the enzymatic face, to a 
highly reduced Loop1 structure which shows no enzymatic face protrusion.  Since in order 
to create the ∆Loop1-Scaffold enzyme, the β-glucanase Loop1 region was replaced with 
that of XET16A, further comparison of the Scaffold and PttXET16A Loop1 region was 
conducted (Figures 159 and 160). 
 






Figure 159 .  Structural analysis of ∆Loop1-Scaffold and PttXET16A Loop1 regions. Note 





Figure 160 .  Structural analysis of ∆Loop1-Scaffold (white) and PttXET16A (red) Loop1 
regions. Note the high Loop1 similarity between the Scaffold and XET16A enzymes (red arrows).  
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Both ∆Loop1-Scaffold and PttXET16A show very homologous Loop1 regions as 
expected.  However analysis of the individual amino acids present in both the PttXET16A 
and Scaffold structures revealed that homologous tryptophan residues had distinct side-




Figure 161 .  Structural analysis of ∆Loop1-Scaffold (white) and PttXET16A (red) Loop1 
tryptophan residues. Note the Scaffold Loop1 tryptophan residue (white licorice) orients towards the 
enzymatic cleft while the XET tryptophan residue (red licorice) orients away from the cleft. 
 






Figure 162 .  Structural analysis of ∆Loop1-Scaffold (white) and PttXET16A (red) Loop1 
tryptophan residues. Note the Scaffold Loop1 tryptophan residue (white licorice) orients towards the 
enzymatic cleft while the XET tryptophan residue (red licorice) orients away from the cleft. 
 
Even though the Scaffold Loop1 tryptophan residue side-chain points into the 
enzymatic face, whereas the tryptophan in the native PttXET16A  does not, this change 
was considered to be relatively minor and at least easily repairable (site-directed 
mutagenesis). Therefore, deletion of the β-glucanase Loop1 region to form the ∆Loop1-
Scaffold enzyme was successful and resulted in the completion of the stated objective of 
opening the enzymatic face for acceptance of branched substrates.  
 
3.6.4.2.  β-strand comparison 
Other further mutations made for construction of the ∆Loop1-Scaffold enzyme 
consisted of 8 point mutations found on the β-strands of the enzymatic face.  These 8 
amino acids were mutated to be homologous with those of PttXET16A in order to 
maximize the negative subsite interactions with branched substrate binding.  In the 
following figures, the mutated amino acids of the ∆Loop1-Scaffold enzyme are compared 
with those of PttXET16A (Figures 163 and 164). 
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Scaffold amino acids black licorice
XET16A amino acids red licorice
 
Figure 163 .  Superimposed ∆Loop1-Scaffold (white) and PttXET16A (red) structures and 
analysis of mutated β-strand residues. Scaffold amino acids are shown in black licorice while 
XET16A amino acids are shown in red licorice. Note the nearly identical positioning of the 8 
mutated residues with those of XET16A. 
Scaffold amino acids black licorice
XET16A amino acids red licorice
 
Figure 164 .  Superimposed ∆Loop1-Scaffold (white) and PttXET16A (red) structures and 
analysis of mutated β-strand residues. Scaffold amino acids are shown in black licorice while 
XET16A amino acids are shown in red licorice.  Note the nearly identical positioning of the 8 
mutated residues with those of XET16A. 




Comparison of the 8 ∆Loop1-Scaffold amino acids mutated in order to be 
homologous with those of PttXET16A, show very few differences.  A slight spatial disparity 
of some amino acid side-chains can be observed.  However, these slight differences 
appear to be of no significance.  Therefore, it can be concluded that the 8 β-strand amino 
acids mutated were correctly incorporated in the ∆Loop1-Scaffold enzyme and their 
incorporation mimicked the side chain positioning and orientation of PttXET16A. 
 
3.6.4.3.  Unpredicted structural changes  
Upon removal of the β-glucanase Loop1 region and replacement with the 
equivalent XET16A Loop1, an unpredicted structural change occurred.  This unpredicted 
change seems to be the result of a loss of side-chain interactions between the removed 
Loop1 and the adjoining Loop2. Removal of these side-chain interactions in the Scaffold 
enzyme resulted in the Loop2 falling into the enzymatic face rather than staying upright as 
seen in the wild-type β-glucanase structure.  Figures 165 and 166 show the relative 





Figure 165 . Loop2 positioning for both Scaffold (white) and β-glucanase (magenta) 
enzymes.  Note with removal of Loop1, Loop2 (red arrows) falls into the enzymatic face rather than 
staying upright as seen in β-glucanase. 






Figure 166 . Loop2 positioning for both Scaffold (white) and β-glucanase (magenta) 
enzymes.  Note with removal of Loop1, Loop2 (red arrows) falls into the enzymatic face rather than 
staying upright as seen in β-glucanase. 
 
The unpredicted structural consequence of removing Loop1 was the fall of Loop2 
into the enzymatic face.  This fall of Loop2 resulted in a large obstruction of the enzymatic 
face and therefore negatively impacted the defined objective of opening the enzymatic 
face for branched subsite acceptance.  Due to obstruction of substrate binding and 
subsequent catalysis, Loop2 falling into the enzymatic face is the most probable cause for 
a total loss of Scaffold enzymatic activity. 
 
3.6.4.4.  Van der Waals radii  
Further analysis of the interactions between loops by van der Waals radii plotting 
showed some striking differences between the wild-type β-glucanase and PttXET16A in 
comparison to the ∆Loop1-Scaffold enzyme.  Differences between Scaffold and β-
glucanase are the result of removal of Loop1 in the Scaffold enzyme and subsequently 
Loop2 falling into the enzymatic face whereas differences between Scaffold and 
PttXET16A are the result of XET16A having a shorter Loop2 amino acid sequence. Shown 
below, in the following three figures, are the plotted van der Waals radii for the three 
enzymes (Figures 167, 168, and 169).  









Figure 167 .  Scaffold loops plotted van der Waals radii. Loop1 is annotated in red, Loop2 
green, Loop3 purple, Loop4 yellow and Loop5 cyan. Note the presence of the felled Loop2 
occupying the enzymatic face.  And also note that Loop3 cannot be observed in its entirety since 







Figure 168 . β-glucanase loops plotted van der Waals radii.  Loop1 is annotated in red, 
Loop2 green, Loop3 purple, Loop4 yellow and Loop5 cyan.  Note the presence of Loop1 occupying 
the enzymatic face while Loop2 is in the rear of the enzyme and totally vertical. 









Figure 169 .  PttXET16A loops plotted van der Waals radii.  Loop1 is annotated in red, 
Loop2 green, Loop3 purple, Loop4 yellow and Loop5 cyan.  Note the reduced presence of Loop1 
while Loop2 is in the front of the enzyme and totally vertical. 
 
Even though ∆Loop1-Scaffold has a Loop1 van der Waals radii signature similar to 
that of PttXET16A, comparison of the Scaffold Loop2 to that of XET shows that the 
Scaffold Loop2 has fallen into the enzymatic face whereas the XET16A Loop2 has a 
shorter amino acid sequence and remains vertical.  Likewise, the β-glucanase Loop2 is the 
same amino acid length as in Scaffold however the β-glucanase Loop2 can be found at 
the rear of the enzyme (behind Loop1) and with vertical positioning. 
No comparison of Scaffold Loop3 can be attained since this area was disorganized 
in the Scaffold X-ray crystal.   
 
3.6.4.5.  Loop2 analysis  
It seems that the PttXET16A Loop2 amino acid sequence was reduced during 
evolution in order to compensate for a lack of side chain interactions with Loop1, as seen 
in β-glucanase, and in order to keep Loop2 from falling into the enzymatic face.  As seen 
in the following amino acid alignment the XET16A Loop2 has been reduced from the 11 
amino acids found in β-glucanase to 6 amino acids. 
β-glucanase Loop2:    L-T-S-P-S-Y-N-K-F-D-G 
PttXET16A  Loop2:    L-D------K-Y----------T-G 




This Loop2 amino acid length difference can also be observed in the X-ray crystal 





Figure 170 .  Comparison of Scaffold and PttXET16A Loop2 structures and sequences. 
Note both Loops start and stop with the same amino acids however XET16A has a shortened 
amino acid sequence preventing Loop2 from falling into the enzymatic face. 
 






Figure 171.  Comparison of Scaffold and PttXET16A Loop2 structures and sequences. 
Note both Loops start and stop with the same amino acids however XET16A has a shortened 
amino acid sequence preventing Loop2 from falling into the enzymatic face. 
 
Since a shortened Loop2 amino acid sequence is necessary for preventing 
obstruction of the enzymatic face, a proposed solution for restoring Scaffold enzymatic 
activity is replacing the β-glucanase Loop2 sequence with that of XET16A.  This proposal 
is not without risk since removal of loop2 might also have unintended structural 
consequences.  However, leaving the Scaffold Loop2 as it is currently found greatly 
reduces the possibility of substrate binding and catalysis. 
 
3.6.4.6.  Global comparisons  
Global structural comparisons of Scaffold and β-glucanase revealed that the 
Scaffold enzyme is generally more compact than that of β-glucanase. The only exception 
being Loop2 invading the enzymatic face.  Also, the far Scaffold negative subsites (-3 and 
-2) have been effectively opened from the wild-type conformation (Figures 172, 173, and 
174).  
 






Figure 172 .  Superimposed ∆Loop1-Scaffold (white wire-frame) and β-glucanase (magenta 
solid) X-ray structures.  Note only one significant Scaffold protrusion into the enzymatic face can be 
observed (red arrow) and this is due to Loop2. 
 
 
Figure 173.   Superimposed ∆Loop1-Scaffold (white solid) and β-glucanase (magenta wire-
frame) X-ray structures.  Note the generally reduced Scaffold size in comparison with β-glucanase 
except where Loop2 protrudes (red arrow) into the enzyme face. 







Figure 174 .  Superimposed ∆Loop1-Scaffold (white solid) and β-glucanase (magenta wire-
frame) X-ray structures.  Note this view is looking down the barrel of the enzymatic cleft and Loop2 
can be observed protruding into the enzymatic cleft (red arrow). 
 
The global structural comparison of the Scaffold and β-glucanase enzymes 
revealed that the overall Scaffold enzymatic structure was retained with the negative 
subsites more open.  However, Scaffold Loop2 effectively invaded the enzymatic face at 
the -I negative subsite resulting in probable interference of substrate binding and catalysis. 
Comparing the overall Scaffold structure to that of XET, a slightly larger Scaffold 
negative subsite area is observed mostly due to Loop2 protrusion into the enzymatic face.  
However, no other undesired or unpredicted structural effects are seen (Figures 175 and 
176). 
 






Figure 175 .  Superimposed ∆Loop1-Scaffold (white wire-frame) and PttXET16A (red solid) 
X-ray structures.  Note Loop2 prevents the desired opening of the negative subsites for branched 





Figure 176 .  Superimposed ∆Loop1-Scaffold (white solid) and PttXET16A (red wire-frame) 
X-ray structures.  Note the slightly larger Scaffold negative subsites and Loop2 protrusion (green 
arrow) 




The comparison of the global Scaffold and PttXET16A structures revealed that the 
Scaffold negative subsites were correctly opened from Loop1 removal; however entrance 
of Loop2 into the enzymatic face effectively closed the space gained from Loop1 removal. 
Superimposed Scaffold, β-glucanase, and PttXET16A structures show that the 
Scaffold enzyme retains the major structural dimension as both β-glucanase and XET16A, 
and the removal of Loop1 opened the -III and -II Scaffold subsites. Also, the Scaffold 
enzyme is more structurally compact than the wild-type β-glucanase (Figures 177, 178, 





Figure 177 . Superimposed Scaffold (white), β-glucanase (magenta) and PttXET16A (red) 
structures. Note only a small portion of the Scaffold structure can be seen in this image due to 
Scaffold being more compact than the other two enzymes. 
 







Figure 178 .  Superimposed Scaffold (white solid), β-glucanase (magenta wire-frame) and 
PttXET16A (red wire-frame) structures. Note the open -3 and -2 subsites and the generally more 





Figure 179 .  Superimposed Scaffold (white solid), β-glucanase (magenta wire-frame) and 
PttXET16A (red wire-frame) structures. Note this view is looking down the barrel of the enzymatic 
cleft and Scaffold can be observed to have a generally more open enzymatic cleft, except where 
Loop2 protrudes. 
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In conclusion, the ∆Loop1-Scaffold enzyme retained the overall shape as both β-
glucanase and PttXET16A, while removal of Loop1 effectively opened the -III and -II 
negative subsites.  Also, the negative subsite β-strand mutations caused no ill effects to 
the Scaffold structure while aligning nicely with the homologous amino acids of XET16A.  
However, removal of loop1 had the unintended consequences of destabilizing Loop2´s 
position thereby causing Loop2 to fall into the enzymatic cleft and furthermore possibly 
obstructing substrate binding and catalysis. 
Activity and specificity could possibly be restored by replacing the β-glucanase 
Loop2 region of the Scaffold chimera with that of PttXET16A.  However, this Loop2 














































CHAPTER 1 Immobilized biocatalyst 1,3-1,4- β-glucanase vector construction 
 
• The addition of an N-terminal His-tag to the E134A nucleophile-less mutant did not affect 
the enzyme’s specific activity. The enzyme remained active upon immobilization on a 
metal affinity resin showing its application for solid-phase glycosynthase reactions. 
 
CHAPTER 2, Engineering of enzyme specificity: a β-glucanase and XET16A 
Chimera 
 
• Replacement of 18 1,3-1,4-β-glucanase loop1 amino acids by the shorted XET16A loop 
(5 amino acids) rendered a folded and stable protein. This ∆loop1 protein showed slight 
hydrolytic activity on 1,3-1,4-β-glucan while no enzymatic activity on xyloglucan. 
 
CHAPTER 3, Engineering of the negative subsites β-strands of the enzymatic cleft 
 
• 8 Amino acid residues on the binding site β-strands of the ∆loop1 protein, found to be 
involved in ligand binding, were mutated to the corresponding XET16A amino acid 
residues. The chimeric protein (Scaffold) was slightly less stable than the parental wild-
type 1,3-1,4-β-glucanase and was purified as an N-His tagged protein from the soluble 
intracellular fraction and from the insoluble fraction by refolding. 
 
• No enzymatic activities were detected for the Scaffold protein, neither hydrolase activities 
on 1,3-1,4-β-glucan and xyloglucan, nor for the nucleophile mutant glycosynthase activities 
(Scaffold-E134A) on linear or branched glycosyl donors. 
 
• Weak ligand binding of 1,3-1,4-β-glucan and xyloglucan was observed by isothermal 
titration calorimetry for the Scaffold protein. Together with the lack of enzymatic activities, 
the observed weak binding of substrates suggests that binding is unspecific and leads to 
unproductive complexes. 
 
• The Scaffold 3-dimensional structure was experimentally acquired by X-ray 
crystallography at a resolution of 2.4 Å.  The Scaffold protein maintains the β-sandwich 
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fold where the core β-strands are essentially identical to those of the parental wild-type β-
glucanase. Three main conclusions to interpret the functional data are envisaged: 
a) The engineered Loop1 was correctly altered, not modifying the location of the 
adjacent β-chains and therefore opening the binding site cleft. This was the major 
design element to accept branched substrates. 
b) The amino acid changes on the binding site β-strands have the designed 
orientation; the basement of the substrate binding cleft seems properly remodelled 
to accept xyloglucan substrates. 
c) However, the Scaffold 3D-structure shows a major movement of another surface 
loop, loop2, which falls into the binding pocked. It approximately occupies the 
cavity created by β-glucanase loop1 removal, and renders a Scaffold protein with a 
locked binding cleft. 
 
Loop2 falling into the enzymatic face is the most probable cause for a total loss of 
Scaffold enzymatic activity. 
 
• The Scaffold protein appears as a good target to start a directed evolution approach 
towards introducing hydrolase and glycosynthase activities for branched substrates.  It is 
proposed first to remove a few amino acid residues in loop2 to obtain a new loop2 with the 
same size as that observed in XET, and then initiate a directed evolution program on the 













































M.1.  Design 
 
Loop1 Computational Details 
The molecular dynamics simulation of the ∆loop1 hybrid was performed using the 
Cornell et al.[116] force field as implemented in the AMBER 7 program [117]. The 
computational setup was the same used for the wild-type β-glucanase [118].  All His residues 
(located in the protein surface) were taken as protonated, whereas all Asp and Glu residues 
were taken as deprotonated, except the acid-base glutamic acid (Glu 96 in the ∆loop1 
hybrid, 109 in the wild-type β-glucanase) and the aspartic acid (Asp 94/107) hydrogen 
bonded to the nucleophile glutamate (Glu 92/105). The disulphide bridge present in the 
wild-type enzyme is lost due to the replacement of cysteine 32 in Loop1 by a histidine. The 
total charge of the protein is the same as for the β-glucanase, since the loss of the positive 
charge of Arg 35 is compensated by the new protonated His (His 25/32) in the Loop1 
region. Therefore, six chlorine atoms were also added to achieve neutrality of the protein 
structure. The system was enveloped in a 56.2Å x 70.4Å x 58.9Å box of equilibrated TIP3P 
water molecules.  
The resulting system was first relaxed with a gradient minimizer in several steps. 
Initially the protein was constrained (i.e. for the first 112500 steps only the solvent is 
allowed to move). Afterwards, the constraint on theprotein residues was progressively 
released, starting for the Loop1 residues (10000 steps minimization), then +/- 2 residues 
surrounding Loop1 (12500 steps) and finally the whole system (12000 steps). After 
minimization, the system was coupled to a heat bathto achieve the desired temperature of 
300K. The solvent was initially equilibrated at 150 K for 20 ps, followed by 20 ps of 
simulation of the whole system at the same temperature. Then the temperature was 
increased up to 300K and the system was equilibrated for 160 ps. The simulation was then 
continued for 4 ns in the NPT ensemble. Analysis of the trajectories was carried out using 
the standard tools of AMBER [117] and VMD [114]. 
 
 
M.2.  Molecular Biology 
 
Polymerase Chain Reaction (PCR) 
(For Ecotaq® DNA polymerase) 
 
Prepare in a thin-walled PCR tube: 
24uL H2O 
5uL 10x Ecotaq DNA polymerase buffer 
10uL 5x Ecotaq High spec buffer 
2uL 50mM MgCl2 
1uL 10mM dNTPs 
3uL 5uM Primer #1 
3uL 5uM Primer #2 
1uL ≥50ng/uL dsDNA template  
 
Then Add: 




PCR Cycling Parameters 
Step Temperature/ Command Time 
1 92oC 2min 
2 92oC 30s 
3 primer specific temp. 30s 
4 72oC 2min 
5 Go to step 2: 30 times   
6 92oC 1min 
7 72oC 10min 
8 4oC for ever 
 
Run PCR product in the appropriate concentration agarose gel (1-2%) 
 
 
Polymerase Chain Reaction (PCR) Colony Insertion Screening 
(For Ecotaq® DNA polymerase) 
 
Prepare in a thin-walled PCR tube: 
25uL H2O 
5uL 10x Ecotaq DNA polymerase buffer 
10uL 5x Ecotaq High spec buffer 
2uL 50mM MgCl2 
1uL 10mM dNTPs 
3uL 5uM Primer #1 
3uL 5uM Primer #2 
With a 20uL pipette, pick a freshly transformed colony and mix thoroughly in the reaction 
mixture.   
 
Then Add: 
1ul 4U/uL Ecotaq DNA polymerase 
 
PCR Screening Cycling Parameters 
Step Temperature/ Command Time 
1 95oC 10min 
2 92oC 30s 
3 primer specific temp. 30s 
4 72oC 2min 
5 Go to step 2: 30 times   
6 92oC 1min 
7 72oC 10min 
8 4oC for ever 
 




Agarose Gel Extraction 
(Adapted from QIAquick® Gel protocol by Qiagen©) 
  
Note: for extraction of DNA fragments (70 bp – 10 kb) from standard, or low-melt 
agarose gels in TAE (Tris·acetate/EDTA) buffer. 
 
1. Excise the DNA fragment from the agarose gel with a cle n, sharp scalpel. 
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of 
gel (100 mg ~ 100 µl). **  The maximum amount of gel slice per QIAquick column 
is 400 mg; for gel slices >400 mg use more than one QIAquick column. 
3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To 
help dissolve gel, mix by vortexing the tube every 2–3 min during the incubation. 
4. After the gel slice has dissolved completely, check that the color of the mixture is 
yellow (similar to Buffer QG without dissolved agarose). 
5. Add 1 gel volume of isopropanol to the sample and mix. ONLY to increase yield of 
DNA fragments <500 bp and >4 kb. 
6. Place a QIAquick spin column in a provided 2 ml collection tube. 
7. To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min. 
8. Discard flow-through and place QIAquick column back in the same collection tube. 
9. Add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min. 
10. Wash with add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min. 
11. Discard the flow-through and centrifuge the QIAquick column for an additional 1 
min at 17,900 x g (13,000 rpm). 
12. Place QIAquick column into a clean 1.5 ml microcentrifuge tube. 
13. To elute DNA, add 50 µl of Buffer EB (10 mM Tris·Cl, pH 8.5) or water (pH 7.0–
8.5) to the center of the QIAquick membrane and centrifuge the column for 1 min. 
Alternatively, for increased DNA concentration, add 30 µl elution buffer to the 
center of the QIAquick membrane, let the column stad for 1 min, and then 
centrifuge for 1 min. 
 
Restriction Digest 
(Adapted from New England Biolabs©) 
 
A "Typical" Restriction Digest:  
Most researchers follow the general rules that 10 units of restriction enzyme is sufficient to 
overcome variability in DNA source, quantity and purity. Generally, 1 µl of enzyme is 
added to 1 ug of purified DNA in a final volume of 50 µl of the appropriate 1X NEBuffer 
followed by incubation for 1 hour at the recommended temperature. If an excess of enzyme 
is used, the length of incubation can often be decreased to save time. Alternatively, you can 








Restriction Enzyme 10 units is sufficient Generally 1µl is used 
DNA 1ug 
10X NEBuffer 5 µL (1X) 
BSA Add to a final concentration of 100 µg/ml (1X) if necessary 
Total Reaction Volume 50uL 
Incubation Time 1hr 
Incubation Temperature Enzyme dependent 
 
Double Restriction Digest 
(Adapted from New England Biolabs©) 
 
Cleaving a DNA substrate with two restriction endonucleases simultaneously 
(double digestion) is a common timesaving procedure. Selecting the best NEBuffer to 
provide reaction conditions that optimize enzyme activity as well as avoid star activity 
associated with some enzymes is an important considerat on. The NEBuffer that results in 
the most activity for both enzymes should be used for the double digest as long as star 
activity is not a factor. Depending on an enzyme's activity rating in a non-optimal 
NEBuffer, the number of units of enzyme or incubation time of the reaction may be 























































































fer 4 2 3 3 4 3 
Eco
RI 3 2 1 2 3 4 2 3 3 3 1 4 3 4 2 2 2 2 4 
AatII 4 -- 4 seq seq 4 seq seq 4 4 4 4 4 4 4 seq 4 seq 4 4 seq 4 4 4 4 4 4 
AvrII 2 4 -- 3 2 4 3 EcoRI 2 2 1 2 2 4 2 3 3 2 1 4 3 4 2 2 2 2 4 
Bam
HI 
3 seq 3 -- 3 3 3 EcoRI 3 seq seq 3 3 3 seq 3 3 3 seq seq 3 seq seq 3 3 3 seq 
BglII 3 seq 2 3 -- 3 3 EcoRI 3 2 2 2 3 3 2 3 3 3 2 seq 3 seq 2 2 2 3 seq 
BsgI 4 4 4 3 3 -- seq seq 4 2 seq 2 4 4 4 3 3 3 4 4 3 4 2 4 2 4 4 
EagI 3 seq 3 3 3 seq -- EcoRI 3 seq seq 3 3 3 seq 3 3 3 seq seq 3 seq seq 3 3 3 seq 
EcoR
I 



































3 4 2 3 3 4 3 EcoRI -- 2 2 2 3 2 2 3 3 3 2 2 3 4 2 2 2 3 4 
HindI
II 
2 4 2 seq 2 2 seq EcoRI 2 -- 2 2 2 2 2 2 2 2 2 2 seq 4 2 2 2 2 seq 
KpnI 1 4 1 seq 2 seq seq 1 2 2 -- 1 1 1 1 2 1 2 1 4 seq seq 1 1 2 1 4 
MseI 2 4 2 3 2 2 3 EcoRI 2 2 1 -- 2 2 2 2 3 3 2 2 3 4 2 2 2 2 4 
NcoI 3 4 2 3 3 4 3 EcoRI 3 2 1 2 -- 4 2 3 3 3 1 4 3 4 2 2 2 2 4 
NdeI 4 4 4 3 3 4 3 EcoRI 2 2 1 2 4 -- 4 3 3 3 4 4 3 4 2 2 2 4 4 
NheI 2 4 2 seq 2 4 seq EcoRI 2 2 1 2 2 4 -- 2 2 2 1 4 seq 4 2 2 2 2 4 
NotI 3 seq 3 3 3 3 3 EcoRI 3 2 2 2 3 3 2 -- 3 3 2 2 3 seq 2 2 3 3 2 
PstI 3 4 3 3 3 3 3 EcoRI 3 2 1 3 3 3 2 3 -- 3 1 2 3 4 2 2 3 3 4 
PvuI 3 seq 2 3 3 3 3 EcoRI 3 2 2 3 3 3 2 3 3 -- 2 2 3 seq 2 2 3 3 seq 
SacI 1 4 1 seq 2 4 seq 1 2 2 1 2 1 4 1 2 1 2 -- 4 seq 4 1 1 4 1 4 
SacII 4 4 4 seq seq 4 seq EcoRI 2 2 4 2 4 4 4 2 2 2 4 -- seq 4 2 4 2 4 4 
SalI 3 seq 3 3 3 3 3 EcoRI 3 seq seq 3 3 3 seq 3 3 3 seq seq -- seq seq 3 3 3 seq 
SmaI 4 4 4 seq seq 4 seq seq 4 4 seq 4 4 4 4 seq 4 seq 4 4 seq -- 4 4 4 4 4 
SpeI 2 4 2 seq 2 2 seq EcoRI 2 2 1 2 2 2 2 2 2 2 1 2 seq 4 -- 2 2 2 4 
SphI 2 4 2 3 2 4 3 EcoRI 2 2 1 2 2 2 2 2 2 2 1 4 3 4 2 -- 2 2 4 
XbaI 2 4 2 3 2 2 3 seq 2 2 2 2 2 2 2 3 3 3 4 2 3 4 2 2 -- 2 4 
XhoI 2 4 2 3 3 4 3 EcoRI 3 2 1 2 2 4 2 3 3 3 1 4 3 4 2 2 2 -- 4 
XmaI 4 4 4 seq seq 4 seq seq 4 seq 4 4 4 4 4 2 4 seq 4 4 seq 4 4 4 4 4 -- 
 
Double Digest Notes:  
 If BSA is a buffer requirement for either enzyme, add it to the double digest 
reaction. BSA will not inhibit any restriction enzyme.  
 The final concentration of glycerol in any reaction should be less than 5% to 
minimize the possibility of star activity. To avoid this situation, an increase in total 
reaction volume may be necessary.  
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 Double digestion is not recommended for certain enzyme combinations. In these 
cases a sequential digest is required. In the tableabove, these combinations are 
indicated by the abbreviation "seq".  
 This data is based on 1-2 hour digests. Overnight double digests should be avoided 
due to possible star activity.  
 
Vector/Insert Ligation 
(Adapted from Molecular Cloning a Laboratory Manual) 
 
In a microfuge tube set up the following ligation mixture: 
 
1µL 25ug/mL restriction digested and agarose gel extracted insert DNA 
2ng restriction digested and agarose gel extracted lin ar plasmid DNA 
1µL 10x T4 ligase buffer 
1unit T4 ligase 
Add ddH2O to 10uL 
 
Incubate overnight at 16oC 
 
Transform chemically or electro-competent E. coli with the ligation product. 
 
***Note the correct vector insert molar ratio might ave to be experimentally found by 





(Adapted from the QuikChange® Site-Directed Mutagenesis Instructions Manual) 
 
Prepare in a thin-walled PCR tube: 
36µL H2O 
5µL 10x Pfu Turbo reaction buffer 
1uL 10mM dNTPs 
1uL 50ng/uL template dsDNA 
3uL 5uM Primer#1 
3uL 5uM Primer#2 
 
Then Add: 










Step Temperature/Command Time 
1 95oC 2min 
2 95oC 30s 
3 Primer Tm+5oC 30s 
4 72oC 1 minute/kb of plasmid length 
5 Go to step 2: 30 times   
6 72oC 10min 
7 4oC for ever 
8 End   
 
 
Dpn I Digestion of Template DNA 
1.  Add 1 µL of the Dpn I restriction enzyme (10 U/µL) directly to each site-directed 
mutagenesis reaction. 
2.  Gently mix the reaction mixture. 
3.  Incubate at 37oC for 1hour 
 
 
Preparing Denatured Double-stranded DNA Templates 
(Adapted from Molecular Cloning by Sambrook and Russell) 
 
1. Transfer 5µg of purified plasmid dsDNA to a 1.5mL microfuge tube.  Adjust 
volume to 50µL with H2O.  Add 10µL of freshly prepared 2N NaOH/ 2mM EDTA 
solution. Incubate mixture for 5 minutes at room tep rature. 
2. Add 30µL of 5M ammonium acetate pH≈7.4 and mix contents by vortexing. 
3. Add 180µL of equilibrated phenol: chloroform:isoamyl alcohol (25:24:1) and mix 
contents by vortexing. Note equilibrate with TE buffer pH 7.6. 
4.  Then separate the phases by centrifugation at maximum speed for 15 minutes at 
room temperature. 
5. Carefully remove upper aqueous phase to a fresh microfuge tube and precipitate the 
DNA by addition of 330µL ice-cold ethanol. Mix conte ts of the tube and place it in 
a dry ice-ethanol bath for 15 minutes. 
6. Recover the denatured DNA by centrifugation at maxium speed for 15 minutes at 
4oC. 
7. Very carefully decant the supernatant without disturbing the DNA pellet, which 
may or may not be visible on the side of the tube. 
8. Recentrifuge the tube for 2 seconds and remove the last traces of ethanol with a 
pipette tip without disturbing the DNA precipitate. 
9. Allow the precipitate to dry at room temperature and resuspended the DNA in H2O 








Multiple Site-directed Mutagenesis 
(adapted from the Multiple site directed mutagenesis of more than 10 sites simultaneously 
and in a single round by Andreas Seyfang and Jean Hu quian Jin) 
 
Primer Dissolving and Pooling 
1. Individually dissolve the Mutagenic, terminal, and anchor primers in H2O at 
100pmol/µL concentrations.  
2. Pool 10uL of mutagenic primers and 3.4µL terminal primers.  
3. Dilute pooled primer mix to 4pmol/µL by adding 6µL of the pooled primer mix to 
144µL of H2O. 
 
Annealing Reaction 
4. Make 10x annealing buffer (200mM Tris-HCl pH 7.5, 500mM NaCl, 100mM 
MgCl2. 
5. Add 160ng of ssDNA (freshly made), 10µL of 4pmol/ul pooled primer mix, 4µL of 
10x annealing buffer, and adjust volume to 40µL with H2O in a thin-walled PCR 
tube. 
6. Carry out annealing reaction in a thermocycler by heating the mixture to 75oC for 
5minutes followed by gradual cooling to 45oC within 30 minutes (-1oC/min) and 
22oC within 12 minutes (-2oC/min). 
7. Place the annealed template-primer mixture on ice for subsequent assembly of the 
mutant strand synthesis reaction. 
 
Mutant strand synthesis by primer extension. 
8. Add 25.4µL Annealing reaction product, 3µL 10x T4 polymerase buffer, 0.6µL 
10mM dNTPs, and 1µL T4 polymerase to a thin walled PCR tube. And mix gently. 
9. Incubate extension mixture at 37oC for 2 hours. 
10. Precipitate extension product by the addition of 170µL ice-cold ethanol. Mix 
contents of the tube and place it in a dry ice-ethanol bath for 15 minutes. 
11. Recover the extension product by centrifugation at m ximum speed for 15 minutes 
at 4oC. 
12. Very carefully decant the supernatant without disturbing the extension product 
pellet, which may or may not be visible on the side of the tube. 
13. Recentrifuge the tube for 2 seconds and remove the last traces of ethanol with a 
pipette tip without disturbing the DNA precipitate. 
14. Allow the precipitate to dry at room temperature. 
 
Mutant strand ligation 
15. To the precipitated extension product add 4µL of 5x T4 ligase buffer, 15µL H20 and 
1µL of T4 DNA ligase. Mix gently. 
16. Incubate ligation mixture at 37oC for 2 hours. 
 
Mutant strand amplification 
17. Add 3µL of forward and reverse anchor primers (6µL total), 10µL 5x High Spec 
buffer, 5µL 10x Ecotaq polymerase buffer, 2µL 50mM MgCl2, 1µL 10mM dNTPs, 
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5µL mutant strand ligation product, 20µL H2O, and 1 µL 4U/µL Ecotaq 
polymerase in a thin-walled PCR tube. 
18. Amplify using a thermocycler with a typical PCR prog am using the specific 
annealing temperature for the anchor primers. 
 
 
M.3.  Expression and purification 
 
 
E. coli media 
 
LB L uria-Burtani Broth (1L) 
10g tryptone 
5g yeast extract 
5g NaCl 
ddH2O fill to 1 liter 
Autoclave sterile 
 
SOC Media (1L) 
• Mix the following: 
20g tryptone 




ddH2O fill to 1 liter 
• Autoclave sterile 
• Make 15mL 20% glucose solution 
• Autoclave sterile 
• Add 14mL of sterile 20% glucose to sterile SOC media 
 
 
2XYT Yeast Extract Tryptone Media (1L) 
16g tryptone 
10g yeast extract 
5g NaCl 





1. Thaw 100uL of thermally competent DH5α cells on ice. 
2. Add ≤5uL of DNA (∼50ng) and gently mix by flicking microfuge tube. 
3. Incubate in water/ice bath (0oC) for 30 minutes. 
4. Transfer to 42oC water bath and incubate for exactly 2 minutes. 
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5. Transfer rapidly back to water/ice bath (0oC) for 5 minutes. 
6. Add 300uL of pre-warmed SOC media and mix by gently flicking microfuge tube. 
7. Incubate in orbital shaker at 37oC with 250rpm for 45 min. 
8. On Petri-plates containing ampicillin or the proper s lectable marker, aliquot 50-
150uL of transformant mixture. 
9. Spread aliquots evenly using a flame sterilized glass-spreader. 
10. Allow 10 minutes for the absorption of the aliquots into the Petri-plates. 
11. Invert plates and place in 37oC incubator overnight.  
12. Transfer transformants to a fresh Petri-plate containi g ampicillin or the proper 




Electroporation of E. coli protocol 
(adapted from Molecular Cloning a Laboratory Manual 3rd edition). 
 
 
A: Preparation of electroporation competent E. coli Cells 
1. Innoculate a single colony of E. coli from a fresh agar plate into a 250mL flask 
containing 50mL of LB medium. Incubate the culture at 37oC with 250rmp 
overnight. 
2. Innoculate two aliquots of 500mL of prewarmed LB medium in separate 2 liter 
flasks with 25mL of the overnight culture. Incubate th  flasks at 37oC with 250rpm.  
Measure the OD600 every 20 minutes. 
3. When the culture reaches an OD600 of exactly 0.4 (∼1hr40min), rapidly transfer the 
flasks to an ice bath for 15 minutes while swirling occasionally for even cooling. 
4. Transfer the cultures to ice-cold sterile centrifuge bottles. Harvest cells at 1000g for 
15min at 4oC. Decant the supernatant and resuspend pellet in 500mL of ice-cold 
ion-purified sterile H2O. 
5. Harvest cells at 1000g for 20 min at 4oC. Decant the supernatant and resuspend the 
cells in 250mL of ice-cold 10% glycerol.  
6. Harvest cells at 1000g for 20 min at 4oC. Decant supernatant, but carefully because 
the bacterial pellet will lose adhesion with the addition of glycerol. Resuspend the 
pellet in 10mL of ice-cold 10% glycerol. 
7. Harvest cells by centrifugation at 1000g for 20 min at 4oC.  Carefully decant 
supernatant and remove any drops of liquid by slowly extracting with a 200uL 
pipettor. 
8. Measure the OD600 of a 1:100 dilution (10uL in 990uL).  Dilute the clls to 
concentration of 2 x 1010 to 3 x 1010 cells/mL (1.0OD600=∼2.5 x 108 cells/mL) with 
ice-cold SOC medium. If the cells were initially harvested at the proper OD600 no 
dilution is necessary. 
9. Dispense 40uL aliquots of the freshly made electrocompetent cells into ice-cold 
sterile 0.5mL microcentrifuge tubes.  Flash freeze by putting in dry-ice ethanol bath. 





B: Electroporation of E. coli Cells 
1. Thaw frozen cells by placing aliquots in an ice-bath with the corresponding number 
of 1mm gap electroporation cuvettes.   
2. Add 10pg to 25ng of DNA (1-2uL) to each microcentrifuge tube. Incubate the 
mixture on ice for 10 min. With the Invitrogen Electroporator II set the charging 
voltage (V) at 2500, the Capacitance (uF) at 25, and the Resistance (Ω ) to 200. 
3. Pipette the DNA/cell mixture into the chilled electroporation cuvette and tap the 
cells to the bottom of the cuvette, where the cells are in contact with both sides of 
cuvette and evenly distributed across the bottom. Dry the condensation on the 
outside of the cuvette and place in the electroporater. 
4. Administer the pulse. A time constant of 4-5 milliseconds with a field strength of 
12.5kV/cm should register on the machine. 
5. As quickly as possible after administering the pulse remove the cuvette and add 
1mL of room temperature SOC medium. 
6. Transfer the cells to a sterile 1.5mL microcentrifuge tube and incubate for 1 hour at 
37oC with 150 revolutions per minute.  
7. Plate different volumes (25-200uL) of the electroporated cells onto LB plates 
containing the appropriate antibiotic. 
8. Store the plates at room temperature until the liquid has been absorbed. 
9. Invert plates and incubate at 37oC overnight. 
 
 
pET16b-Scaffold-His and pET16b-β-glucanase-His 
Expression and Purification Procedure 
 
Expression solutions and media: 
 
Ampicillin 20mg/mL . 
In a 25mL volumetric flask add: 
• 500mg Ampicillin 
• Fill with ddH2O 
• Invert flask to solubilize ampicillin 
• Syringe Filter Sterile (0.45µm) 
• Aliquot 1mL in 1.5mL microfuge tubes 
• Store at -20oC 
 
20% Glucose (w/v) 
• Heat solution in a beaker while stirring for solubiization 
• Transfer to a media bottle (leaving sufficient space for boiling). 
• Autoclave to sterilize. 
 
LB L uria-Burtani Broth (for overnight culture) 
In a 2L Erlenmeyer flask add: 
10g tryptone 




Add 950mL H2O 
Add a cotton filled cheese-cloth stopper 
Cover with aluminum foil 
Autoclave sterile 
 
LB L uria-Burtani Broth (for expression) 
In another 2L Erlenmeyer flask add: 
10g tryptone 
5g yeast extract 
5g NaCl 
Add 1L H2O 
Add a cotton filled cheese-cloth stopper 
Cover with aluminum foil 
Autoclave sterile 
 
Affinity Chromatography Stock Solutions: 
 
Binding Buffer : 20mM Tris-HCl, 0.5M NaCl pH8.0 
Elution Buffer : 20mM Tris-HCl, 0.5M NaCl, 0.5M Imidazol pH8.0 
Ni2+ Solution: 100mM NiSO4 
Strip Buffer : 20mM Tris-HCl, 0.5M NaCl, 50mM EDTA pH8.0 
Storage Buffer: 20% Ethanol, 20mM Tris-HCl, 0.5M NaCl pH8.0 
 
• A [5x] binding buffer solution (100mM Tris-HCl 2.5M NaCl) can be made and 
subsequently be used for both the [1x] binding and elution buffers. Note adjust pH 
at [1x ] concentration and NOT at [5x]. 
• Filter all buffers (0.45µm) and store at 4oC. 
 
 
1. Transform chemically competent BL21DE3-Star cells with the pET16b-Scaffold-
His or pET16b-β-glucanase-His plasmid. 
2. Plate onto LB+1% glucose agar Petri dishes containig150µL of 20mg/mL 
ampicillin. Incubate at 37oC overnight. 
3. Next morning, inoculate 2mL LB medium +10µL 20mg/mL ampicillin +100µL 
20% Glucose with a single transformant colony. Incubate at 37oC 250rpm. 
4. In the evening, inoculate 950mL LB medium + 50mL 20% glucose +5mL 20mg/mL 
ampicillin with 20µL of the starter culture (step 3). Incubate at 37oC 250rpm. 
5. Next morning, centrifuge 1L overnight culture GSA 4500rpm for 12min at room 
temperature. Thoroughly resuspend cell pellet in 1L of pre-warmed (37oC )LB 
medium. Incubate at 37oC 250rpm. Add 0.238g of IPTG (1mM). Induce for 4 hours. 
6. Centrifuge 1L induced culture GSA 4500rpm for 12min at 4oC. Thoroughly 
resuspend cell pellet in 125mL of ice cold Binding Buffer (20mM Tris-HCl, 0.5M 
NaCl pH8.0) 
7. Add resuspended cells to cell disrupter (15.6 kpsi 4oC). Catch disrupted cells in a 
GSA centrifuge bottle. As the cells are being disrupted, rinse the sample cup with 
25 mL binding buffer to insure all cells enter the cell disruptor. 
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8. Centrifuge the disrupted cells GSA 8500rpm for 12min at 4oC.  
9. Decant the soluble supernatant into SS34 centrifuge t b s and centrifugeSS34 
18000rpm for 12min at 4oC. 
10. Filter soluble supernatant through a 0.45um filter. Store filtrate in ice-H2O bath. 
11. Charge filtrate, by use of a peristaltic pump, into pre-conditioned 2x(5mL HP 
Chelating columns) connected in series. 
12. After charging protein use the following ÄKTA FPLC™ procedure: 
 
1. Place inlet tube A in 1L of “on ice” Binding Buffer (20mM Tris-HCl, 0.5M NaCl 
pH8.0) and inlet tube B in 1L of “on ice”  Elution Buffer (20mM Tris-HCl, 0.5M 
NaCl 0.5M Imidazol pH8.0) 
2. Manually perform pump wash of pump A and pump B using the UNICORN® 
software. 
3. Manually execute a 2mL/min flow rate of pump A until a stable A280 and 
conductivity is attained in order to equilibrate tubing with Binding Buffer. 
4. Pause the 2mL/min flow rate and connect the  2x(5mL HP Chelating columns) 
connected in series to the ÄKTA FPLC™. 
5. Continue 2mL/min flow rate and rinse columns until a stable A280 and conductivity 
is attained. 
• Next use the following ÄKTA FPLC™ parameters for purification: 
 
Variable Value 
Column His-Trap HP 5mL 
Column Pressure Limit 0.3MPa 
Flow Rate 2mL/min 
Equilibrate with 3CV (15mL) 
Flowthrough Tube Type 18mm 
Flowthrough Fraction Size 8mL 
Wash Column with 3CV (15mL) 
Elution Fraction Tube Type 18mm 
Target Concentration B 100% 
Length of Linear Gradient 50CV (250mL) 
Clean with 0CV 
 
 
• Finally, dialyze elution fractions into pre-chilled 4oC Kinetic Buffer (87mM 
NaH2PO4, 6.5mM Citric Acid, 100µM CaCl2, pH 7.4) 
 
Inclusion bodies purification and refolding 
(Adapted from: Rapid and efficient purification and refolding of a (His)6-tagged 
recombinant protein produced in E. coli as inclusion bodies by GE lifescience). 
 
 
1. Resuspend cell paste from a 1L culture in 40mL (20mM Tris-HCl pH 8.0) 
2. Disrupt cells by sonication, on ice and centrifuge th  disrupted cells (SS34 
18000rpm for 12min at 4oC). 
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3. The pellet, containing the inclusion bodies, resuspend in 30mL ice cold 2M urea, 
20mM Tris-HCl, 0.5M NaCl, 2% Triton X-100, pH 8.0 
4. Sonicate resuspended pellet and centrifuge (SS34 18000rpm for 12min at 4oC). 
5. Repeat steps 3 and 4. 
6. Resuspend pellet in  50mL (20mM Tris-HCl, 0.5M NaCl, 8M Urea, 1mM β-
mercaptoethanol, pH8.0). 
7. Stir for 30-60 minutes at room temperature. 
8. Centrifuge (SS34 18000rpm for 12min at 4oC). 
9. Filter sample through 0.45µm filter. 
10.  Load sample onto a previously prepared 2x(5mL HP Chelating columns) connected 
in series. 
11. Wash  sample with 20mM Tris-HCl, 0.5M NaCl, 8M Urea, 1mM β-
mercaptoethanol, pH8.0 
12. Follow the ÄKTA FPLC™ procedure shown pET16b-Scaffold-His and pET16b-β-
glucanase-His using a linear elution gradient with 20mM Tris-HCl, 0.5M NaCl, 8M 
Urea, 1mM β-mercaptoethanol, 0.5M imidazol pH8.0. 
13. Dialyze elution fractions pertaining to the recombinant protein in 87mM phosphate, 








A.- Buffers and Stock solutions: 
 
Electrophoresis Buffer [5x] 
• 7.5 g Tris-base (Merck) 
• 36 g Glycine (Merck) 
• 2.5 g SDS (Scharlau) 
• Fill to 500 ml with H2O Milli-Q 
Notes: Adjust to pH≈ 8.3 with HCl 5N (HCl (c) : H2O Milli-Q; 1:1): Weigh SDS with 
filter mask: Store at room temperature 
 
Charge Buffer [5x] 
• 4 ml H2O Milli-Q 
• 1 ml Solution C 
• 0.8 ml glycerol (Merck) 
• 1.6 ml Solution D 
• 0.4 ml β- mercaptoethanol (Bio-Rad) 
• 0.5 mg bromophenol blue (Bio-Rad) (small spatula) 
Notes: Aliquot in 1 ml fractions in 1.5mL Eppendorfs; Store at room temperature; 






• Solution acrylamide/ bis- acrylamide (30%) Mix ratio 29:1 Sigma, Ref. A-3574 
Notes: Store at 4ºC;  Acrylamide has a limited shelf lif . 
 
Solution B (1.5 M  Tris-HCl) 
• 9.08 g Tris-base (Merck) 
• Add 40 ml H2O Milli-Q 
• Adjust to pH 8.8 with HCl 5N 
• Fill to 50 ml with H2O Milli-Q 
Notes: Store at 4ºC  
 
Solution C (0.5 M Tris-HCl) 
• 3.0 g Tris-base (Merck) 
• Add 30 ml of H2O Milli-Q 
• Adjust to pH 6.8 with HCl 5N 
• Fill to 50 ml with H2O Milli-Q 
Notes: Store at 4ºC  
 
Solution D (10%(w/V) SDS) 
• 10 g SDS (Scharlau) 
• 100 ml H2O Milli-Q 
Notes: Weigh SDS with filter mask; Store at room tep rature. 
 
Solution G (20% Ammonium Persulfate) (w/V) 
• 100 mg (NH4)2S2O7 (Bio-Rad) 
• 0.5 ml H2O Milli-Q 
Notes: Prepare fresh for every PAGE 
 
B.- Gel Preparation 
 
Running Gel preparation:  
 
% Acrylamide H2O Milli-Q (ml)  Solution A (ml) Solution B (ml)  Solution D (µl) 
12 3.4 4.0 2.5 100 
14 2.7 4.7 2.5 100 
16 2.1 5.3 2.5 100 
 
 a) Once Acrylamide, H2O, Solution A, Solution B, and Solution D are mixed add: 
• 50 µl Solution G 
• 5 µl TEMED 
b) Mix thoroughly and dispense using a Pasteur pipette (leaving space for the 
stacking gel). Hint: leaving the Pasteur pipette filled with the running gel 
mixture will simulate the conditions inside the gel plates. Therefore when the 
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mixture, inside the Pasteur pipette, is no longer liquid the gel will also be 
polymerized. 
c) Cover running gel with isobutanol by use of Pasteur pipette. 
d) After approximately 30 minutes, absorb the isobutanol using Whatman filter 
paper.  
 
Stacking Gel preparation: 
a) Mix: 
• 6.1 ml H2O Milli-Q 
• 2.5 ml Solution C 
• 100 µl Solution D 
• 1.3 ml Solution A 
 
b) Add: 
• 50 µl Solution G. 
• 10 µl TEMED 
 
c) Fill using Pasteur pipette. 
 
d) Add gel comb 
 
Hint: leaving the Pasteur pipette filled with the stacking gel mixture will simulate 
the conditions inside the gel plates. Therefore when t  mixture, inside the Pasteur 




C.- Electrophoresis conditions.  
 
1) Place gels in electrophoresis support with the short plates facing towards the interior. 
 
2) Prepare the electrophoresis buffer: 70 ml 5x electrophoresis buffer + 280 ml Milli-Q 
H2O. Mix buffer without making foam. Fill inner electrophoresis cavity with buffer. Add 
remaining buffer to outer electrophoresis area. 
3) Prepare samples and marker.  
MARKER Preparation 
In 500 µl microfuge tube add 2 µl of Bio-Rad Low Range standard marker, 4 µl 5x 
charge buffer  and 14 µl Milli-Q H 2O, mix by pipetting. 
4. SAMPLE Preparation 
In 500 µl microfuge tube add 10 µl of sample, 4 µl 5x charge buffer, and 6 µl Milli-Q 
H2O, mix by pipetting. And cap tightly. 
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Introduce samples into a 95 ºC water bath for 10 minutes. After 10 minutes remove 
samples and let cool to room temperature. Centrifuge samples for 10 seconds to 
condense.  
4) Add 20 µl samples to PAGE wells using a pipette. 
5) Place the top onto the PAGE box, making sure to align the positive and negative diodes 
correctly. Apply 160 V (constant) for approximately 1 hour. Watch the bromophenol gel 




1) Separate the gel plates by use of a gel wedge in order to remove the gel being careful not 
to tear the gel in the process. Remove the stacking gel by use of the gel wedge. Place the 
running gel into the staining solution. Hint: the running gel can be transferred to the 
staining solution easily by using a stream of H2O from a water bottle. 
2) Cover the gel with the Coomassie staining solution. Coomassie staining solution consists 
of 1% Coomassie Brillant Blue R (Sigma) in a mixture of Acetic Acid (glacial), 
Methanol, and H2O (2:9:9). 
3) Place recipient on an orbital shaker for 15-20 minutes with slight shaking.  
4) After time has elapsed decant staining solution. Save staining solution. Note: staining 
solution can be recycled many times.  
5) Add contrast solution to gel. 
 
CONTRAST (rapid destaining) 
6) Cover gel with a H2O, Methanol, Acetic acid (glacial) 5:4:1 mixture. Place on an orbital 
shaker with slight shaking. When the contrast solution becomes blue with Coomassie, 
decant the contrast solution and add more contrast solu ion until protein bands become 
visible.  
7) Once gel becomes destained, transfer the gel to H2O in order to reverse gel shrinkage.  
Place on an orbital shaker with slight shaking for 5 to 10 minutes. 
8) The gel can be saved by introducing the gel in betwe n plastic wrap and heat sealing. 
9) Once the gel is conserved, scan the gel into the computer for a permanent record. 
 
PAGE Silver Staining 
(Adapted from: Molecular Cloning a Laboratory Manual by Sambrook J. and Russell D.) 
 
Materials 
• Acetic Acid 1% 
• Developing Solution: Prepare fresh for each use, an aqueous solution of 2.5% sodium 
carbonate, 0.02% formaldehyde. 
• Ethanol 30% 
• Fixing Solution: Ethanol: glacial acetic acid: H2O 30:10:60 
• Silver nitrate solution: Prepare fresh for each use, 0.1% solution of AgNO3 diluted from 







• IMPORTANT Wear gloves and handle the gel gently because pressure and 
fingerprints will produce staining artifacts. In addition, it is essential to use clean 
glassware and deionized H2O because contaminants greatly reduce the sensitivity of 
silver staining 
 
1. Separate proteins by electrophoresis through an SDS-polyacrylamide gel. 
2. Fix the proteins by incubating the gel for 4-12hours at room temperature with gentle 
shaking in at least 5 gel volumes of fixing solution. 
3. Discard the fixing solution, and add at least 5 gel volumes of 30% ethanol. Incubate 
the gel for 30 minutes at room temperature with gentle shaking. 
4. Repeat step 3. 
5. Discard the ethanol, and add 10 gel volumes of deionized H2O. Incubate the gel for 
10 minutes at room temperature with gentle shaking (the gel will slightly swell 
during rehydration). 
6. Repeat step 5 twice.  
7.  Discard the last of the H2O washes, and, wearing gloves add 5 gel volumes of silver 
nitrate solution. Incubate the gel for 30 minutes at room temperature with gentle 
shaking. 
8. Discard the silver nitrate solution, and wash both sides of the gel (20 seconds each) 
under a stream of deionized water.  Note: allowing the gel to dry out will result in 
staining artifacts. 
9. Add 5 gel volumes of developing solution.  Incubate th  gel at room temperature 
with gentle agitation. Watch the gel carefully. Stained bands of protein should 
appear within a few minutes.  Continue incubation until the desired contrast is 
obtained.  Note: prolonged incubation leads to a high background of silver staining 
within the gel. 
10. Quench the reaction by washing the gel in 1% acetic acid for a few minutes. Then 
wash the gel several times with deionized H2O (10 minutes per wash). 
11. Preserve the gel. 
 
Urea denaturation Fluorescence 
(Using a Jobin Yvon SPEX Fluoromax-2 spectrofluorimeter). 
 
Maximum emission fluorescence wavelength scanning 
• protein in 87mM phosphate, 6.5mM citric buffer pH7.2 with 100µM CaCl2 at 
37oC 
• Excitation was at 280nm (4nm slit). 
• Emission acquisition intervals of 1.0nm. 
• integration time of 0.2 seconds (4 nm slit). 
 
Urea denaturation 
• Protein in 87mM phosphate, 6.5mM citric buffer pH7.2 with 100µM CaCl2 in the 
presence of different urea concentrations ranging from 0 to 8 molar 
•  Incubated at 37oC for 16 hours.  





Isothermal titration calorimetry  
 
• Calorimeter: Microcal® VP-ITC  
• Assay conditions: 20mM Tris-HCl, 0.5M NaCl, pH7.5 at 250C.  
 
 
M.5.  Enzyme kinetics 
 
Xyloglucan transferase Colorimetric Iodine Plate Asay 
Buffers and solutions 
50mM citric acid buffer pH 5.5 
1.5mg/mL xyloglucan in 50mM citric acid buffer pH 5.5 
3.5 mg/mL xyloglucan oligosaccharides (XGO’s) in 50mM citric acid buffer pH 5.5 
 
Carbohydrate solution 
Ratio 1:2 xyloglucan to XGO respectively 
 
Color reagent solution 






1. Mix I 2, KI, and sodium sulfate in ddH2O to make Color reagent solution. 
2. Make carbohydrate solution 
3. In a 96 well plate add 20µL/well of stop solution to columns 2-12. 
4. Add 50µL/well of enzyme to column 1 of the 96 well plate. 
5. Pipette 150µL/well of carbohydrate solution into column 1 of the 96 well plate 
while starting time. 
6. Withdraw 20µL/well of reaction solution from column 1 and add to columns 
containing stop solution. 
7. After all time points are concluded add 160µL/well of color reagent solution. 
8. Measure the optical density immediately at 590nm 
 
 
Congo Red hydrolase activity plate assay 
 
Make: 
• 10mg/mL B-glucan solution and autoclave sterile 
• 20mg/mL Agar solution and autoclave sterile 




1. Add ≈30mL of Agar solution (still liquid) to each Petri-dish, and let solidify. 
2. Add 500uL of 10mg/mL B-glucan solution to each Petri-dish, spread evenly and let 
dry. 
3. Add 20uL of enzyme to B-glucan/agar plate, and let dry.
4. Incubate at 37oC overnight. 
5. Inundate enzyme/B-glucan/agar plate with Congo red solution for 5 minutes 
swirling lightly.  
6. Decant excess Congo Red solution. 
7. Observe depolymerized halo. 
 
 
DNS Reducing Ends Assay 
 
Reactive Preparation 
• Dissolve 1.68g of  3,5-dinitrosalicilic acid in 100mL H20 MQ (solution 1). 
•  Add 60mL of 2M NaOH to solution 1.   
• Dissolve 50g of Potassium sodium tartrate tetrahydrate OCOCH(OH)CH(OH)COONa 
· 4H2O in 125mL H2O MQ (solution 2).   




1) Make a 20mM Glucose stock solution.  Make serial dilutions from the glucose stock 
ranging from 20mM to 1mM. Store glucose stock at 4oC.   
2) Preincubate 500 µL of glucose serial dilutions for 5 minutes at 50oC. Next add 500 
µL of DNS reactive and incubate at 100oC for 10 minutes. 





1) Pre-incubate microfuge tubes containing equal glucan concentration in 
phosphate/citric buffer pH7.2 at 37 0C. 
2) Add enzyme to a final volume of 500µL incubate a 37 0C and take time point 
aliquots as wanted. 
3) To stop rxn add 500µL of DNS solution, mix and incubate at 100 0C for 10 minutes. 
4) Let rxns cool to room temperature and read absorbance t 530nm. 
 
 
Fluoride Selective Electrode Monitoring 
Rection monitored with: fluoride selective electrode (Sentek) interfaced with a 
Cyberscan 2500® potentiometer (Eutech Instruments) 
 
• All enzymes and substrates in 87mM phosphate, 6.5mM citric buffer pH7.2 
with 100µM CaCl2. 
Methods  
 233 
• final volume of 0.5 mL with stirring in a water bath at 35 °C 
• Sodium fluoride standards for calibration curves (10µM to 10M) were prepared 
under the same experimental conditions. 
 
 
High Performance Liquid Chromatography (HPLC) 
 
• All HPLC glycosynthase activity assays were carried out using Agilent 1100 
series HPLC 
• Column: NovaPak (4µm 3.9x150mm) 
• Flow rate: 1mL/min  
• Solvent: 10% MeOH in H2O 
• UV detector: 316 nm 





Chromogenic substrate hydrolysis 
 
• Spectrophotometer:  Helios Alpha™  
• Software package: VISIONpro™  
• Cell pathlength: 1cm  
• Substrate: Glcβ4Glcβ3Glc-MU 
• Substrate extinction coefficient:  ∆ε365=5136 M-1* cm-1 






















































All primers were designed using the three following rules of thumb: 
1. Previous codon usage present in the wild-type β-glucanase gene. 
2. Minimum base change needed for mutation. 
3. If possible, a primer Tm≈55oC was designed. 
 
 
pET16b Primers:  
 
N-terminal Primer  (31 bases) Tm= 74.2oC 
5’-CATATGCTCGAGCAAACGGGCGGGTCGTTTT-3’ 
 
Violet= XhoI site 
Yellow= First round annealing Tm= 57.9oC 
CAA= Gln (first amino acid of β-glucanase)  
Blue= extra nucleotides 
 
Notes: Addition of XhoI restriction site and extra nucleotides for efficient cleavage. 
Removal of Sart Codon.   This primer works equally well for both native and hybrid β-
glucanase constructs 
 
C-terminal Primer  (40 bases) Tm= 70.7oC 
5’-TATTGCTCAGCTTATCTTTTTGTGTAACGCACCCAATTGT-3’ 
 
Violet= Bpu1102I restriction site 
Yellow= First round annealing. Tm= 59.6oC 
TTA= Stop Codon 
Blue= extra nucleotides. 
 
Notes: Addition of Bpu1102I  (BlpI) restriction site, stop codon, and extra nucleotides 
for efficient restriction site cleavage. This primer works equally well for both native and 
hybrid β-glucanase constructs. 
 
pET16b-No-His-N-term Primer  (31 bases) Tm= 74.5oC 
5’-TATACCATGGCCCAAACGGGCGGGTCGTTTT-3’ 
 
Blue = Nucleotide Overhang addition 
Green = NcoI Restriction Site addition 
Red = Gln (first amino acid of β-Glucanase) 
Red Letters = Alanine Codon Addition (to conserve restriction site)  
 
Notes: The alanine addition is as if one amino acid of the signal peptide is still present.  
The native signal peptide ends with Ser-Ala and β-glucanase starts with Gln, as 
follows: Ser-Ala-Gln.  Normally the signal peptide is cleaved between the Ala-Gln 
linkage, however in order to conserve the NcoI restriction site the alanine codon was 
added. Also, Tm is relatively high due to adenosine scarcity in amplification region. 
This primer works equally well for both native and hybrid β-glucanase constructs. 
 
 
pET16b-Reverse Primer  (26 bases) Tm=57.4oC 
5´-AGGGGTTATGCTAGTTATTGCTCAGC-3´ 
 





E141A-Antisense Primer  (25 bases) Tm=55.3oC  
5´-GGTTTTGATGCAGCAAACTCTTATC-3´ 
 
K26T-Sense Primer  (16 bases) Tm=58.1oC 
5´-CGAGCAAACGGGCGGG-3´ 
 
K26T-Antisense Primer  (16 bases) Tm=58.1oC 
5´-CCCGCCCGTTTGCTCG-3´ 
 
E134A-Sense Primer  (26 bases) Tm=65.1oC 
5´-TGGGATGCGATCGACATCGAATTTCT-3´ 
 
E134A-Antisense Primer  (26 bases) Tm=65.1oC 
5´-AGAAATTCGATGTCGATCGCATCCCA-3´ 
 
E134S-Sense Primer (22 bases) Tm=55.1oC 
5´-CCTTGGGATTCTATCGACATCG-3´ 
 






∆Loop1 Primers:  
 
N-terminal 3´ Primer (34 bases) Tm=71.1oC 
5´-GGTCAAAAGCCCATTTTTGCCATAACCCCGTATT-3´ 
 
Yellow= First round annealing. Tm= 53.5oC 
Blue= overlapping fragment. 
 
 
C-terminal 5´ Primer (36 bases) Tm=77.0oC 
5´- GGGCTTTTGACCACGTCTCCATGACGTCGTTAGGGG -3´ 
 
Yellow= First round annealing. Tm= 62.0oC 
Blue= overlapping fragment. 
 
N-term-loop1-ext Primer  (40 bases) Tm=78.8oC 
5´-AACGACGTCATGGAGACGTGGTCAAAAGCCCATTTTTGCC-3´ 
 
Yellow= First round annealing. Tm= 57.2oC 
Green= overlapping extension. 
 
 
Scaffold Primers:  
 
pET16b-loop1-Strand-1 Primer (5´phosphorylated) (34 bases) Tm=69.3oC 
  5´- CGGTCCCGTAGAAGTATAGAACGCAGACACGATC-3´ 
 
Bold and underlined = Codons altered 





pET16b-loop1-Strand-2 Primer (5´phosphorylated) (35 bases) Tm=68.6oC 
  5´- GCACCATTCCATAAGCTCATATAAATCTTTCCCGG-3´ 
 
Bold and underlined = Codons altered 
Yellow= mismatch nucleotides 
 
 
pET16b-loop1-Strand-3 Primer (5´phosphorylated) (37 bases) Tm=72.6oC 
5´- GTTTGAACGGACTGGTTACCTCCGCCGTCAAACTTAT-3´ 
 
Bold and underlined = Codons altered 
Yellow= mismatch nucleotides 
 
 








Scaffold Reverse Primer (49 bases) Tm=75.8oC 
5´- AGCGGATAACAATTTCACACAGGTGCTCAGCTTATCTTTTTGTGTAACG -3´ 
 
Bold = homology with pET16b vector 
Green= Contains Bpu1102I restriction site 
 
 
Scaffold Forward Primer (5´phosphorylated) (41 bases) Tm= 80.5oC 
  5´- CCCGTTTGCTCGAGCATATG GTCGTGACTGGGAAAACCCTG-3´ 
 
Bold = homology with pET16b 
Green= contains XhoI restriction site 
 





Scaffold Repair Primers:  
 
R65Q Forward Primer  (21 bases) Tm=57.3oC 
5’-GAACGGACTGGTTACCTCCGC-3’ 
 
Yellow= highlight marks nucleotides for mutation 
 
 
R65Q Reverse Primer (21 bases) Tm=57.3oC 
5’-GCGGAGGTAACCAGTCCGTTC-3’ 
 





XhoI  Forward Primer (18 bases) Tm= 61oC 
5’- CCCGCCCGTTTGCTCGAG -3’ 
 
Yellow= highlight marks nucleotides for mutation 
 
XhoI Reverse Primer (18 bases) Tm= 61oC 
5’-CTCGAGCAAACGGGCGGG- 3’ 
 














































Lichenase protein sequence alignment: 
 
 
UniProtKB/TrEMBL entry Primary accession number  : taxonomy 
 
P07980 Bacillus amyloliquefaciens  
P37073 Brevibacillus brevis (Bacillus brevis)    
P27051 Bacillus licheniformis    
P23904 Paenibacillus macerans (Bacillus macerans)    
P45797 Paenibacillus polymyxa (Bacillus polymyxa) 
Q45648 Lichenase [Precursor]Bacillus sp.    
P04957 Bacillus subtilis    
Q45691 Bacillus subtilis     
P29716 Clostridium thermocellum 
O14421 Cochliobolus carbonum (Bipolaris zeicola)    
P17989 Fibrobacter succinogenes (Bacteroides succinogenes)    
O14412 Orpinomyces sp. (strain PC-2)    
Q84415 Paramecium bursaria Chlorella virus 1 (PBCV-1)    
P45798 Rhodothermus marinus (Rhodothermus obamensis)    




Yellow highlight negative subsite B-strand amino acids which point towards the enzyme face 
Green loop amino acid pointing towards active site  
Violet XET amino acid alignment disparity 




sp|P07980|GUB_BACAM/1-1564   ---------------------------------------------MKRVLLI-------- 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------MVKSKYLVFI-------- 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------MSYRVKRMLM-------- 
sp|P23904|GUB_PAEMA/1-1564   --------------------------------------------MKKKSCFT-------- 
sp|P45797|GUB_PAEPO/1-1564   --------------------------------------------MMKKKSWF-------- 
tr|Q45648/1-1564             --------------------------------------------MKKKLVLF-------- 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------MPYLKRVLLL-------- 
tr|Q45691/1-1564             ---------------------------------------------MKRVLLI-------- 
tr|Q59328/1-1564             MYKRLLSSVLIIMLLLSAWSPISVQASDGINDIRGHWAEEDLNKWMEKGILVGYQDGTIR 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------MKNRVISLLM-------- 
tr|O14421/1-1564             --------------------------------------------MSLKSLFV-------- 
sp|P17989|GUB_FIBSU/1-1564   -------------------------------------------MNIKKTAVK-------- 
tr|O14412/1-1564             ----------------------------------------------MKSIIS-------- 
tr|Q84415/1-1564             --MSQVDTVVDSVVDVENHQPTHI---DTFPYNKRVIESKPKKNMIVRGVVI-------- 
sp|P45798|GUB_RHOMR/1-1564   ---------------------------------MCTMPLMKLKKMMRRTAFL-------- 
sp|Q53317|XYND_RUMFL/1-1564  --------MKKSIFKRYAAAVGLMASVLMFTAVPTTSNAADDQKTGKVGGFDWEMWNQNY 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             PDNNITRAEFVTLINKVFGLYELSREQFADVEDSKWYSREILKARAAGYIAGYGSNVFKP 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  TGTVSMNPGAGSFTCSWSGIENFLARM--------------------------------G 
 
sp|P07980|GUB_BACAM/1-1564   ---------------------------------------------LVT------------ 
sp|P37073|GUB_BACBR/1-1564   -----------------------------------------SVFSLLF------------ 
sp|P27051|GUB_BACLI/1-1564   --------------------------------------------LLVT------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             -----------------------------------------SMCLLLFSGL--------- 
sp|P04957|GUB_BACSU/1-1564   ---------------------------------------------LVT------------ 
tr|Q45691/1-1564             ---------------------------------------------LVT------------ 
tr|Q59328/1-1564             DNYITRQEAVVIIAKVFELQSGSNYTSKFKDGSLVKEYAKDSVSALVEKGYIAGYEDGTF 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------ASLLL------------- 
tr|O14421/1-1564             ------------------------------------------SAPLLWRGV--------- 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------IAALS------------- 
tr|Q84415/1-1564             -----------------------------------------CMAILIFGGAIA------- 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------LSVLI------------- 
sp|Q53317|XYND_RUMFL/1-1564  KNYDDQKKNYKAFGDIVLTYDVEYTPRGNSYMCIYGWTRNPLMEYYIVEGWGDWEPPGND 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             RPDNYITRAETIKILNKIIPSLYNEKGDYKNEEVAGNALINTEGVILKDTVINGDLYLAQ 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  GVDNFGTTTIDGKTYKIRKSMRYNQPSIEGTKTFPQYWSVRTTSGSRNNTTNYMKDQVSV 
 
sp|P07980|GUB_BACAM/1-1564   ----------GLFMSLC------------------------------------------- 
sp|P37073|GUB_BACBR/1-1564   ----------GVFVVGF------------------------------------------- 
sp|P27051|GUB_BACLI/1-1564   ----------GLFLSLS------------------------------------------- 
sp|P23904|GUB_PAEMA/1-1564   ----------LVTTFAF------------------------------------------- 
sp|P45797|GUB_PAEPO/1-1564   ----------TLMITGV------------------------------------------- 
tr|Q45648/1-1564             ----------ISGLVQS------------------------------------------- 
sp|P04957|GUB_BACSU/1-1564   ----------GLFMSLF------------------------------------------- 
tr|Q45691/1-1564             ----------GLFMSLC------------------------------------------- 
tr|Q59328/1-1564             GIQNGDVTLDGVNVKGTVFVNGGGSDSIHFINTKINRVVVNKTGVRIVTSGNTSVESVVV 
sp|P29716|GUB_CLOTM/1-1564   ----------VLSVIVA------------------------------------------- 
tr|O14421/1-1564             ----------TALPAGP------------------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   ----------SALAVAA------------------------------------------- 
tr|O14412/1-1564             ----------VLGLISK------------------------------------------- 
tr|Q84415/1-1564             ----------TAIVVSS------------------------------------------- 
sp|P45798|GUB_RHOMR/1-1564   ----------GCSMLGS------------------------------------------- 




sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             KSGAKLEEKELTGDGFKNVTVDSQLSAGNEIIFVGDFEQVDVLADDALLETKEAKMKLRI 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  YLKENFESGEGNWSGRGSAKVKSSSGYDGTKGIFVSGREDTWNGASINLDELTFKAGETY 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------GITSSVSA----QTGGSF 
sp|P37073|GUB_BACBR/1-1564   -------------------------------------------SHQGVKAEEERPMGTAF 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------TFAASASA----QTGGSF 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------SLIFSVSA---------- 
sp|P45797|GUB_PAEPO/1-1564   -----------------------------------------ISLFFSVSA---------- 
tr|Q45648/1-1564             -----------------------------------------PQVAEAAER----PIGTAF 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------AVTATASA----QTGGSF 
tr|Q45691/1-1564             ------------------------------------------GITSSVSA----QTGGSF 
tr|Q59328/1-1564             FGQRIKVNGKAIEKSSKNYIVNGELISTEEEPGPSDAPGAEDDQNSGSPGSSTNPAPTKN 
sp|P29716|GUB_CLOTM/1-1564   -----------------------------------------PFYKAEAAT----VVNTPF 
tr|O14421/1-1564             -----------------------------------------GSWTHGNST----IVSSSD 
sp|P17989|GUB_FIBSU/1-1564   -------------------------------------------AAAALTT---------- 
tr|O14412/1-1564             ------------------------------------------TMAAPAPA----PVPGTA 
tr|Q84415/1-1564             -----------------------------------------DNSSDQAPA----PAPGPA 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------DRSDKAPH---------- 
sp|Q53317|XYND_RUMFL/1-1564  SLGTAVMQDFESSVDFKLTLQYTDADGKENYDEVKTVTAAKGQWVDLSNSSYTIPSGATG 
 
sp|P07980|GUB_BACAM/1-1564   -------------------------FEPF------------------N---SYNSGLWQK 
sp|P37073|GUB_BACBR/1-1564   -------------------------YESF------------------D---AFDDERWSK 
sp|P27051|GUB_BACLI/1-1564   -------------------------YEPF------------------N---NYNTGLWQK 
sp|P23904|GUB_PAEMA/1-1564   -------------------LAGSVFWEPL------------------S---YFNRSTWEK 
sp|P45797|GUB_PAEPO/1-1564   -------------------FAGNVFWEPL------------------S---YFNSSTWQK 
tr|Q45648/1-1564             -------------------------VETF------------------E---SYDSERWSK 
sp|P04957|GUB_BACSU/1-1564   -------------------------FDPF------------------N---GYNSGFWQK 
tr|Q45691/1-1564             -------------------------FEPF------------------N---SYNSGLWQK 
tr|Q59328/1-1564             ---------------PNEEWR-LVWSDEF------------------N-GSEINMANWSY 
sp|P29716|GUB_CLOTM/1-1564   -------------------------VAVF------------------S---NFDSSQWEK 
tr|O14421/1-1564             -------------------FSAAAAYNLI------------------D---TYDASNWAS 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             -------------------WNGSHDVMDF------------------N---YHESNRFEM 
tr|Q84415/1-1564             LIYKGAYIDEPPPFEPKAGFE-AMWWDEF------------------D-GEEIDRTKWYI 
sp|P45798|GUB_RHOMR/1-1564   -------------------WE-LVWSDEF------------------DYSGLPDPEKWDY 
sp|Q53317|XYND_RUMFL/1-1564  LVLYVEVPESKTDFYMDGAYAGVKGTKPLISISSQSVDPPVTEPTNPTNPTGPSVTKWGD 
 
sp|P07980|GUB_BACAM/1-1564   A----------------------------------------------------------- 
sp|P37073|GUB_BACBR/1-1564   A----------------------------------------------------------- 
sp|P27051|GUB_BACLI/1-1564   A----------------------------------------------------------- 
sp|P23904|GUB_PAEMA/1-1564   A----------------------------------------------------------- 
sp|P45797|GUB_PAEPO/1-1564   A----------------------------------------------------------- 
tr|Q45648/1-1564             A----------------------------------------------------------- 
sp|P04957|GUB_BACSU/1-1564   A----------------------------------------------------------- 
tr|Q45691/1-1564             A----------------------------------------------------------- 
tr|Q59328/1-1564             DDPT-------------------------------------------------------- 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             KFN--------------------------------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             QPDI-------------------------------------------------------- 
sp|P45798|GUB_RHOMR/1-1564   DVGG-------------------------------------------------------- 
sp|Q53317|XYND_RUMFL/1-1564  ANCDGGVDLSDAIFIMQFLANPNKYGLTGTETNHMTNQGKVNGDVCEHGSGLTEDDAVSI 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             ------------------------------------------------------------ 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  QKYLIRAISELPESYLEGHDPSKTTTTTTRITTTTTTTTTTTTSKTTTTTTTTSPAMHGG 
 
sp|P07980|GUB_BACAM/1-1564   -----------------------------DGYSNGDMFNCTWRANNVSMTSLGEMRLALT 
sp|P37073|GUB_BACBR/1-1564   -----------------------------GVWTNGQMFNATWYP--EQVTADGLMRLTIA 
sp|P27051|GUB_BACLI/1-1564   -----------------------------DGYSNGNMFNCTWRANNVSMTSLGEMRLSLT 
sp|P23904|GUB_PAEMA/1-1564   -----------------------------DGYSNGGVFNCTWRANNVNFTNDGKLKLGLT 
sp|P45797|GUB_PAEPO/1-1564   -----------------------------DGYSNGQMFNCTWRANNVNFTNDGKLKLSLT 
tr|Q45648/1-1564             -----------------------------GVWSNGQMFNATWYPEQVTFSN-GKMKLQIE 
sp|P04957|GUB_BACSU/1-1564   -----------------------------DGYSNGNMFNCTWRANNVSMTSLGEMRLALT 
tr|Q45691/1-1564             -----------------------------DGYSNGDMFNSTWRADNVSMTSSGEMRLALT 
tr|Q59328/1-1564             -----------------------------NGRWNGEVQSYT---QNNAYIKDGALVIEAR 
sp|P29716|GUB_CLOTM/1-1564   -----------------------------ADWANGSVFNCVWKPSQVTFSN-GKMILTLD 
tr|O14421/1-1564             -----------------------------FEDIADPTHGFVDYVTLQQAQQYGLFKTQNN 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             -----------------------------SNWPNGEMFNCRWTPNNDKFEN-GKLKLTID 
tr|Q84415/1-1564             ---------------------------VDYYTGNRQIQHYIDSPSTIEVSNDTLHIIANN 
sp|P45798|GUB_RHOMR/1-1564   -----------------------------HGWGNQELQYYTRARIENARVGGGVLIIEAR 


















sp|P07980|GUB_BACAM/1-1564   ------------SPSYNKFDCGENRSV--------------QTYGYGLYEVRMK--PAKN 
sp|P37073|GUB_BACBR/1-1564   KK----------TTSARNYKAGELRTN--------------DFYHYGLFEVSMK--PAKV 
sp|P27051|GUB_BACLI/1-1564   ------------SPSYNKFDCGENRSV--------------QTYGYGLYEVNMK--PAKN 
sp|P23904|GUB_PAEMA/1-1564   ------------SSAYNKFDCAEYRST--------------NIYGYGLYEVSMK--PAKN 
sp|P45797|GUB_PAEPO/1-1564   ------------SPANNKFDCGEYRST--------------NNYGYGLYEVSMK--PAKN 
tr|Q45648/1-1564             KEDN--------ETASPPYKAGELRTN--------------DFYHYGLFEVSMK--PAKS 
sp|P04957|GUB_BACSU/1-1564   ------------SPAYNKFDCGENRSV--------------QTYGYGLYEVRMK--PAKN 
tr|Q45691/1-1564             ------------SPSYNKFDCGENRSV--------------QTYGYGLYEVRMK--PAKN 
tr|Q59328/1-1564             KEDITEP-----SGETYHYTSSKLITK------------GKKSWKYGKFEIRAK--MPQG 
sp|P29716|GUB_CLOTM/1-1564   RE----------YGGSYPYKSGEYRTK--------------SFFGYGYYEVRMK--AAKN 
tr|O14421/1-1564             QVYMGVDSTSTLNPNGPGRRSVRIQSK--------------TAYNRALVIADFAHVPGSA 
sp|P17989|GUB_FIBSU/1-1564   ------------NVSAKDFSGAELYTL--------------EEVQYGKFEARMK--MAAA 
tr|O14412/1-1564             RD-------------GSGYTCGEYRTK--------------NYYGYGMFQVNMK--PIKN 
tr|Q84415/1-1564             PGEVQYNETSS-NYDQTYYTSARINTKTTGGHWYPGMEVNGTTWNTIRVEARLK--APRG 
sp|P45798|GUB_RHOMR/1-1564   HE----------PYEGREYTSARLVTR------------GKASWTYGRFEIRAR--LPSG 
sp|Q53317|XYND_RUMFL/1-1564  QKWTNDKN----PDWDPRYSGGEFRTN--------------NFYHYGYYECSMQ--AMKN 
 
sp|P07980|GUB_BACAM/1-1564   TGIVSSFFTYTGPTE---GTPW---DEIDI-EFLGKDTTKVQFNYYTN-------GAGN- 
sp|P37073|GUB_BACBR/1-1564   EGTVSSFFTYTGEWDWD-GDPW---DEIDI-EFLGKDTTRIQFNYFTN-------GVGG- 
sp|P27051|GUB_BACLI/1-1564   VGIVSSFFTYTGPTD---GTPW---DEIDI-EFLGKDTTKVQFNYYTN-------GVGN- 
sp|P23904|GUB_PAEMA/1-1564   TGIVSSFFTYTGPAH---GTQW---DEIDI-EFLGKDTTKVQFNYYTN-------GVGG- 
sp|P45797|GUB_PAEPO/1-1564   TGIVSSFFTYTGPSH---GTQW---DEIDI-EFLGKDTTKVQFNYYTN-------GVGG- 
tr|Q45648/1-1564             TGTVSSFFTYTGPWDWE-NDPW---DEIDI-EFLGKDTTKIQFNYFTN-------GVGG- 
sp|P04957|GUB_BACSU/1-1564   TGIVSSFFTYTGPTD---GTPW---DEIDI-EFLGKDTTKVQFNYYTN-------GAGN- 
tr|Q45691/1-1564             TGIVSSFFTYTGPTE---GTPW---DEIDI-EFLGKDTTKVQFNYYTN-------GAEN- 
tr|Q59328/1-1564             QGIWPAIWMMPEDEPFY--GTWPKCGEIDIMELLGHEPDKIYGTIHFG-------EPHK- 
sp|P29716|GUB_CLOTM/1-1564   VGIVSSFFTYTGPSD---NNPW---DEIDI-EFLGKDTTKVQFNWYKN-------GVGG- 
tr|O14421/1-1564             CGSWPAFWMV--------GPNWPNQGEIDIYEGVHLSSSN-QVTLHTSPGCNPSIGPGGE 
sp|P17989|GUB_FIBSU/1-1564   SGTVSSMFLYQNGSEIADGRPW---VEVDI-EVLGKNPGSFQSNIITG-------KAGA- 
tr|O14412/1-1564             PGVVSSFFTYTGPSD---GTKW---DEIDI-EFLGYDTTKVQFNYYTN-------GQGH- 
tr|Q84415/1-1564             PGVVGAFWMLPIDNSCF--------PEIDIFETPYCERASM-GTWYVNKDVPR--GISK- 
sp|P45798|GUB_RHOMR/1-1564   RGTWPAIWMLPDRQTYG-SAYWPDNGEIDIMEHVGFNPDVVHGTVHTK-------AYNH- 
sp|Q53317|XYND_RUMFL/1-1564  DGVVSSFFTYTGPSD---DNPW---DEIDI-EILGKNTTQVQFNYYTN-------GQGK- 
 
sp|P07980|GUB_BACAM/1-1564   ------HEKFADLGFD-AA----------------NAYHTYAFDWQPNSIK-WYVDGQLK 
sp|P37073|GUB_BACBR/1-1564   ------NEFYYDLGFD-AS----------------ESFNTYAFEWREDSIT-WYVNGEAV 
sp|P27051|GUB_BACLI/1-1564   ------HEKIVNLGFD-AA----------------NSYHTYAFDWQPNSIK-WYVDGQLK 
sp|P23904|GUB_PAEMA/1-1564   ------HEKVISLGFD-AS----------------KGFHTYAFDWQPGYIK-WYVDGVLK 
sp|P45797|GUB_PAEPO/1-1564   ------HEKIINLGFD-AS----------------TSFHTYAFDWQPGYIK-WYVDGVLK 
tr|Q45648/1-1564             ------NEHYHELGFD-AA----------------DDFNTYAFEWRPESIR-WFVNGELV 
sp|P04957|GUB_BACSU/1-1564   ------HEKIVDLGFD-AA----------------NAYHTYAFDWQPNSIK-WYVDGQLK 
tr|Q45691/1-1564             ------HEKLADLGFD-AA----------------NAYHTYAFDWQPNSIK-WYVDWQLK 
tr|Q59328/1-1564             ---ESQGTYTLPEGQT-FA----------------DDFHVYSIEWEPGEIR-WYIDGKLY 
sp|P29716|GUB_CLOTM/1-1564   ------NEYLHNLGFD-AS----------------QDFHTYGFEWRPDYID-FYVDGKKV 
tr|O14421/1-1564             TGRRLAGDCGADGGFN-GCGIQADNPVSFGTPFNANGGGVYATLWTSSGVKVWYFATRNI 
sp|P17989|GUB_FIBSU/1-1564   ---QKTSEKHHAVSPA-AD----------------QAFHTYGLEWTPNYVR-WTVDGQEV 
tr|O14412/1-1564             ------HEHIHYLGFD-AS----------------QGFHTYGFFWARNSIT-WYVDGTAV 
tr|Q84415/1-1564             ------HGTTITESYDKFC----------------DEYVTYAVEWNADYIA-FYAGDAET 
sp|P45798|GUB_RHOMR/1-1564   ---LLGTQRGGSIRVPTAR----------------TDFHVYAIEWTPEEIR-WFVDDSLY 
sp|Q53317|XYND_RUMFL/1-1564  ------HEKLYDLGFD-SS----------------EAYHTYGFDWQPNYIA-WYVDGREV 
 
sp|P07980|GUB_BACAM/1-1564   HTA----TTQIPA----APGK---------------IMMNLWNGTGVDDWLGSYNGVN-P 
sp|P37073|GUB_BACBR/1-1564   HTA----TENIPQ----TPQK---------------IMMNLWPGVGVDGWTGVFDGDNTP 
sp|P27051|GUB_BACLI/1-1564   HTA----TTQIPQ----TPGK---------------IMMNLWNGAGVDEWLGSYNGVT-P 
sp|P23904|GUB_PAEMA/1-1564   HTA----TANIPS----TPGK---------------IMMNLWNGTGVDDWLGSYNGAN-P 
sp|P45797|GUB_PAEPO/1-1564   HTA----TTNIPS----TPGK---------------IMMNLWNGTGVDSWLGSYNGAN-P 
tr|Q45648/1-1564             HTA----TENIPQ----TPQK---------------IMMNLWPGIGVDGWTGRFNGEDTP 
sp|P04957|GUB_BACSU/1-1564   HTA----TNQIPT----TPGK---------------IMMNLWNGTGVDEWLGSYNGVN-P 
tr|Q45691/1-1564             HTA----TTQIPT----APGK---------------IMMNLWNGTGVSDWLGSYNGVN-P 
tr|Q59328/1-1564             HVA----NDWYSR----DPYLADDYTYPAPFDQNFFLILNISVGGGWPGYP-DETTVF-P 
sp|P29716|GUB_CLOTM/1-1564   YRG----TRNIPV----TPGK---------------IMMNLWPGIGVDEWLGRYDGRT-P 
tr|O14421/1-1564             PANIKSGNPDPSA----WGTP---------------IANFGNNGCDFDAKFRDLNIVF-D 
sp|P17989|GUB_FIBSU/1-1564   RKTEGGQVSNLTG----TQG----------------LRFNLWSSES-AAWVGQFDESKLP 
tr|O14412/1-1564             YTA----YDNIPD----TPGK---------------IMMNAWNGIGVDDWLRPFNGRT-N 
tr|Q84415/1-1564             PVF----VTGKEI----WAGKCDANDTDAPYNRPFYIILNTSIGSAWGGIP--LNDIF-P 
sp|P45798|GUB_RHOMR/1-1564   YRFPNERLTDPEADWRHWPFD-----------QPFHLIMNIAVGGAWGGQQGVDPEAF-P 
sp|Q53317|XYND_RUMFL/1-1564  YRA----TQDIPK----TPGK---------------IMMNAWPGLTVDDWLKAFNGRT-P 
 
sp|P07980|GUB_BACAM/1-1564   IYAHYDWMR--------------------------------------------------- 
sp|P37073|GUB_BACBR/1-1564   VYSYYDWVR--------------------------------------------------- 
sp|P27051|GUB_BACLI/1-1564   LSRSLHWVR--------------------------------------------------- 
sp|P23904|GUB_PAEMA/1-1564   LYAEYDWVK--------------------------------------------------- 
sp|P45797|GUB_PAEPO/1-1564   LYAEYDWVK--------------------------------------------------- 
tr|Q45648/1-1564             VVTQYDWVK--------------------------------------------------- 
sp|P04957|GUB_BACSU/1-1564   LYAHYDWVR--------------------------------------------------- 
tr|Q45691/1-1564             LYAHYDWVR--------------------------------------------------- 
tr|Q59328/1-1564             QQMVVDYVRVYQKDKYPHREKPAKEEVKPREPLEDGNYIYNGGFDVDDSAAVGVDGVPYT 
sp|P29716|GUB_CLOTM/1-1564   LQAEYEYVK--------------------------------------------------- 
tr|O14421/1-1564             VTFCGDWAGGV------------------------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   LFQFINWVKVY------------------------------------------------- 
tr|O14412/1-1564             ISAYYDWVS--------------------------------------------------- 
tr|Q84415/1-1564             AVLDVDYVRVS------------------------------------------------- 
sp|P45798|GUB_RHOMR/1-1564   AQLVVDYVRVY------------------------------------------------- 
sp|Q53317|XYND_RUMFL/1-1564  LTAHYQWVT--------------------------------------------------- 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             SYWTFLTASGGAATVNVEEGVMHVQIENGGTTDYGVQLLQAPIHLEKGAKYKASFDMKAE 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ----------------YRK----------------------------------------- 
sp|P37073|GUB_BACBR/1-1564   ----------------YTP----------------------------------------- 
sp|P27051|GUB_BACLI/1-1564   ----------------YTK----------------------------------------- 
sp|P23904|GUB_PAEMA/1-1564   ----------------YTS----------------------------------------- 
sp|P45797|GUB_PAEPO/1-1564   ----------------YTS----------------------------------------- 
tr|Q45648/1-1564             ----------------YTP----------------------------------------- 
sp|P04957|GUB_BACSU/1-1564   ----------------YTK----------------------------------------- 
tr|Q45691/1-1564             ----------------YTK----------------------------------------- 
tr|Q59328/1-1564             NPRQVKLKIGGDGDRGWKDYAAIPPFTVSTEMTNYEFEFTMKDDTDVKARFEFNMGLDDN 
sp|P29716|GUB_CLOTM/1-1564   ----------------YYP----------------------------------------- 
tr|O14421/1-1564             ----------------WGS----------------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   ---------------KYTPGQGEGGSDFTLDWTDNFDTFDGSRWGKGDWTFDGNRVDLTD 
tr|O14412/1-1564             ----------------YDA----------------------------------------- 
tr|Q84415/1-1564             ---------------GIRD----------------------------------------- 
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sp|P45798|GUB_RHOMR/1-1564   ---------------RWVE----------------------------------------- 
sp|Q53317|XYND_RUMFL/1-1564  ----------------YNK----------------------------------------- 
 
sp|P07980|GUB_BACAM/1-1564   ----------------------K------------------------------------- 
sp|P37073|GUB_BACBR/1-1564   ----------------------LQNYQ--------------------------------- 
sp|P27051|GUB_BACLI/1-1564   ----------------------R------------------------------------- 
sp|P23904|GUB_PAEMA/1-1564   ----------------------N------------------------------------- 
sp|P45797|GUB_PAEPO/1-1564   ----------------------N------------------------------------- 
tr|Q45648/1-1564             ----------------------LEELG--------------------------------- 
sp|P04957|GUB_BACSU/1-1564   ----------------------K------------------------------------- 
tr|Q45691/1-1564             ----------------------K------------------------------------- 
tr|Q59328/1-1564             DVWIDNVKLIKTEDAPVIDPSEIARPPLLSGNYIYNGTFDQGPNRMGFWNFVVDSTAKAT 
sp|P29716|GUB_CLOTM/1-1564   ----------------------NGVPQ--------------------------------- 
tr|O14421/1-1564             ----------------------TTRAQ--------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   KNIYSRDGMLILALTRKGQESFNGQVP--------------------------------- 
tr|O14412/1-1564             ----------------------PRN----------------------------------- 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ----------------------------------IHQ----------------------- 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ----------------------------------CYNEKNNKYKKCKKTKVK-------- 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             YYIGSDVNERRFETRIEKGGTSRGAIRLVQPGINIENGKTYKVSFEASAANTRTIEVEIA 
sp|P29716|GUB_CLOTM/1-1564   ----------------------------------DNPTPTPTIAPSTPTNPNLPLKGDVN 
tr|O14421/1-1564             ----------------------------------VNPSCVAYVASQPQNFSESYWLINSV 
sp|P17989|GUB_FIBSU/1-1564   ----------------------------------RDDEPAPQSSSSAPASSSSVPASSSS 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------NGVQHSSQGQNPWG---- 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             SNLHNSSIFATTFEISKESKIYEFEFTMDKDSDKNGELRFNLGGSNVNVYIDNVVMKRVS 
sp|P29716|GUB_CLOTM/1-1564   GDGHVNSSDYSLFKRYLLRVIDRFPVGDQSVADVNRDGRIDSTDLTMLKRYLIRAIPSL- 
tr|O14421/1-1564             KVYSV------------------------------------------------------- 
sp|P17989|GUB_FIBSU/1-1564   VPASSSSAFVPPSSSSATNAIHGMRTTPAVAKEHRNLVNAKGAKVNPNGHKRYRVNFEH- 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             TDEVEGNLILNGVFNGLAGWGYGGYEPGSADFESHEEQFRAIISSVGNEGWNVQLYQDNV 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             PLEQGQTYEVSFDAKSTIDRKIIVQLQRNGTSDNNWDSYFYQEVELTNELKTFKYEFTMS 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             KPTDSASRFNFALGNTENKTYAPHEIIIDNVVVRKVATPSALILNGTFDDGMDHWLLYWG 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             DGEGNCDVTDGELEINITKVGTADYMPQIKQENIALQEGVTYTLSLKARALEARSIKVDI 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
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sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 
sp|Q53317|XYND_RUMFL/1-1564  ------------------------------------------------------------ 
 
sp|P07980|GUB_BACAM/1-1564   ------------------------------------------------------------ 
sp|P37073|GUB_BACBR/1-1564   ------------------------------------------------------------ 
sp|P27051|GUB_BACLI/1-1564   ------------------------------------------------------------ 
sp|P23904|GUB_PAEMA/1-1564   ------------------------------------------------------------ 
sp|P45797|GUB_PAEPO/1-1564   ------------------------------------------------------------ 
tr|Q45648/1-1564             ------------------------------------------------------------ 
sp|P04957|GUB_BACSU/1-1564   ------------------------------------------------------------ 
tr|Q45691/1-1564             ------------------------------------------------------------ 
tr|Q59328/1-1564             LDSSYNWYGGTIFDLTTEDAVYTFTFTQSKSINNGVLTINLGTIEGKTSAATTVYLDDIL 
sp|P29716|GUB_CLOTM/1-1564   ------------------------------------------------------------ 
tr|O14421/1-1564             ------------------------------------------------------------ 
sp|P17989|GUB_FIBSU/1-1564   ------------------------------------------------------------ 
tr|O14412/1-1564             ------------------------------------------------------------ 
tr|Q84415/1-1564             ------------------------------------------------------------ 
sp|P45798|GUB_RHOMR/1-1564   ------------------------------------------------------------ 








Xyloglucan endotransglycosylase protein sequence al ignment:  
 
UniProtKB/TrEMBL entry Primary accession number  : taxonomy 
 
Q8GZD5 Populus tremula x Populus tremuloides (XET16A) 
Q41614 Tropaeolum majus (Common nasturtium)    
O65102 Actinidia deliciosa (Kiwi)    
O65734 Cicer arietinum (Chickpea) (Garbanzo)    
Q41638 Phaseolus angularis (Adzuki bean) (Vigna angularis) 
Q39099 Arabidopsis thaliana (Mouse-ear cress)    
Q9XIW1 Arabidopsis thaliana (Mouse-ear cress)    
Q41542 Triticum aestivum (Wheat)    
P93668 Hordeum vulgare (Barley) 
O80431 Nicotiana tabacum (Common tobacco)    
Q40144 Solanum lycopersicum (Tomato) (Lycopersicon esculentum)    
P24806 Arabidopsis thaliana (Mouse-ear cress)    
Q38857 Arabidopsis thaliana (Mouse-ear cress)    
Q38910 Arabidopsis thaliana (Mouse-ear cress) 
Q9SEB0 Arabidopsis thaliana (Mouse-ear cress) 
Q38911 Arabidopsis thaliana (Mouse-ear cress)    
Q43527 Solanum lycopersicum (Tomato) (Lycopersicon esculentum)  
Q43528 Solanum lycopersicum (Tomato) (Lycopersicon esculentum)    
P93671 Hordeum vulgare (Barley)    
P93672 Hordeum vulgare (Barley)    
Q9ZSU4 Arabidopsis thaliana (Mouse-ear cress) 
P93046 Arabidopsis thaliana (Mouse-ear cress)    
Q07524 Tropaeolum majus (Common nasturtium) 
O04906 Arabidopsis thaliana (Mouse-ear cress) 
Q38909 Arabidopsis thaliana (Mouse-ear cress)    




Yellow highlight negative subsite B-strand amino acids which point towards the enzyme face 
Green loop amino acid pointing towards active site  
Violet XET amino acid alignment disparity 





XET16A/1-372                                     -MAAAYPWTLFLGMLVMVSG-TMGAALRKPVDV----------AFGRNYVPTWAFDHIKY 
tr|Q41614-Tropaeolummajus(Common/1-372           --MTSPKWFLFLGILVMATG-AMGAAPKRPVAV----------PFGRNYAPTWAFDHIKY 
tr|O65102-Actinidia/1-372                        ---------LTLGLFLMVSA-TMATAPRKPVDV----------PFGRNYVPTWAFDHIKY 
tr|O65734-Cicer/1-372                            MSSSFSFWTLCLILASLVSS-SFCAAPRKPVDV----------PFGRNYYPTWAFDHIKY 
tr|Q41638-Phaseolus/1-372                        ---MGSSLWTCLILLSLASA-SFAANPRTPIDV----------PFGRNYVPTWAFDHIKY 
tr|Q39099-Arabidopsis/1-372                      MTVSSSPWALMALFLMVSSTMVMAIPPRKAIDV----------PFGRNYVPTWAFDHQKQ 
tr|Q9XIW1-Arabidopsis/1-372                      --MGRLSSTLCLTFLILATV-AFGVPPKKSINV----------PFGRNYFPTWAFDHIKY 
tr|Q41542-Triticum/1-372                         ---MKATAGALLAVVAAVLLRGVAAAPRKPVDV----------PFDKNYVPTWAQDHIHY 
tr|P93668(EXT)-Hordeum/1-372                     --MKATAGALLAVVATVLLRGIAAAPPRKPVDV----------PFEKNYVPTWAEDHIHY 
tr|O80431(EXGT)-Nicotiana/1-372                  ---MGLKGLLFSIVLINLSLLGLCGYPRKPVDV----------PFWKNYEPSWASHHIKY 
tr|Q40144_Lycopersicon/1-372                     --MGIIKGVLFSIVLINLSLVVFCGYPRRPVDV----------PFWKNYEPSWASHHIKF 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    ---MSPFKIFFFTTLLVAAFSVSAA------------------DFNTDVNVAWGNGRGKI 
tr|Q38857-TCH4/1-372                             ------------------------------------------------------------ 
tr|Q38910(XTR-6)-Arabidopsis/1-372               ----MAMISYSTIVVALLASFMICSVSA---------------NFQRDVEITWGDGRGQI 
tr|Q9SEB0-Arabidopsis/1-372                      ----MDRSTFILSLLFTLTV-STTTLFSPVFAG----------TFDTEFDITWGDGRGKV 
tr|Q38911-Arabidopsis/1-372                      -MGPSSSLTTIVATVLLVTLFGSAYAS----------------NFFDEFDLTWGDHRGKI 
tr|Q43527-Lycopersicon/1-372                     ---MLLQQLSVLALLLLLCPVWAD-------------------NFYQDATVTFGDQRAQI 
tr|Q43528-Lycopersicon/1-372                     -----MLLQLSLLTLVLLSPVSAD-------------------NFYQDAAVTFGDQRAQI 
tr|P93671_Hordeum/1-372                          ---MARMGASVLSILLASCALAAA-------------------SFDKEFDVTWGDGRGKI 
tr|P93672-Hordeum/1-372                          ------MRTVELGIVAMACLVAVARAG----------------NFFQDSEMSWGDGRGKV 
tr|Q9ZSU4-Arabidopsis/1-372                      MACFATKQPLLLSLLLAIGFFVVAASAG---------------NFYESFDITWGNGRANI 
tr|P93046-Arabidopsis/1-372                      -----MALSLIFLALVVLCP-SSGHSQRSPSPGYYPSSRVPTSPFDREFRTLWGSQHQRR 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  --MPPNILSIFLHLLPILMFSSSCLGQGPPSPGYYPSSQITSLGFDQGYTNLWGPQHQRV 
tr|O04906-Arabidopsis/1-372                      ----METLSRLLVFMSLFSGLVSGFALQNLPIT----------SFEESYTQLFGDKNLFV 
tr|Q38909-Arabidopsis/1-372                      ----MGFITRFLVFMSLFTSLVSGFALQKLPLI----------QFDEGYTQLFGDQNLIV 






















XET16A/1-372                                     FNGG--NEIQLHLDKYT-GTGFQSKGSYLFGHFSMQMKLVPGDSAGTVTAFYLSSQ---N 
tr|Q41614-Tropaeolummajus(Common/1-372           FNGG--SDIQLHLDKYT-GTGFQSKGSYLFGHFSMQIKLVPGDSAGTVTAFYLSSQ---N 
tr|O65102-Actinidia/1-372                        FNGG--SEIQLHLDKYT-GTGFQSKGSYLFGHFSMQIKMVPGDSAGTVTAFYLSSQ---N 
tr|O65734-Cicer/1-372                            FNGG--SEIQLHLDKST-GTGFQSKGSYLFGHFSMNIKMVPGDSAGTVTAFYLSST---N 
tr|Q41638-Phaseolus/1-372                        LNGG--SEIQLHLDKYT-GTGFQSKGSYLFGHFSMYIKLVPGDSAGTVTAFYLSST---N 
tr|Q39099-Arabidopsis/1-372                      FNGG--SELQLILDKYT-GTGFQSKGSYLFGHFSMHIKLPAGDTAGVVTAFYLSST---N 
tr|Q9XIW1-Arabidopsis/1-372                      LNGG--SEVHLVLDKYT-GTGFQSKGSYLFGHFSMHIKMVAGDSAGTVTAFYLSSQ---N 
tr|Q41542-Triticum/1-372                         VNGG--REVQLSLDKTT-GTGFQTRGSYLFGHFSMHIKLVGGDSAGTVTAFYLSSQ---N 
tr|P93668(EXT)-Hordeum/1-372                     VNGG--REVQLSLDKTT-GTGFQTRGSYLFGHFSMHIKLVGGDSAGTVTAFYLSSQ---N 
tr|O80431(EXGT)-Nicotiana/1-372                  LNGG--STADLVLDRSS-GAGFQSKKSYLFGHFSMKLRLVGGDSAGVVTAFYLSSN---N 
tr|Q40144_Lycopersicon/1-372                     LNGG--TTTDLILDRSS-GAGFQSKKSYLFGHFSMKMRLVGGDSAGVVTAFYLSSN---N 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    LNNG--QLLTLSLDKSS-GSGFQSKTEYLFGKIDMQIKLVPGNSAGTVTTFYLKSE---G 
tr|Q38857-TCH4/1-372                             -------------------------NEYLFGKVSMQMKLVPGNSAGTVTTLYLKSP---G 
tr|Q38910(XTR-6)-Arabidopsis/1-372               TNNG--DLLTLSLDKAS-GSGFQSKNEYLFGKIDMQIKLVAGNSAGTVTAYYLKSP---G 
tr|Q9SEB0-Arabidopsis/1-372                      LNNG--ELLTLSLDRAS-GSGFQTKKEYLFGKIDMQLKLVPGNSAGTVTAYYLKSK---G 
tr|Q38911-Arabidopsis/1-372                      FNGG--NMLSLSLDQVS-GSGFKSKKEYLFGRIDMQLKLVAGNSAGTVTAYYLSSQ---G 
tr|Q43527-Lycopersicon/1-372                     QDGG--RLLALSLDKIS-GSGFQSKNEYLFGRFDMQLKLVPGNSAGTVTTFYLSSQ---G 
tr|Q43528-Lycopersicon/1-372                     QDGG--RLLTLSLDKIS-GSGFQSKNEYLFGRFDMQLKLVPGNSAGTVTTFYLSSQ---G 
tr|P93671_Hordeum/1-372                          LNNG--QLLTLGLDKVS-GSGFQSKHEYLFGKIDMQLKLVPGNSAGTVTAYYLSSQ---G 
tr|P93672-Hordeum/1-372                          VDGG--RGLDLTLDKTS-GSGFQSKSEYLFGKIDMQIKLVPGNSAGTVTTFYLSSQ---G 
tr|Q9ZSU4-Arabidopsis/1-372                      FENG--QLLTCTLDKVS-GSGFQSKKEYLFGKIDMKLKLVAGNSAGTVTAYYLSSK---G 
tr|P93046-Arabidopsis/1-372                      EQ----DVVTLWLDKST-GSGFKSLRPYRSGYFGASIKLQPGFTAGVDTSLYLSNNQEHP 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  DQGS----LTIWLDSTS-GSGFKSINRYRSGYFGANIKLQSGYTAGVITSFYLSNNQDYP 
tr|O04906-Arabidopsis/1-372                      HQDG--KSVRLTLDERT-GSGFVSNDYYLHGFFSASIKLPSDYTAGVVVAFYMSNGDMYE 
tr|Q38909-Arabidopsis/1-372                      HRDG--KSVRLTLDERT-GSGFVSNDIYLHGFFSSSIKLPADYSAGVVIAFYLSNGDLYE 
tr|P93670_Hordeum/1-372                          NDDGIAQQVALTLDQGNGGSGFSSKDKYLYGEFSVQMKLIGGNSAGTVTSFYLTSGE--G 
 
XET16A/1-372                                     SEHDEIDFEFLGNRTGQPYILQTNVFTGGKGD-----REQRIYLWFDPTKEFHYYSVLWN 
tr|Q41614-Tropaeolummajus(Common/1-372           SEHDEIDFEFLGNKTGQPYILQTNVFTGGKGD-----REQRIYLWFDPTKDYHSYSVLWN 
tr|O65102-Actinidia/1-372                        SEHDEIDFEFLGNRTGQPYILQTNVFTGGKGD-----REQRIYLWFDPTKDYHAYSVLWN 
tr|O65734-Cicer/1-372                            SEHDEIDFEFLGNRTGQPYILQTNVFTGGQGN-----KEQRIFLWFDPTKEFHRYSILWN 
tr|Q41638-Phaseolus/1-372                        AEHDEIDFEFLGNRTGQPYILQTNVFTGGKGD-----REQRIYLWFDPTTQYHRYSVLWN 
tr|Q39099-Arabidopsis/1-372                      NEHDEIDFEFLGNRTGQPAILQTNVFTGGKGN-----REQRIYLWFDPSKAYHTYSILWN 
tr|Q9XIW1-Arabidopsis/1-372                      SEHDEIDFEFLGNRTGQPYILQTNVFTGGAGN-----REQRINLWFDPSKDYHSYSVLWN 
tr|Q41542-Triticum/1-372                         SEHDEIDFEFLGNRTGQPYILQTNVFSGGKGD-----REQRIYLWFDPTKDYHSYSVLWN 
tr|P93668(EXT)-Hordeum/1-372                     SEHDEIDFEFLGNRTGQPYILQTNVFSGGKGD-----REQRIYLWFDPTKDYHSYSVLWN 
tr|O80431(EXGT)-Nicotiana/1-372                  AEHDEIDFEFLGNRTGQPYILQTNVFTGGKGD-----REQRIYLWFDPTKGYHSYSVLWN 
tr|Q40144_Lycopersicon/1-372                     AEHDEIDFEFLGNRTGQPYILQTNVFTGGKGN-----REQRIYLWFDPTKGYHSYSVLWN 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    STWDEIDFEFLGNMSGDPYTLHTNVYTQGKGD-----KEQQFHLWFDPTANFHTYSILWN 
tr|Q38857-TCH4/1-372                             TTWDEIDFEFLGNSSGEPYTLHTNVYTQGKGD-----KEQQFKLWFDPTANFHTYTILWN 
tr|Q38910(XTR-6)-Arabidopsis/1-372               STWDEIDFEFLGNLSGDPYTLHTNVFTQGKGD-----REQQFKLWFDPTSDFHTYSILWN 
tr|Q9SEB0-Arabidopsis/1-372                      DTWDEIDFEFLGNLTGDPYTMHTNVYTQGKGD-----REQQFHLWFDPTADFHTYSVLWN 
tr|Q38911-Arabidopsis/1-372                      ATHDEIDFEFLGNETGKPYVLHTNVFAQGKGD-----REQQFYLWFDPTKNFHTYSIVWR 
tr|Q43527-Lycopersicon/1-372                     AGHDEIDFEFLGNSSGQPYTVHTNVYSQGKGN-----KEQQFRLWFDPTSPFHTYSIVWN 
tr|Q43528-Lycopersicon/1-372                     AGHDEIDFEFLGNSSGLPYTVHTNVYSQGKGN-----KEQQFRLWFDPTSSFHTYSIVWN 
tr|P93671_Hordeum/1-372                          PTHDEIDFEFLGNVTGEPYTLHTNVFTQGQGQ-----REQQFRLWFDPTNDFHTYSILWN 
tr|P93672-Hordeum/1-372                          TAHDEIDFEFLGNVTGEPYTLHTNVFAQGQGQ-----REQQFRLWFDPTKAFHTYSIIWN 
tr|Q9ZSU4-Arabidopsis/1-372                      TAWDEIDFEFLGNRTGHPYTIHTNVFTGGKGD-----REMQFRLWFDPTADFHTYTVHWN 
tr|P93046-Arabidopsis/1-372                      GDHDEVDIEFLGTTPGKPYSLQTNVFVRGSGDRNVIGREMKFTLWFDPTQDFHHYAILWN 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  GKHDEIDIEFLGTIPGKPYTLQTNVFIEGSGDYNIIGREMRIHLWFDPTQDYHNYAIYWT 
tr|O04906-Arabidopsis/1-372                      KNHDEIDFEFLGNIREKEWRVQTNIYGNGSTH---SGREERYNLWFDPTEDFHQYSILWS 
tr|Q38909-Arabidopsis/1-372                      KNHDEIDFEFLGNIRGREWRIQTNIYGNGSTH---LGREERYNLWFDPTEDFHQYSILWS 
tr|P93670_Hordeum/1-372                          DGHDEIDIEFMGNLSGDPYVMNTNVWASGDGK-----KEHQFYLWFDPTADFHTYKIVWN 
 
XET16A/1-372                                     MYMIVFLVDDVPIRVFKNCKDLGVKFPFNQPMKIYSSLWN-ADDWATRGGLEKTDWSKAP 
tr|Q41614-Tropaeolummajus(Common/1-372           LYQIVFFVDDVPIRVFKNSKDLGVKFPFNQPMKIYSSLWN-ADDWATRGGLEKTDWSKAP 
tr|O65102-Actinidia/1-372                        LYQIVFFVDDVPIRIFKNSKDLGVKFPFDQPMKIYSSLWN-ADDWATRGGLEKTDWSKAP 
tr|O65734-Cicer/1-372                            MYQIVFFVDDVPIRVFKNSKDLGVKFPFDQPMKIYNSLWN-ADDWATRGGLEKTDWSKAP 
tr|Q41638-Phaseolus/1-372                        MYQIVFYVDDYPIRVFKNSNDLGVKFPFNQPMKIYNSLWN-ADDWATRGGLEKTDWSKAP 
tr|Q39099-Arabidopsis/1-372                      MYQIVFFVDNIPIRTFKNAKDLGVRFPFNQPMKLYSSLWN-ADDWATRGGLEKTNWANAP 
tr|Q9XIW1-Arabidopsis/1-372                      MYQIVFFVDDVPIRVFKNSKDVGVKFPFNQPMKIYSSLWN-ADDWATRGGLEKTNWEKAP 
tr|Q41542-Triticum/1-372                         LYMIAFFVDDTPIRVFKNSKDLGVRYPFDQPMKLYSSLWN-ADDWATRGGREKTDWSKAP 
tr|P93668(EXT)-Hordeum/1-372                     LYMIAFFVDDTPIRVFKNSKDLGVRYPFDQPMKLYSSLWN-ADDWATRGGREKTDWSKAP 
tr|O80431(EXGT)-Nicotiana/1-372                  TFQIVIFVDDVPIRAFKNSKDLGVKFPFNQPMKIYSSLWD-ADDWATRGGLEKTDWSNAP 
tr|Q40144_Lycopersicon/1-372                     TYLIVIFVDDVPIRAFKNSKDLGVKFPFNQPMKIYSSLWD-ADDWATRGGLEKTNWANAP 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    PQRIILTVDTHPLESLKTMSLSVSCFQRTKPMRMVRQFMERQSDWATK----RRSWLKL- 
tr|Q38857-TCH4/1-372                             PQRIIFTVDGTPIREFKNMESLGTLFPKNKPMRMYSSLWN-ADDWATRGGLVKTDWSKAP 
tr|Q38910(XTR-6)-Arabidopsis/1-372               PQRIIFSVDGTPIREFKNMESQGTLFPKNQPMRMYSSLWN-AEEWATRGGLVKTDWSKAP 
tr|Q9SEB0-Arabidopsis/1-372                      PHHIVFMVDDIPVREFKNLQHMGIQYPKLQPMRLYSSLWN-ADQWATRGGLVKTDWSKAP 
tr|Q38911-Arabidopsis/1-372                      PQHIIFLVDNLPIRVFNNAEKLGVPFPKSQPMRIYSSLWN-ADDWATRGGLVKTDWSKAP 
tr|Q43527-Lycopersicon/1-372                     SQRIIFLVDNIPIRVFNNHEKLGVAFPKNQAMRVYASLWN-ADDWATQGGRVKTDWSMAP 
tr|Q43528-Lycopersicon/1-372                     SQRIIFLVDNIPIRVFNNHEALGVAYPKNQAMRVYASLWN-ADDWATQGGRVKTDWSMAP 
tr|P93671_Hordeum/1-372                          PKHIIFMVDDMPIRDFKNLEGKGIAFPKNQPMRLYSSLWN-ADDWATQGARVKTDWSHAP 
tr|P93672-Hordeum/1-372                          PQHVIFAVDGTAIRDFKNHEARGVSFPKSQPMRLYASLWN-ADDWATQGGRVKTDWSKAP 
tr|Q9ZSU4-Arabidopsis/1-372                      PVNIIFLVDGIPIRVFKNNEKNGVAYPKNQPMRIYSSLWE-ADDWATEGGRVKIDWSNAP 
tr|P93046-Arabidopsis/1-372                      PNQIVFFVDDVPIRTYNRKNEA--IFP-TRPMWVYGSIWD-ASDWATENGRIKADYRYQP 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  PSEIIFFVDDVPIRRYPRKSDA--TFP-LRPLWVYGSVWD-ASSWATENGKYKADYRYQP 
tr|O04906-Arabidopsis/1-372                      DSHIIFFVDNVPIREVKRTAEMGGHFP-SKPMSLYTTIWD-GSKWATNGGKYGVNYKYAP 
tr|Q38909-Arabidopsis/1-372                      LSHIIFYVDNVPIREVKRTASMGGDFP-AKPMSLYSTIWD-GSKWATDGGKYGVNYKYAP 
tr|P93670_Hordeum/1-372                          PKNIIFQVDDVPVRTFKKYDDL--PYPSSQPMTVHATLWD-GSYWATRHGDVKIDWTQAP 
 
XET16A/1-372                                     FIASYRSFH-IDGCEASV--EAKFCA-------TQG------AR-WWDQKEFQDLDAFQY 
tr|Q41614-Tropaeolummajus(Common/1-372           FIASYKGFH-VDGCEASV--EAKFCA-------TQG------KR-WWDQKEFQDLDGYQW 
tr|O65102-Actinidia/1-372                        FVAAYKSFH-IDGCEASV--EAKFCA-------TQG------KR-WWDQNDFRDLDADQY 
tr|O65734-Cicer/1-372                            FVAGYKSFH-IDGCEASV--NAKFCA-------TQG------KR-WWDQPEFRDLDAAQW 
tr|Q41638-Phaseolus/1-372                        FIASYKGFH-IDGCEASV--NAKFCD-------TQG------KR-WWDQPEFRDLDAAQW 
tr|Q39099-Arabidopsis/1-372                      FVASYKGFH-IDGCQASV--EAKYCA-------TQG------RM-WWDQKEFRDLDAEQW 
tr|Q9XIW1-Arabidopsis/1-372                      FVASYRGFH-VDGCEASV--NAKFCE-------TQG------KR-WWDQKEFQDLDANQY 
tr|Q41542-Triticum/1-372                         FVASYRGFH-VDGCEAS--AEAKFCA-------TQG------AR-WWDQPEFQDLDAAQY 
tr|P93668(EXT)-Hordeum/1-372                     FVASYRGFH-VDGCEAS--AEAKLCA-------TQG------AR-WWDQPEFQDLDAAQY 
tr|O80431(EXGT)-Nicotiana/1-372                  FTASYTSFH-VDGCEAATPQEVQVCN-------TKG------MR-WWDQKAFQDLDALQY 
tr|Q40144_Lycopersicon/1-372                     FTASYTSFH-VDGCEAATPQEVQVCN-------TKG------MK-WWDQKAFQDLDALQY 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    IGLKLHSWL-LTETLRLTRNQTPIGT---------L------KK-WIQQAK---LDSNGF 
tr|Q38857-TCH4/1-372                             FTASYRGFQ-QEACVWS--NGKSSCPNASKQGTTTG-------S-WLSQE----LDSTAQ 
tr|Q38910(XTR-6)-Arabidopsis/1-372               FTASYRGFN-EEACVVI--NGQSSCPNVSGQGSTGS---------WLSQE----LDSTGQ 
tr|Q9SEB0-Arabidopsis/1-372                      FTASYRNFR-ADACVSS--GGRSSCP-------AGS------PR-WFSQR----LDLTAE 
tr|Q38911-Arabidopsis/1-372                      FTAYYRGFN-AAACTASSGCDPKFKS-------SFG------DG---KLQVATELNAYGR 
tr|Q43527-Lycopersicon/1-372                     FTASYRNFN-TNACVWSAASSTSSCGGSKTDSVNND------QA-WQTQE----LNGNDR 
tr|Q43528-Lycopersicon/1-372                     FTASYRNFN-TNACVWSAATSTSSCGGSKTESVNND------ET-WQTQQ----LNANGR 
tr|P93671_Hordeum/1-372                          FSASYRGFK-ADACVVTA-GGRPRCGASMGTEAAPGTGASGAAGEWYNQE----LDLTLQ 
tr|P93672-Hordeum/1-372                          FVASFRNFN-ADACVMS--GGAQRCPAGTMEASAAG------GGSWWNQE----LSGMGY 
tr|Q9ZSU4-Arabidopsis/1-372                      FKASYRNFNDQSSCSRTSSSKWVTCE-------PNS------NS-WMWTT----LNPAQY 
tr|P93046-Arabidopsis/1-372                      FVAKYKNFK-LAGCTAD---SSSSCR-------PPS------PA-PMRNRG---LTRQQM 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  FVGKYEDFK-LGSCTVE---AASSCN-------PAS------VS-PYGQ-----LSQQQV 
tr|O04906-Arabidopsis/1-372                      YIARFSDLV-LHGCPVDPIEQFPRCD-------EGA------AE---DMRAAQEITPSQR 
tr|Q38909-Arabidopsis/1-372                      YVSQFTDLI-LHGCAVDPTEKFPSCK-------DEA------VQ---NLRLASEITESQR 
tr|P93670_Hordeum/1-372                          FVVNYRGYT-SNGCVSN--GGSSACP-------AGS------DA-WMSTE----LDAKAL 
 
XET16A/1-372                                     RRLSWVRQKYTIYNYCTDRSRYPS-M------PPECKRDRDI------------------ 
tr|Q41614-Tropaeolummajus(Common/1-372           RRLLWVRNKWTIYNYCNDRVRYPT-I------SPECKRDRDI------------------ 
tr|O65102-Actinidia/1-372                        RRLQWVRSKYTI------------------------------------------------ 
tr|O65734-Cicer/1-372                            RRLRWVRQKFTIYNYCTDRKRLPQ-I------PPECTRDRDI------------------ 
tr|Q41638-Phaseolus/1-372                        QKLAWVRNKYTIYNYCTDRKRYSQ-V------PPECTRDRDI------------------ 
tr|Q39099-Arabidopsis/1-372                      RRLKWVRMKWTIYNYCTDRTRFPV-M------PAECKRDRDA------------------ 
tr|Q9XIW1-Arabidopsis/1-372                      KRLKWVRKRYTIYNYCTDRVRFPV-P------PPECRRDRDI------------------ 
tr|Q41542-Triticum/1-372                         RRLAWVRKEHTIYNYCTDHDRYAA-M------APECKRDRDV------------------ 
Alignments 
 249 
tr|P93668(EXT)-Hordeum/1-372                     RRLAWVRKEHTIYNYCTDRERYAA-M------SPECKRDRDV------------------ 
tr|O80431(EXGT)-Nicotiana/1-372                  RRLRWVRQKYTIYNYCTDRKRYPT-L------PPECTKDRDI------------------ 
tr|Q40144_Lycopersicon/1-372                     RRLRWVRQKYTVYNYCTDKARYPV-P------PPECTKDRDI------------------ 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    RRIT-------------------------------------------------------- 
tr|Q38857-TCH4/1-372                             QRMRWVQRNYMIYNYCTDAKRFPQGL------PKECLAA--------------------- 
tr|Q38910(XTR-6)-Arabidopsis/1-372               EQMRWVQNNYMIYNYCTDAKRFPQGL------PRECLAA--------------------- 
tr|Q9SEB0-Arabidopsis/1-372                      DKMRVVQRKYMIYNYCTDTKRFPQGF------PKECRH---------------------- 
tr|Q38911-Arabidopsis/1-372                      RRLRWVQKYFMIYNYCSDLKRFPRGF------PPECKKSRV------------------- 
tr|Q43527-Lycopersicon/1-372                     NRLRWVQQKYMIYNYCADAKRFSQGL------SPECKRSRF------------------- 
tr|Q43528-Lycopersicon/1-372                     NRIRWVQQKYMIYNYCADANRFSQGF------SPECKRSRF------------------- 
tr|P93671_Hordeum/1-372                          QRMRWVQSNYMIYNYCTDPKRVAKGV------PAECSM---------------------- 
tr|P93672-Hordeum/1-372                          RRMRWVQRKFMIYNYCTDPKRVAQGV------PAECKLR--------------------- 
tr|Q9ZSU4-Arabidopsis/1-372                      GKMMWVQRDFMIYNYCTDFKRFPQGL------PKECKL---------------------- 
tr|P93046-Arabidopsis/1-372                      AALTWAQRNFLVYNYCHDPKRDHT-Q------TPEC------------------------ 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  AAMEWVQKNYMVYNYCDDPTRDHT-L------TPEC------------------------ 
tr|O04906-Arabidopsis/1-372                      SKMDVFRRRLMTYSYCYDRARYNVALSECVVNPAEAQRLRVYDPVRFGGIPRRHRNGKHR 
tr|Q38909-Arabidopsis/1-372                      NKMEIFRQKHMTYSYCYDHMRYKVVLSECVVNPAEAKRLRVYDPVTFGGIPHGHRRGKHR 
tr|P93670_Hordeum/1-372                          GTVAWAESKYMSYDYCTDGWRFPNGF------PAECSRRN-------------------- 
 
XET16A/1-372                                     ------------ 
tr|Q41614-Tropaeolummajus(Common/1-372           ------------ 
tr|O65102-Actinidia/1-372                        ------------ 
tr|O65734-Cicer/1-372                            ------------ 
tr|Q41638-Phaseolus/1-372                        ------------ 
tr|Q39099-Arabidopsis/1-372                      ------------ 
tr|Q9XIW1-Arabidopsis/1-372                      ------------ 
tr|Q41542-Triticum/1-372                         ------------ 
tr|P93668(EXT)-Hordeum/1-372                     ------------ 
tr|O80431(EXGT)-Nicotiana/1-372                  ------------ 
tr|Q40144_Lycopersicon/1-372                     ------------ 
sp|P24806|MER5_ARATH_MERI-5-Arabidopsis/1-372    ------------ 
tr|Q38857-TCH4/1-372                             ------------ 
tr|Q38910(XTR-6)-Arabidopsis/1-372               ------------ 
tr|Q9SEB0-Arabidopsis/1-372                      ------------ 
tr|Q38911-Arabidopsis/1-372                      ------------ 
tr|Q43527-Lycopersicon/1-372                     ------------ 
tr|Q43528-Lycopersicon/1-372                     ------------ 
tr|P93671_Hordeum/1-372                          ------------ 
tr|P93672-Hordeum/1-372                          ------------ 
tr|Q9ZSU4-Arabidopsis/1-372                      ------------ 
tr|P93046-Arabidopsis/1-372                      ------------ 
tr|Q07524_Cellulase(EC3.2.1.4)-Tropaeolum/1-372  ------------ 
tr|O04906-Arabidopsis/1-372                      SKRSRVDGTESI 
tr|Q38909-Arabidopsis/1-372                      S-RSRLARTESI 
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